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1Introducti on
Most treatments and interventi ons in health care are aimed at opti mizing clinical outcomes. Clinical 
outcome refers to the degree to which pati ents who survived a disease have returned to daily 
functi oning. Clinical outcomes can be measured with diff erent scales and from a variety of perspecti ves. 
The spectrum ranges from survival or functi onal scales focused on acti viti es in daily living scored by 
a physician1, 2, to multi dimensional questi onnaires addressing pati ent percepti on regarding physical, 
mental and emoti onal wellbeing (quality of life).3, 4
 Measurement of clinical outcomes may serve diff erent purposes, such as prognosti c research 
and outcomes research. Prognosti c research involves esti mati ng the probability of a pati ent developing 
a certain clinical outcome over ti me, based on clinical and other characteristi cs.5 Outcomes research 
refers to the analyses of clinical outcomes related to health care practi ces and interventi ons.6 This 
includes examining variati on in outcomes across diff erent setti  ngs and determining the added value of 
new outcome measures. 
 This thesis presents the methodology and clinical implicati ons of outcome predicti on, assessment 
of between-hospital variati on in clinical outcomes and evaluati on of stati sti cal effi  ciency of new outcome 
measures. These topics will be studied in the fi eld of acute neurology.
Predicti on
Observed or expected improvement or deteriorati on in pati ent outcomes is an important driver for 
changes in clinical management. Early identi fi cati on of pati ents at high risk for poor functi onal outcome 
in a specifi c clinical setti  ng may assist clinicians with treatment decisions, inclusion of pati ents in 
randomized clinical trials (RCTs) or benchmarking quality of care.7, 8
 A prognosti c factor is any characteristi c that is associated with a subsequent clinical outcome.9
For instance, older age is associated with a higher risk of death (in most diseases as well as in healthy 
subjects). Multi variable prognosti c models combine several prognosti c factors to esti mate the risk of 
a specifi c endpoint for an individual pati ent.8 An example is the Corti costeroid Randomisati on Aft er 
Signifi cant Head injury (CRASH) model which esti mates the risk of 14-day mortality or 6-month 
unfavorable outcome (death or severe disability) for pati ents with traumati c brain injury. The model 
consists of age, measures for clinical severity, and major extracranial injury (Figure 1.1).10
 Standards and recommendati ons for the reporti ng of studies on multi variable prognosti c models 
have been published.8, 11 Development of a prognosti c model consists of several steps, including 
selecti on and coding of predictors and defi ning the outcome of interest.12, 13 The validity or quality of 
a prognosti c model should be evaluated in the derivati on cohort (internal validati on) as well as in a 
new setti  ng that diff ers from the derivati on cohort (external validati on). Several performance measures 
to determine model validity have been proposed. Prognosti c models should adequately disti nguish 
between pati ents with and without the outcome of interest (= model discriminati on). Moreover, good 
agreement between observed and predicted outcome rates (= model calibrati on) is required to provide 
reliable predicti ons for pati ents in a specifi c clinical setti  ng.11-13 In additi on to model discriminati on and 
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calibrati on, the clinical usefulness of prognosti c models should be evaluated, especially for models 
aiming to support clinical decision making.11-13
Figure 1.1. Web calculator from the CRASH prognosti c model (available from htt p://www.crash.lshtm.ac.uk/Risk%20
calculator/index.html). 10
CT, computed tomography; CI, confi dence interval.
Outcome analyses
Besides outcome predicti on, measurement of clinical outcomes is also important to examine outcome 
variati on in clinical outcomes across setti  ngs. Diff erences in clinical outcomes between hospitals and 
countries are present in many diseases, but are highly undesirable when caused by diff erences in 
management. Such diff erences may reﬂ ect poor implementati on or even a lack of evidence-based 
diagnosti c and therapeuti c policies. Gaining insight in these outcome diff erences with random eff ects 
modeling creates the opportunity to evaluate practi ce variati on.
 Further, the introducti on of new methods of outcome measurement requires evaluati on of their 
added value in research or practi ce. Most current functi onal outcome scales may not be granular 
enough to detect small changes in clinical status, do not incorporate all aspects that can contribute to 
the level of disability and exclude pati ent percepti on on physical and mental well-being.14-16 Therefore, 
a trend exists towards new outcome measures incorporati ng both functi onal outcome and quality of 
life (pati ent-reported outcome measures [PROMs]).17 New outcome measures should be stati sti cally 
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1effi  cient to obtain reliable esti mates of treatment eff ect (i.e. the degree of benefi t or harm of an 
interventi on) in clinical trials. Because the true treatment eff ect is unknown in empirical data, the only 
valid method to assess stati sti cal effi  ciency of a new outcome measure is a simulati on study.
Random eﬀ ects modeling
Between-center and between-country diff erences in pati ent outcomes are ideally esti mated with 
random eff ects (multi level) models. Other than the fi xed eff ects (regression) models that are oft en 
used for prognosti c modeling, random eff ects models also take into account the clustering of pati ents 
within hospitals and countries.18 These models facilitate esti mati on of unexplained outcome diff erences 
by enabling adjustment for diff erences in pati ent characteristi cs (i.e. case-mix, at pati ent level), as 
well as structure and process characteristi cs at hospital level. Structure characteristi cs relate to the 
organizati on of care in a hospital, e.g. the number of pati ents treated. Process characteristi cs concern 
treatment in individual pati ents. A decrease in between-center and between-country diff erences aft er 
correcti on for case-mix and structure or process characteristi cs indicates that variati on in these factors 
aff ects pati ent outcomes. 
 Random eff ects models also account for random variati on due to small sample sizes per hospital 
and country. However, esti mates of between-center and between-country diff erences remain subject 
to substanti al uncertainty. The smaller the sample size per hospital or country, the more uncertain the 
esti mates for diff erences in clinical outcomes.19
Simulati ons 
In short, simulati ons are computer experiments that involve creati ng data to reproduce a specifi c 
scenario, such as a RCT with a known treatment eff ect.20 This simulated dataset can then be used to 
evaluate the power of the stati sti cal approach required to analyze a new outcome measure, for example 
ordinal logisti c or linear regression. A simulati on study also facilitates comparison of new and existi ng 
outcome measures and diff erent stati sti cal approaches in the same clinical scenario.20
 Besides being stati sti cally effi  cient, new outcome measures should also facilitate interpretati on of 
treatment eff ects. Treatment eff ects in clinical trials are currently oft en expressed on the odds rati o or 
hazard rati o scale, and researchers and clinicians are used to working with these scales. A new outcome 
measure should not complicate interpretati on of trial results.  
Acute neurological diseases
Acute neurological diseases have a heterogeneous disease course and are oft en associated with poor 
clinical outcomes, which sti mulates measurement of clinical outcomes in terms of prognosis, variati on 
across setti  ngs and new assessment methods. In this thesis, outcome predicti on and outcome analyses 
are applied to three acute neurological diseases: ischemic stroke, aneurysmal subarachnoid hemorrhage 
and traumati c brain injury. 
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Ischemic stroke
Ischemic stroke occurs when a thrombus is blocking an intracranial artery. This type of stroke accounts 
for over 80% of all strokes and is a major cause of mortality and disability.21 In 2017, over 29,000 
pati ents were admitt ed to hospitals because of ischemic stroke in the Netherlands.22 Disrupti on of the 
blood supply to the brain causes acute neurological defi cits, including impaired speech, paresis of arms 
or legs, facial paralysis, visual loss or even coma. Atherosclerosis and cardioembolism are the main 
causes of ischemic stroke.23
  Pati ents with ischemic stroke should be treated as soon as possible to recover blood ﬂ ow to the 
brain (ti me = brain). Unti l recently, this could mainly be att empted with intravenous thrombolysis (IVT, 
administrati on of intravenous alteplase) within 4.5 hours aft er stroke onset to dissolve the thrombus 
blocking the vessel. Over the past fi ve years, acute treatment for ischemic stroke has undergone major 
change.24 Intra-arterial treatment (IAT, endovascular removal of the thrombus) within 6 hours aft er 
stroke onset has been proven eff ecti ve for pati ents with a proximal anterior circulati on occlusion in 
multi ple RCTs.25-30 Recent trials, although conducted in selected groups of pati ents with ischemic stroke, 
have shown that IAT is also benefi cial within 16 or even 24 hours aft er “last seen well”.31, 32 However, 
trials present average treatment eff ects and benefi t of IAT may vary among individual pati ents with 
ischemic stroke. This is an example of a clinical scenario where applicati on of a prognosti c model 
esti mati ng individual benefi t of IAT may support treatment decisions.33
 The most widely used primary outcome measure in trials for acute stroke interventi ons is the 
modifi ed Rankin Scale (mRS).34, 35 The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death) 
measuring the degree of disability or dependence in everyday life (Table 1.1).2 The mRS is oft en assessed 
at 3 months aft er stroke onset, because most improvement in functi onal outcome is expected to occur 
within this ti me window.34 Although IAT has improved functi onal outcome aft er ischemic stroke, many 
pati ents experience long-term neurological sequelae in terms of functi onal, cogniti ve and behavioral 
problems that require rehabilitati on or nursing home care.16, 36 Effi  cient hospital discharge planning is 
therefore essenti al.
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Table 1.1. Modifi ed Rankin Scale
Category Interpretati on
0 No symptoms at all
1 No signifi cant disability despite symptoms; able to perform all usual acti viti es
2 Slight disability; unable to perform all previous acti viti es, but able to take care of self without assistance
3 Moderate disability; requiring some help, but able to walk without assistance
4 Moderately severe disability; unable to walk without assistance and unable to att end to own 
bodily needs without assistance
5 Severe disability; requiring constant nursing care and att enti on
6 Dead
Subarachnoid hemorrhage
Subarachnoid hemorrhage (SAH) is a type of hemorrhagic stroke and accounts for 5% of all strokes. 
In SAH, blood originati ng from an intracranial artery accumulates in the subarachnoid space. Of all 
spontaneous SAHs, 85% is caused by the rupture of an intracranial aneurysm and called an aneurysmal 
subarachnoid hemorrhage (aSAH).37 aSAH oft en occurs in the working populati on (most pati ents are 
<60 years of age) and is associated with poor outcome, with mortality rates around 35%.38, 39 This makes 
aSAH a disease with a major individual and economic health impact.40 The key symptom for aSAH is a 
sudden-onset headache, described by pati ents as “the worst headache ever”. 
  Acute treatment for pati ents with aSAH consists of occlusion of the aneurysm to prevent rebleeding. 
This can be achieved by either endovascular coiling or neurosurgical clipping of the aneurysm. Coiling is 
a less invasive treatment than clipping, and is associated with bett er short-term outcomes in pati ents in 
good clinical conditi on with a ruptured aneurysm suitable for both interventi ons.41 Besides rebleeding, 
other main complicati ons in the acute phase aft er aSAH include vasospasm and delayed cerebral 
ischemia (DCI), and hydrocephalus.37, 38 The main evidence-based opti ons for medical treatment or 
preventi on of complicati ons aft er aSAH include administrati on of oral nimodipine and maintenance 
of euvolemia to prevent DCI, and drainage of cerebrospinal ﬂ uid in pati ents with hydrocephalus.42
However, so far, many trials studying interventi ons to potenti ally prevent or treat complicati ons aft er 
aSAH did not show any additi onal benefi t.42-45 Because aSAH has a heterogeneous disease course and 
evidence-based treatment opti ons for complicati ons aft er aSAH are scarce, it is expected that general 
management diff ers between hospitals and countries, which may likely impact on clinical outcomes.
  Functi onal outcome aft er aSAH is oft en measured with either the mRS or the Glasgow Outcome 
Scale (GOS) (Table 1.1 and 1.2).1, 2 Similar to the mRS, the GOS is an ordinal scale ranging from 1 (death) 
to 5 (good recovery). Survivors of aSAH oft en experience defi cits on both functi onal and cogniti ve 
domains. Even if pati ents have made “good” functi onal recovery, defi cits on the cogniti ve domain 
(e.g. problems with memory, executi ve functi on and language) may cause impaired quality of life for a 
minimum of 2-3 years aft er aSAH.46
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Table 1.2. Glasgow Outcome Scale (Extended)
Category GOS Category GOSE Interpretati on
1 = Dead 1 = Dead Dead
2 = Vegetati ve state 2 = Vegetati ve state Unable to interact with the environment, 
unresponsive
3 = Severe disability 3 = Lower severe disability
4 = Upper severe disability
Full assistance in acti viti es of daily living
Parti al assistance in acti viti es of daily living
4 = Moderate disability 5 = Lower moderate disability
6 = Upper moderate disability
Independent, but cannot resume work, school 
or all previous acti viti es
Some disability exists, but can partly resume 
work or previous acti viti es
5 = Good recovery 7 = Lower good recovery
8 = Upper good recovery
Minor physical or mental defi cits that aff ect 
daily life
Full recovery with minor symptoms that do not 
aff ect daily life
Traumati c brain injury
Traumati c brain injury (TBI) is a leading cause of injury-related death and disability.47, 48 In 2016, there 
were over 27 million new cases of TBI worldwide, with more than 46,000 new cases of TBI in the 
Netherlands.47 In short, TBI is defi ned as an injury to the brain induced by an external force. The 
epidemiology of TBI has changed substanti ally over the past years, especially regarding age distributi on 
and injury mechanism. Currently, the main causes of TBI are falls and motor vehicle road accidents.47, 48
 TBI is a disease with substanti al variati on in pathophysiology, clinical presentati on, and prognosis.48
Clinical severity of TBI is currently classifi ed according to the Glasgow Coma Scale (GCS). This is a scale 
for assessment of impaired consciousness based on eye, motor and verbal response ranging from 3 
(unresponsive pati ent) to 15 (fully awake and oriented pati ent).49 There are three categories of severity: 
mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS 3-8) TBI. This thesis focuses mainly on pati ents 
with moderate and severe TBI. Age, clinical severity, intracranial abnormaliti es on brain computed 
tomography (CT), secondary insults (i.e. hypoxia and hypotension) and laboratory characteristi cs have 
been identi fi ed as prognosti c factors for poor functi onal outcome in pati ents with moderate and severe 
TBI and.10, 50, 51 Moreover, TBI is oft en accompanied by extracranial injuries. 
 Management of the primary injury and secondary brain damage, such as raised intracranial 
pressure due to swelling of the brain, may include medical or surgical treatment. As for aSAH, 
knowledge on the best treatment strategies for pati ents with TBI is scarce, because many trials on 
potenti ally eff ecti ve interventi ons were inconclusive.48, 52 Questi onnaires among physicians from 71 
European centers have shown that substanti al between-hospital variati on exists in treatment policies 
and organizati on of care.53-58 Moreover, large diff erences have been observed between hospitals in 
clinical outcomes of TBI pati ents, which may be a reﬂ ecti on of the variati on in treatment policies.59
 Functi onal outcome aft er TBI is oft en scored according to the Glasgow Outcome Scale (GOS) 
ranging from 1 (death) to 5 (complete recovery), or the Glasgow Outcome Scale Extended (GOSE) which 
is a slightly more granular 8-point scale (Table 1.2).1 TBI survivors oft en face a combinati on of physical, 
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1psychiatric, emoti onal and cogniti ve disabiliti es. The variety in long-term impairments among individual 
pati ents requires personalized rehabilitati on strategies delivered by a multi disciplinary team.15, 48
Data sources
Analyses in this thesis will mainly be based on data from a variety of clinical trials and observati onal 
cohort studies in acute neurological diseases (Table 1.3).
Predicti on
The following data sources will be used for analyses on outcome predicti on:
-      Retrospecti ve cohorts of aSAH pati ents admitt ed to the intensive care unit from two university 
hospitals in the Netherlands between 2006 and 2011.
-      The Paracetamol (Acetaminophen) In Stroke (PAIS) study, Promoti ng Acute Thrombolysis in 
Ischemic StrokE (PRACTISE) study and Preventi ve Anti bioti cs in Stroke Study (PASS) conducted 
between 2003 and 2014. These trials were aimed at improving care for ischemic and/or 
hemorrhagic stroke pati ents by evaluati ng treatment and implementati on strategies.60-62
-      The Collaborati ve European NeuroTrauma Eff ecti veness Research in Traumati c Brain Injury 
(CENTER-TBI) project. This is a prospecti ve observati onal cohort study aimed at identi fying 
best clinical care and improving characterizati on and classifi cati on of TBI.63 Parti cipants 
for the core study were recruited between December 2014 and December 2017 from 59 
neurotrauma centers in 18 countries across Europe and Israel.
Outcome analyses
Random eff ects analyses regarding outcome diff erences across hospitals and countries will be based 
on a selecti on of data from the Subarachnoid Hemorrhage Internati onal Trialists (SAHIT) repository 
including multi ple RCTs and observati onal studies in pati ents with aSAH.64 Data from the Intraoperati ve 
Hypothermia during Surgery for Intracranial Aneurysm (IHAST), magnesium sulfate in aneurysmal 
subarachnoid hemorrhage (MASH) and Tirilazad mesylate in pati ents with aneurysmal subarachnoid 
hemorrhage (Tirilazad) trials conducted between 1991 and 2011 will be used.65-69
 Simulati ons will be performed on data from the Multi center Randomized Clinical Trial of 
Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), designed to evaluate 
whether acute intra-arterial treatment (within 6 hours of symptom onset) plus usual care would be 
more eff ecti ve than usual care alone in pati ents with ischemic stroke and a proximal arterial occlusion 
in the anterior cerebral circulati on. Pati ents were recruited from 16 Dutch centers between December 
2010 and March 2014.25
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Table 1.3. Overview of data sources that will be used for analyses
Study Number of pati ents used 
for analysis in this thesis
Design
Ischemic stroke
PAIS 1227 RCT
PRACTISE 1589 Cluster RCT
PASS 2107 RCT
MR CLEAN 500 RCT
Aneurysmal subarachnoid hemorrhage
Cohort Erasmus University Medical Center 307 Single-center retrospecti ve 
observati onal cohort study
Combined cohort Erasmus University Medical 
Center and University Medical Center Groningen
285 Multi center retrospecti ve 
observati onal cohort study
Combined cohort based on data from studies in 
the SAHIT repository
- IHAST
- MASH
- Tirilazad
5972
RCT
RCT
RCT
Traumati c brain injury
CENTER-TBI 1742 Multi center prospecti ve 
observati onal cohort study
RCT, randomized clinical trial; PAIS, Paracetamol (Acetaminophen) In Stroke (Netherlands Trial Register, NTR2365); 
PRACTISE, Promoti ng Acute Thrombolysis in Ischemic StrokE (Internati onal Standard Randomised Controlled 
Trial Number (ISRCTN) registry ISRCTN20405426); PASS, Preventi ve Anti bioti cs in Stroke Study (ISRCTN registry 
ISRCTN66140176); Multi center Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in 
the Netherlands (ISRCTN registry ISRCTN10888758); SAHIT, Subarachnoid Hemorrhage Internati onal Trialists; IHAST, 
Intraoperati ve Hypothermia during Surgery for Intracranial Aneurysm (NCT00029133); MASH, magnesium sulfate in 
aneurysmal subarachnoid hemorrhage (ISRCTN68742385 and NTR50); Tirilazad, Tirilazad mesylate in pati ents with 
aneurysmal subarachnoid hemorrhage; CENTER-TBI, Collaborati ve European NeuroTrauma Eff ecti veness Research 
in Traumati c Brain Injury (European Union FP 7th Framework program; grant 602150).
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1Aims and outline of this thesis
The overall aim of this thesis is to identi fy pati ents at high risk for poor outcome aft er acute neurological 
diseases and to enhance knowledge on outcome variati on and stati sti cal effi  ciency of new outcome 
measures.
Specifi c research questi ons are: 
1.      What characteristi cs are associated with poor outcome aft er acute neurological diseases?
2.      What is the methodological quality of existi ng prognosti c models in acute neurological 
diseases?
3.      Do these models provide reliable predicti ons for pati ents in specifi c clinical setti  ngs? 
4.      What are the diff erences in clinical outcomes between pati ents with aSAH in a range of 
internati onal hospitals, and can these diff erences be explained by variati on in case-mix?
5.      What is the stati sti cal effi  ciency of new outcome measures for acute neurological diseases?
Part II of this thesis investi gates diff erent aspects of outcome predicti on in acute neurological diseases 
and answers research questi ons 1-3. Chapter 2 describes the associati on of early serum lactate 
and glucose levels with delayed cerebral ischemia and functi onal outcome aft er aSAH. Chapter 3
aims to identi fy prognosti c factors for disability and functi onal outcome early aft er ischemic stroke 
and describes the development of a prognosti c model to support effi  cient discharge planning. An 
overview of contemporary models for predicti on of functi onal outcome in pati ents with moderate and 
severe TBI is presented in Chapter 4. Related to this topic, Chapter 4.1 contains a lett er discussing 
the methodological quality of a newly developed model for long-term outcome aft er TBI. Chapter 5 
describes the external validati on of a prognosti c model for mortality aft er aSAH in a specifi c clinical 
setti  ng. Additi onally, the importance of external validati on and updati ng of a clinical predicti on model 
is shortly discussed in Chapter 5.1. Chapter 6 describes the performance and potenti al applicati ons of 
the most widely known prognosti c models for functi onal outcome aft er moderate and severe TBI in a 
contemporary European cohort.
Part III focuses on the analyses of clinical outcomes and answers research questi ons 4 and 5. In Chapter 
7, random eff ects modeling is used to assess the presence and magnitude of diff erences in functi onal 
outcome aft er aSAH between hospitals and countries in a large repository consisti ng of multi ple RCTs 
and observati onal studies. In ischemic stroke, a new outcome measure incorporati ng both functi onal 
outcome and quality of life has been proposed called the uti lity-weighted mRS. Chapter 8 describes 
a simulati on study evaluati ng the stati sti cal effi  ciency of this outcome measure. In response to a 
discussion initi ated by the founders of the UW-mRS, the importance of criti cally studying the stati sti cal 
effi  ciency and interpretability of a new outcome measure is emphasized in Chapter 8.1.
Part IV summarizes the main fi ndings of this thesis. Chapter 9 consists of a discussion of the results of 
previous chapters and provides recommendati ons for future studies and clinical practi ce.
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Abstract
Objecti ve: In criti cally ill pati ents, elevated blood lactate at admission is associated with poor outcome, 
but aft er aneurysmal subarachnoid hemorrhage, this has not been investi gated. We studied the 
associati on between early circulati ng lactate and glucose with delayed cerebral ischemia and poor 
outcome. Lactate and glucose were both studied, hypothesizing that both may be increased due to 
sympatheti c acti vati on aft er subarachnoid hemorrhage similar to criti cally ill pati ents.
Design: Retrospecti ve cohort study.
Setti  ng: ICUs of two academic hospitals in the Netherlands.
Pati ents: Pati ents with aneurysmal subarachnoid hemorrhage admitt ed to the ICU within 24 hours aft er 
the bleed surviving beyond 48 hours aft er ICU admission and who had at least one lactate measurement 
within 24 hours aft er admission.
Interventi ons: None.
Measurements and main results: In 285 pati ents, maximal lactate and glucose levels within the fi rst 24 
hours aft er admission were determined. Early lactate and glucose were related with delayed cerebral 
ischemia–related infarcti on and poor outcome (a modifi ed Rankin Scale score of 4, 5, or death at 3 mo). 
Delayed cerebral ischemia occurred in 84 pati ents (29%), and 106 pati ents (39%) had poor outcome. 
Multi variable analyses were performed with adjustment of established predictors for delayed cerebral 
ischemia and outcome: age, sex, World Federati on of Neurological Surgeons grade at admission and 
Hijdra sum scores. Early lactate and glucose were strongly related (Spearman ρ = 0.55; p <0.001). Lactate 
and glucose were both independently associated with delayed cerebral ischemia and poor outcome in 
multi variable analyses with either lactate or glucose as covariates. When both lactate and glucose were 
included, only glucose showed an independent associati on with delayed cerebral ischemia (odds rati o, 
1.14; 95% CI, 1.01–1.28) and only lactate showed an independent associati on with poor outcome (odds 
rati o, 1.42; 95% CI, 1.11–1.81).
Conclusions: Early lactate and glucose levels aft er aneurysmal subarachnoid hemorrhage are 
associated with delayed cerebral ischemia and poor outcome, suggesti ng that they may be considered 
in conjuncti on with other parameters for future prognosti c models.
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Introducti on
Subarachnoid hemorrhage (SAH) caused by a ruptured intracranial aneurysm is a devastati ng cause 
of stroke.1,2 Delayed cerebral ischemia (DCI) occurs in about one third of the pati ents and is the 
leading cause of disability and death in pati ents who survive the fi rst 24 hours.3 The exact underlying 
pathophysiological mechanisms of DCI remain obscure, but multi focal cerebral hypoperfusion is 
considered a fi nal common pathway.4,5 Prognosti c factors for DCI and functi onal outcome aft er SAH 
have been studied, but clinical predictors that are readily available at admission aft er aneurysmal SAH 
and are not subject to interobserver variability, such as scoring systems for the amount of subarachnoid 
blood on CT, are less well established.6-8 Easily obtainable biomarkers at admission may help early 
risk assessment of a complicated course and may provide further insights into pathophysiological 
mechanisms when such factors have a causal link to the outcome.9
 In criti cally ill pati ents, lactate levels are fi rmly associated with adverse outcomes.10,11 Although 
accumulati on of cerebral ti ssue lactate has been associated with poor neurological outcome in pati ents 
with SAH and other types of brain injury,12,13 the prognosti c value of blood lactate levels in SAH pati ents, 
which are more easily available than brain lactate, has not been investi gated. In contrast, several 
studies have shown that circulati ng glucose is related with outcome in SAH.14-16 Lactate and glucose 
are two key metabolites that are inti mately connected: fi rst, because glucose is a direct precursor of 
lactate; second, because various stress conditi ons can increase the circulati ng levels of both lactate and 
glucose.17 Indicators of sympatheti c stress have been associated with both increased lactate in criti cally 
ill pati ents18 and DCI and poor outcome aft er SAH.19-24
 The objecti ve of this study was to determine whether early increases in circulati ng lactate and 
glucose levels are associated with DCI and poor outcome aft er aneurysmal SAH.
Methods
Study design and populati on
In this retrospecti ve cohort study, we included adult pati ents with aneurysmal SAH admitt ed to the 
ICUs of two university hospitals in the Netherlands (University Medical Center Groningen and Erasmus 
Medical Center Rott erdam). Pati ents with SAH were identi fi ed by disease codes as registered in the 
Dutch Nati onal Intensive Care Evaluati on or the Internati onal Classifi cati on of Diseases code retrieved 
from the hospital’s pati ent registry, indicati ng SAH in the period between November 2006 and 
December 2011. Retrieval of subjects was crosschecked with the ICU Pati ent Data Management System. 
In the Nati onal Intensive Care Evaluati on registry database, pati ent characteristi cs, presence of chronic 
disease and comorbidity, reason for admission, disease, ICU course, and outcome characteristi cs are 
prospecti vely collected.25
 Inclusion criteria were 1) 18 years old or older, 2) admitt ed to ICU within 24 hours aft er the initi al 
bleed, 3) at least one lactate and glucose measurement available within 24 hours aft er admission, 4) 
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SAH, proven by CT or cerebrospinal ﬂ uid spectrophotometry, and 5) ruptured intracranial aneurysm as 
the presumed cause of spontaneous SAH, preferably demonstrated by digital subtracti on angiography 
or CT angiography.
 Pati ents who met any of the following criteria were not eligible 1) nonaneurysmal (e.g., 
perimesencephalic or traumati c) SAH, 2) death less than 48 hours aft er admission, 3) pregnancy, 4) no 
CT scan on admission available. Pati ents dying within 48 hours aft er admission were excluded because 
these pati ents frequently had dismal prognosis soon aft er admission and inclusion in analyses on DCI 
and outcome was not considered as relevant.
 During admission, included pati ents in both centers were treated according to a standardized 
protocol that consisted of absolute bed rest unti l aneurysm treatment, oral doses of nimodipine, 
cessati on of anti hypertensive medicati on, and IV administrati on of ﬂ uid with the aim of normovolemia.
 Because this study only involved the anonymized retrospecti ve evaluati on of clinical and 
laboratory parameters acquired during routi ne clinical care, informed consent was waived as approved 
by the insti tuti onal Medical Ethics Committ ee of both centers.
Data collecti on and outcomes
The method of aneurysm treatment (endovascular coiling, neurosurgical clipping, or no treatment) 
was collected from the electronic pati ent record at each hospital. The amount of blood at admission CT 
scans was evaluated using Hijdra sum scores, ranging from 0 to 30 for cisternal amount of blood and 
from 0 to 12 for ventricular amount of blood.26 Neurological conditi on at admission was assessed by the 
World Federati on of Neurological Surgeons (WFNS) grade.27 Poor neurological conditi on at admission 
was defi ned as WFNS grade 4 or 5. 
 All blood lactate and glucose levels within the fi rst 24 hours aft er admission were collected at 
both hospitals. If more than one measurement was performed during this period, the highest level was 
used for all analyses and was referred to as “maximum lactate” and “maximum glucose”.17
 The two main outcomes were DCI defi ned as a new hypodensity on CT not otherwise explained 
than by cerebral infarcti on due to DCI within 30 days aft er admission, according to earlier proposed 
defi niti ons,28 and poor outcome according to the modifi ed Rankin Scale (mRS).
 Day of DCI occurrence was the day of brain CT at which the new hypodensity was detected, or the 
day of clinical symptoms if this obviously occurred the day before a brain CT was performed. The mRS, 
measuring the degree of dependence or disability in daily acti viti es, was retrieved from the electronic 
pati ent record or from the primary care physician and assessed at 3 months aft er SAH. Poor outcome 
was defi ned as an mRS score of 4, 5, or death. 
Stati sti cal analysis
Pati ent baseline characteristi cs are presented as medians with interquarti le range (IQR) for conti nuous 
variables and frequencies (percentage) for categorical variables. Aft er testi ng for normality, conti nuous 
variables were analyzed using the unpaired Student t test (normal distributi on) or Mann-Whitney U 
test. Diff erences between categorical variables were assessed with a chi-square or Fisher exact test. 
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The associati on between maximum lactate and glucose levels within the fi rst 24 hours aft er SAH and 
DCI was assessed with logisti c regression analysis, adjusted for established predictors for DCI-related 
infarcti on (age, sex, clinical conditi on at admission [WFNS grade]), and the amount of subarachnoid 
blood (cisternal and ventricular Hijdra sum scores). Analysis was similarly performed for poor outcome. 
Ordinal variables (Hijdra sum scores) were dichotomized at their median, and clinical conditi on at 
admission was dichotomized in good (WFNS, 1–3) and poor (WFNS, 4–5) grades, whereas conti nuous 
variables were used unaltered for the analyses. Results are presented as odds rati os (ORs) with 
corresponding 95% CI. Receiver operati ng characteristi c curves with corresponding area under the 
curve (AUC) and diagnosti c test values (sensiti vity, specifi city, positi ve predicti ve value, and negati ve 
predicti ve values [PPV/NPV]) based on the median values of lactate and glucose in all included pati ents 
were calculated.
 Stati sti cal analyses were performed using SPSS (Stati sti cal Package for Social Sciences, version 22). 
A p value of less than 0.05 was considered stati sti cally signifi cant for all analyses.
Results
Study populati on
Aft er exclusion of 240 pati ents according to exclusion criteria, 285 pati ents were eligible for analyses 
(Figure 2.1). Pati ents with lacking lactate or glucose data (n = 112) more oft en (p < 0.001) had a lower 
WFNS (corresponding to bett er neurological status at admission), and less ventricular blood (p = 0.019), 
but did not signifi cantly diff er with regard to sex, age, or cisternal amount of blood on initi al CT. Data 
for DCI were complete for all 285 pati ents. Ten pati ents had nonretrievable data on mRS. DCI-related 
infarcti on aft er SAH occurred in 84 pati ents (29%), and 106 pati ents (39%) had poor outcome. Outcome 
was assessed at a mean of 3.3 months aft er admission (sd ± 1.0). Baseline demographic and clinical 
characteristi cs are presented in Table 2.1. The medians of the collected maximum values were 1.6 
mmol/L (IQR, 1.0–2.7) for lactate and 9.3 mmol/L (IQR, 8.0–11.1) for glucose. 
 The median number of measurements during the fi rst 24 hours aft er admission was 4 (IQR, 2–6) 
for lactate and 5 (IOR, 3–7) for glucose. The median ti me to occurrence of DCI was 6 days (IQR, 4–11 
d) aft er SAH. Pati ents who developed DCI had a signifi cantly higher maximum lactate level during the 
fi rst 24 hours aft er admission than pati ents without DCI (2.1 mmol/L [IQR, 1.2–3.1 mmol/L] vs 1.5 
mmol/L [IQR, 1.0–2.5 mmol/L]; p = 0.006) (Table 2.2). Pati ents who developed DCI also had a higher 
maximum glucose level (10.3 mmol/L [IQR, 8.6–11.8 mmol/L] vs 9.1 mmol/L [IQR, 7.8–10.7 mmol/L]; p 
= 0.002) (Table 2.2). Pati ents with poor outcome had a higher lactate level during the fi rst 24 hours aft er 
admission than pati ents with good outcome (2.2 mmol/L [IQR, 1.3–3.1 mmol/L] vs 1.4 mmol/L [IQR, 
0.9–2.3 mmol/L]; p < 0.001), which was also seen for glucose (10.4 mmol/L [IQR, 8.7–12.2 mmol/L] vs 
8.9 mmol/L [IQR, 7.6–10.1 mmol/L]; p < 0.001) (Table 2.2). A substanti al correlati on existed between 
lactate and glucose levels (Spearman ρ = 0.55; p < 0.001).
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Figure 2.1. Pati ent ﬂ ow of included subjects according to inclusion and exclusion criteria. 
DCI, infarcti on caused by delayed cerebral ischemia; mRS, modifi ed Rankin Scale; SAH, subarachnoid hemorrhage.
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Table 2.1. Baseline characteristi cs of study populati on (n = 285)
Baseline variable Value
(Median or %)
Age, median (IQR) 55 (47-65)
Female sex (%) 189 (66)
Poor clinical conditi on on admission (World Federati on of Neurological 
Surgeons grade ≥ 4) (%)
141 (49)
Aneurysm treatment
     Endovascular coiling
     Neurosurgical clipping
     None
154 (54)
80 (28)
51 (19)
Amount of subarachnoid blood, median (IQR)
     Cisternal Hijdra score
     Ventricular Hijdra score
21 (12.5-29.0)
3.0 (1.0-6.0)
Maximum lactatea within fi rst 24 hr aft er SAH, median (IQR) 1.6 (1.0-2.7)
Maximum glucosea within fi rst 24 hr aft er ASH, median (IQR) 9.3 (8.0-1.1)
IQR, interquarti le range; SAH, subarachnoid hemorrhage.
aUnit of measurement mmol/L.
Table 2.2. Medians of maximum lactate and glucose during the fi rst 24 hours aft er admission related to delayed 
cerebral ischemia and outcome
Variable
DCI
(n = 84; 29%)
No DCI
(n = 201; 71%) pa
Maximum lactate,b median (IQR) 2.1 (1.2-3.1) 1.5 (1.0-2.5) 0.006
Maximum glucose,b median (IQR) 10.3 (8.6-11.8) 9.1 (7.8-10.7) 0.002
Variable
Poor outcome
(n = 106; 39%)
Good outcome
(n = 169; 61%) pa
Maximum lactate, median (IQR) 2.2 (1.3-3.1) 1.4 (0.9-2.3) < 0.001
Maximum glucose, median (IQR) 10.4 (8.7-12.2) 8.9 (7.6-10.1) < 0.001
DCI, delayed cerebral ischemia-related infarcti on on cerebral CT; IQR, interquarti le range.
aMann-Whitney U test.
bUnit of measurement: mmol/L.
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Main outcomes
Maximum lactate during the fi rst 24 hours aft er admission was associated with higher risk for DCI (OR, 
1.33; 95% CI 1.12–1.58), which persisted aft er adjustment for known predictors (OR, 1.25; 95% CI, 
1.04–1.51). Higher lactate levels were also associated with a higher risk for poor outcome (OR, 1.52; 
95% CI, 1.25–1.85 and adjusted OR, 1.56; 95% CI, 1.25–1.94) (Table 2.3). The associati on between 
maximum glucose and DCI was signifi cant in both univariable and multi variable analyses (Table 2.3). 
In multi variable analysis with both glucose and lactate levels as independent variables in the model, 
only glucose was independently associated with DCI (OR, 1.14; 95% CI, 1.02–1.28). In contrast, in 
multi variable analysis with both glucose and lactate levels as independent variables in the model for 
outcome, only lactate was independently associated with poor outcome (OR, 1.42; 95% CI, 1.11–1.81) 
(Table 2.4). Age was associated with decreased risk of DCI (OR, 0.97; 95% CI, 0.96–0.99) and increased 
risk for poor outcome (OR, 1.04; 95% CI, 1.02–1.07).
 In a sensiti vity analysis using the mean values instead of maximum values of lactate and glucose, 
the associati ons found did not change (data not shown).
 The receiver-operati ng characteristi c curves and corresponding AUCs are shown in Appendix 2.A. 
AUCs of early lactate and glucose for DCI were 0.60 (p = 0.006) and 0.62 (p = 0.002), respecti vely, and 
for poor outcome 0.68 for both lactate and glucose (p < 0.001). For lactate (cutoff  value at the median) 
sensiti vity, specifi city, PPV and NPV were 58%, 44%, 36%, and 76% for DCI and 64%, 39%, 64%, and 73% 
for poor outcome; for glucose (cutoff  value at the median) sensiti vity, specifi city, PPV, and NPV were 
60%, 44%, 37%, and 77% for DCI and 64%, 38%, 64%, and 73% for poor outcome.
Table 2.3. Univariable and multi variable associati ons of either lactate or glucose during the fi rst 24 hours aft er 
admission with delayed cerebral ischemia and poor outcome
Odds rati o (95% CI)
Outcomes and characteristi cs Univariable Multi variablea
Delayed cerebral ischemia-related infarcti on on cerebral CT 
(n = 285)
Maximum lactate (per 1-mmol/L increase) 1.33 (1.12-1.58) 1.25 (1.04-1.51)
Maximum glucose (per 1-mmol/L increase) 1.19 (1.08-1.31) 1.17 (1.05-1.30)
Poor outcome (n = 275)
Maximum lactate (per 1-mmol/L increase) 1.52 (1.25-1.85) 1.56 (1.25-1.94)
Maximum glucose (per 1-mmol/L increase) 1.25 (1.13-1.39) 1.20 (1.07-1.34)
aAjusted for age, sex, clinical conditi on at admission, and amount of cisternal and ventricular blood.
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Table 2.4. Multi variable analyses with both glucose and lactate within 24 hours aft er admission as independent 
variables in the model: associati on with delayed cerebral ischemia or poor outcome
Outcomes and characteristi cs β
Associati ons, odds rati o
(95% CI) p
Delayed cerebral ischemia (n = 285)
    Age (yr) -0.036 0.97 (0.94-0.99) 0.003
    Sex 0.303 1.35 (0.75-2.42) 0.307
    WFNS grade 0.235 1.27 (0.69-2.31) 0.445
    Cisternal Hijdra score 0.337 1.40 (0.80-2.45) 0.236
    Ventricular Hijdra score -0.129 0.88 (0.49-1.57) 0.662
    Maximum lactate (per 1-mmol/L increase) 0.116 1.12 (0.91-1.38) 0.269
    Maximum glucose (per 1-mmol/L increase) 0.131 1.14 (1.01-1.28) 0.027
Outcome (n = 275)
    Age (yr) 0.042 1.04 (1.02-1.07) <0.001
    Sex 0.615 0.54 (0.30-0.99) 0.045
    WFNS grade 0.489 1.63 (0.90-2.65) 0.106
    Cisternal Hijdra score 0.584 1.79 (1.03-3.14) 0.041
    Ventricular Hijdra score 0.402 1.49 (0.84-2.65) 0.171
    Maximum lactate (per 1-mmol/L increase) 0.349 1.42 (1.11-1.81) 0.005
    Maximum glucose (per 1-mmol/L increase) 0.103 1.11 (0.98-1.26) 0.112
WFNS, World Federati on of Neurological Surgeons.
Discussion
The main fi ndings of our study are that maximum lactate and glucose levels early aft er aneurysmal 
SAH are associated with both an increased risk of DCI-related cerebral infarcti on and poor outcome. 
Lactate and glucose were strongly related. When lactate and glucose were simultaneously entered in 
the multi variable analysis, only lactate emerged as an independent predictor of poor outcome and only 
glucose emerged as an independent predictor of DCI. To our knowledge, we are the fi rst to report the 
associati on of blood lactate and poor outcome aft er SAH.
Relati onship with previous literature
Because catecholamine levels (epinephrine/norepinephrine) have a prognosti c value in pati ents with 
SAH,29 our fi ndings suggest that lactate and glucose levels may rise as a consequence of increased stress. 
Sympatheti c acti vati on in pati ents in the acute phase of SAH reﬂ ects the severity of SAH and is related 
to the development of DCI and consequently poor outcome.30 Excessive release of catecholamines has 
also been suggested to be the principal cause of neurogenic pulmonary edema and cardiac dysfuncti on 
aft er SAH.19-21 Cardiac dysfuncti on is a risk factor for poor clinical outcome aft er SAH, which is partly 
explained by a higher risk for DCI.23 Likewise, prolonged elevated heart rate due to sympatheti c 
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acti vati on is associated with major adverse cardiopulmonary events and higher risk of DCI aft er SAH, 
whereas lower heart rate has been associated with lower incidence of DCI.22,24 The excessive release 
of catecholamines in the acute phase of SAH might thus be a plausible explanati on for the increased 
lactate levels during the fi rst 24 hours aft er SAH with both DCI and poor neurological outcome.
 When lactate levels were considered in the analysis for the associati on between maximum glucose 
and outcome, glucose ceased to be independently associated with outcome. This interacti on between 
lactate and glucose has been shown previously in criti cally ill pati ents with adrenergic stress.17 In a recent 
prospecti ve randomized trial in 497 pati ents who received either placebo or dexamethasone before 
cardiac surgery, we have demonstrated that the glucocorti coid component of stress can also induce 
increases not only in glucose but also in lactate levels.31 Therefore, our fi ndings may complement the 
noti on that increased serum lactate levels may be related to sympatheti c acti vati on. However, for DCI, 
we found that lactate disappeared as a prognosti c factor when glucose was added as an independent 
variable in the analysis. A possible explanati on for this eff ect in DCI is the proposed mechanism of lactate 
being preferenti al fuel for the brain and therefore a glucose-sparing substrate, whereas our fi nding is 
also in line with previous studies reporti ng elevated glucose as a risk factor for cerebral ischemia, which 
may be mediated by increased corti sol.12,32
 Although we found elevated serum lactate levels only very slightly above the upper limit of the 
reference range in our pati ents with DCI and poor outcome (median, 2.1 and 2.2 mmol/L, respecti vely), 
this relati ve hyperlactatemia has previously been independently associated with an increased hospital 
mortality rate in criti cally ill pati ents.33,34 Therefore, our fi ndings are not unique in this respect.
Implicati ons of study ﬁ ndings
In SAH pati ents, predicti on of a complicated course remains diffi  cult. Established predictors of DCI and 
poor outcome are amount of subarachnoid blood, clinical conditi on at admission, age, and smoking.6,7
On the basis of results of our study, lactate and glucose are easily available parameters at admission 
that may be considered for future prognosti c models for poor outcome and DCI. It should be noted that 
in spite of the associati ons found neither lactate nor glucose values are currently suffi  cient to predict 
outcomes with certainty in any individual pati ent.
 An important questi on that warrants further evaluati on is why lactate or glucose levels measured 
in SAH pati ents during the fi rst 24 hours aft er admission can be used to predict development of DCI 
and poor outcome weeks or months later. This may eventually be helpful to improve individual decision 
making or even lactate-guided management in these pati ents.
 The proposed mechanism of stress-related increase of lactate levels might have therapeuti c 
consequences. As elevated heart rate and systolic blood pressure are seen during exposure to stress,35,36
treatment with β-blockers might help in reducing stress-related lactate levels. In previous research, 
the associati on between β-blockade and improved outcome aft er SAH has already been suggested.22,37
Importantly, lactate levels are easily available in contrast to catecholamine measurements, which 
renders lactate a much more feasible biomarker for sympatheti c acti vati on in routi ne clinical practi ce. 
We cannot enti rely exclude that elevated lactates in our pati ents partly originated from cerebral lactate 
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release into the systemic circulati on due to cerebral anerobic metabolism in an injured brain38 although 
the strong associati on with glucose may argue in favor of the sympatheti c hypothesis.
 A fi rst step for further research should be confi rmati on of our fi ndings in prospecti ve studies and, 
when confi rmed, assessment of the pathophysiological relati on of increased lactate with physiological 
derangements related to SAH, such as sympatheti c acti vati on, volume status, or cardiac functi on. In 
additi on, our fi ndings indicate that lactate may hold promise as a variable to be included in future 
predicti on models on outcome. For such predicti on models to become useful for every individual 
pati ent, they should have good discriminati ve ability with regard to clinical outcomes. It is important to 
note that multi ple external validati ons of these fi ndings are necessary before they should be applied 
outside the setti  ng of this study.
Strengths and weaknesses
An important strength of this study is, fi rst, the completeness of data concerning the DCI endpoint. 
Second, the inclusion of pati ents treated at two university hospitals in the Netherlands corroborates 
the external validity of our fi ndings for similar setti  ngs although external validity outside the academic 
setti  ng and in diff erent countries was not investi gated. Importantly, adding treatment center as an 
independent variable to the analyses (data not shown) did not change our results. Third, we used 
maximum lactate levels within the fi rst 24 hours aft er admission, of which the prognosti c value has 
been confi rmed in previous research in diff erent setti  ngs.17,39
 Several limitati ons of our study need to be considered. First, the possibiliti es for stati sti cal 
adjustment were limited to variables that were available in the database and we cannot exclude that 
important variables for adjustment were missing. Further evaluati on of the prognosti c value of lactate 
levels in SAH using additi onal prospecti vely collected parameters such as catecholamines is therefore 
required. Second, we only assessed CT-proven DCI. Mild forms of DCI with only clinical symptoms were 
not included in this study, which underesti mates the number of pati ents with DCI. However, DCI resulti ng 
in a cerebral infarcti on has been shown to be clinically more relevant as a clinical endpoint.28,40 Third, 
administrati on of epinephrine, dobutamine, and/or metf ormin was not taken into account as a potenti al 
confounder. The use of these drugs can aff ect lactate levels.41 Fourth, exclusion of a large number of 
pati ents without lactate measurements within the fi rst 24 hours aft er admission may have introduced 
bias. Because pati ents with lacking lactate and glucose measurements had bett er neurological status at 
admission and less ventricular blood, our results probably apply to pati ents who were in a somewhat 
worse conditi on at admission. Finally, our results only apply to pati ents who survive the fi rst 48 hours of 
admission and do not have dismal prognosis very early aft er admission.
Chapter 2
- 42 -
Conclusions
This study shows that maximum early lactate and glucose levels in the acute phase aft er aneurysmal 
SAH are associated with an increased risk for DCI-related infarcti on and poor outcome. These 
routi nely available laboratory measurements may help to improve identi fi cati on of pati ents at risk for 
complicati ons or poor outcome aft er SAH by studying them in conjuncti on with other parameters in 
future prognosti c models. Confi rmati on of the pathophysiological signifi cance of increased lactate 
and glucose in prospecti ve research seems warranted in SAH, especially with regard to sympatheti c 
acti vati on and its potenti al adverse consequences.
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Appendix
Appendix 2.A. ROC plots of early blood lactate and glucose values (test) versus (A and B) delayed cerebral ischemia 
or (C and D) poor outcome (“disease”).
ROC, receiver operati ng characteristi c; DCI, delayed cerebral ischemia; AUC, area under the receiver operati ng 
characteristi c curve; CI, confi dence interval 
Early circulati ng lactate and glucose levels aft er aSAH correlate with poor outcome and DCI
- 47 -
2
AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICA-
TION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HE-
MATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION 
ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES 
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POXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT 
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AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION 
LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRIL-
LATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMA-
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ON TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACH-
NOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE 
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Abstract
Introducti on: We aimed to develop and validate a prognosti c score for disability at discharge and 
functi onal outcome at three months in pati ents with acute ischemic stroke based on clinical informati on 
available on admission.
Pati ents and methods: The Dutch Stroke Score (DSS) was developed in 1227 pati ents with ischemic 
stroke included in the Paracetamol (Acetaminophen) In Stroke study. Predictors for Barthel Index (BI) 
at discharge (‘DSS-discharge’) and modifi ed Rankin Scale (mRS) at three months (‘DSS-3 months’) were 
identi fi ed in multi variable ordinal regression. The models were internally validated with bootstrapping 
techniques. The DSS-3 months was externally validated in the PRomoti ng ACute Thrombolysis in 
Ischemic StrokE study (1589 pati ents) and the Preventi ve Anti bioti cs in Stroke Study (2107 pati ents). 
Model performance was assessed in terms of discriminati on, expressed by the area under the receiver 
operati ng characteristi c curve (AUC), and calibrati on.
Results: At model development, the strongest predictors of Barthel Index at discharge were age per 
decade over 60 (odds rati o=1.55, 95% confi dence interval (CI) 1.41–1.68), Nati onal Insti tutes of Health 
Stroke Scale (odds rati o=1.24 per point, 95% CI 1.22–1.26) and diabetes (odds rati o=1.62, 95% CI 
1.32–1.91). The internally validated AUC was 0.76 (95% CI 0.75–0.79). The DSS-3 months, additi onally 
consisti ng of previous stroke and atrial fi brillati on, performed similarly at internal (AUC 0.75, 95% CI 
0.74–0.77) and external validati on (AUC 0.74 in PRomoti ng Acute Thrombolysis in Ischemic StrokE [95% 
CI 0.72–0.76] and 0.69 in Preventi ve Anti bioti cs in Stroke Study [95% CI 0.69–0.72]). Observed outcome 
was slightly bett er than predicted.
Discussion: The DSS had sati sfactory performance in predicti ng BI at discharge and mRS at three 
months in ischemic stroke pati ents.
Conclusion: If further validated, the DSS may contribute to effi  cient stroke unit discharge planning 
alongside pati ents’ contextual factors and therapeuti c needs.
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Introducti on
In 2015, over 26,000 pati ents were admitt ed to hospitals because of ischemic stroke in the Netherlands.1
Most of these pati ents need rehabilitati on to achieve bett er recovery in the fi rst months aft er stroke 
and reduce long-term disability. In the Netherlands, around 8% of all stroke pati ents is referred to an 
inpati ent rehabilitati on centre.2 Typically, these pati ents are too disabled to be discharged home, but 
they are cogniti vely and physically fi t enough to parti cipate in intensive therapy sessions and have 
suffi  cient social support to return home within two to four months. Alternati vely, pati ents may be 
referred to skilled nursing and geriatric rehabilitati on faciliti es. These pati ents are oft en elderly, suff er 
from comorbiditi es and have a poorer functi onal prognosis. Sti ll, the majority of stroke pati ents (60%) is 
discharged home, mostly with community rehabilitati on.2 Discharge planning may depend on multi ple 
factors such as comorbiditi es and contextual factors (e.g. the presence of a healthy caregiver and 
premorbid level of functi oning). The importance of the contextual factors increases as the functi onal 
prognosis of the stroke decreases. Therefore, early predicti on of functi onal outcome may contribute to 
effi  cient discharge planning. 
 The most widely used functi onal outcome measure in acute stroke is the modifi ed Rankin Scale 
(mRS). The mRS measures the degree of disability in daily acti viti es. It is scored on an ordinal scale ranging 
from 0 (no symptoms) to 6 (death).3 Another frequently used outcome measure in rehabilitati on is the 
Barthel Index (BI), measuring performance in 10 basic acti viti es of daily living (ADL).4 BI is associated 
with durati on of hospital stay.5
 Previous studies identi fi ed many prognosti c factors for outcome (measured by BI or mRS) 
aft er acute stroke.6 Prognosti c factors can be combined in a model to identi fy pati ents at risk for 
poor outcome.7 Although several prognosti c models exist to predict outcome in stroke, very few are 
adequately validated for use in daily clinical practi ce.8 We aimed to develop and validate a prognosti c 
score for disability (BI) at discharge and functi onal outcome (mRS) at three months aft er acute ischemic 
stroke based on clinical informati on available on admission.
Methods
Derivati on cohort
Data from the Paracetamol (Acetaminophen) In Stroke (PAIS) study were used for model development.9
PAIS was a multi centre, randomised placebo-controlled phase III trial assessing the eff ect of high dose 
paracetamol on the functi onal outcome in pati ents with acute stroke. In short, pati ents were eligible 
for inclusion if they were diagnosed with acute ischemic stroke or intracerebral hemorrhage, had a 
prestroke mRS<2 and study treatment could be started within 12 h aft er onset of symptoms. We used 
data of all pati ents with ischemic stroke included in PAIS.
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Outcome measures
We used the BI at discharge as the outcome measure for short-term disability. The BI is an ordinal scale 
used to measure performance in ADL. The scale ranges from 0 to 20, with higher scores indicati ng a 
greater likelihood of being able to carry out ADL independently.4 In PAIS, the BI was measured at 14 
days aft er enrolment or at hospital discharge if this occurred earlier (70% of the pati ents stayed for 3 
days).9 However, choice of the opti mal rehabilitati on route mostly depends on more than just discharge 
outcome.10 Therefore, we additi onally evaluated functi onal outcome at three months with the mRS. 
The mRS is an ordinal scale used to measure the degree of disability in daily acti viti es and ranges from 0 
(no symptoms) to 6, with mRS 5 indicati ng severe disability and mRS 6 indicati ng death.3
Model development
To identi fy predictors of disability and functi onal outcome, we selected variables that were clinically 
relevant and/or previously reported to predict outcome aft er stroke in the literature.6 These variables 
were sex, age, Nati onal Insti tutes of Health Stroke Scale (NIHSS) score, diabetes, previous stroke, atrial 
fi brillati on and hypertension. All predictors were entered into multi variable ordinal regression with 
backward selecti on with p<0.2 for inclusion, separately for BI at discharge and mRS at three months. 
The fi nal associati ons were presented as a set of odds rati os (ORs) and 95% confi dence intervals 
(CIs) to indicate the individual predictor eff ects. ORs from an ordinal logisti c regression model can be 
interpreted as a common OR for shift ing over the full outcome range.11
 The resulti ng models, the Dutch Stroke Score (DSS) for BI at discharge (‘DSS-discharge’) and mRS 
at three months (‘DSS-3 months’), were internally validated using standard bootstrapping procedures to 
avoid an opti misti c esti mate of the model performance, which oft en occurs when model performance 
is only evaluated directly in the derivati on cohort (apparent validati on). In the bootstrap procedure, 
random samples are drawn from the original sample, each with the same number of pati ents as the 
original sample. In each of these samples the modeling steps are repeated and the resulti ng models 
are subsequently evaluated on the original sample. The mean model performance in all 500 bootstrap 
models represents the expected performance of the models in future, similar pati ents.12
Validati on cohorts
For external validati on, we used data from the PRomoti ng ACute Thrombolysis in Ischemic StrokE 
(PRACTISE) study and Preventi ve Anti bioti cs in Stroke Study (PASS). PRACTISE was a clusterrandomised 
trial designed to evaluate an implementati on strategy to increase the proporti on of pati ents treated 
with intravenous thrombolysis.13 PRACTISE registered adult pati ents with acute stroke admitt ed within 
24 h aft er onset of symptoms and had no age restricti ons. We used data from ischemic stroke pati ents 
admitt ed within 4 h as in these pati ents detailed clinical data were available. 
  PASS was a multi centre, randomised, open-label trial designed to assess whether or not preventi ve 
anti microbial therapy with ceft riaxone improves functi onal outcome in pati ents with acute stroke.14
PASS included adult pati ents with clinical symptoms of a stroke (ischemic or hemorrhagic) admitt ed 
within 24 h aft er symptom onset. We used data of all pati ents with ischemic stroke included in PASS.
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Model validati on
The validity of the DSS-3 months was assessed in terms of discriminati on and calibrati on. The external 
validati on cohorts did not have data on BI at discharge. Discriminati on refers to how well the model 
disti nguishes between those who have good outcome (mRS 0–2) vs. those who have poor outcome 
(mRS 3–6) at three months. Discriminati on was assessed by calculati ng the ordinal area under the 
curve (AUC) of the receiver operati ng characteristi c (ROC) curve.15 The AUC ranges from 0.5 for non-
informati ve models to 1.0 for perfect models.12 Calibrati on indicates the agreement between predicted 
and observed probabiliti es. Calibrati on was assessed graphically in a calibrati on graph, and expressed 
as the calibrati on slope and an intercept. The calibrati on slope is ideally equal to 1 and describes the 
eff ect of the predictors in the validati on cohort versus in the derivati on cohort. The intercept indicates 
whether predicti ons are systemati cally too high or too low, and should ideally be zero.12
 At external validati on, the discriminati ve power of a model may be inﬂ uenced by diff erences in 
predictor eff ects, but also by diff erences in distributi on of pati ent characteristi cs (case-mix) between 
the derivati on and validati on cohort.16 In a more homogeneous populati on, discriminati on between 
pati ents with good vs. poor outcome is more diffi  cult than in a heterogeneous populati on. To take 
this into account, we calculated the case-mix-corrected AUC. The case-mix-corrected AUC reﬂ ects the 
discriminati ve power of a model, assuming that the regression coeffi  cients are correct for the validati on 
populati on. It was calculated by simulati ng new outcome values for all pati ents in the validati on dataset, 
based on the predicted risks for each pati ent.16
 Aft er external validati on, we fi tt ed the DSS-3 months on the combined data of all three trials 
to get the best esti mates for the regression coeffi  cients.17 The DSS-discharge and DSS-3 months were 
presented in a score chart, as a score plot simplifi ed to fi ve BI and mRS outcome classes (based on 
clinically relevant cutoff s), and as formulas to calculate the predicted outcomes.
 All stati sti cal analyses were performed using R soft ware, version 3.3.2 (R foundati on for stati sti cal 
computi ng, Vienna, Austria). The calibrati on plots were created with an updated version of the val.prob
functi on (rms library in R). Missing values in the development and validati on cohorts were stati sti cally 
imputed using a multi ple imputati on method exploiti ng correlati ons between predictor variables and 
between predictor variables and the outcome variables (mice functi on in R). Complete case analyses 
were done for comparison with the imputed analyses.
Results
Study populati on
For model development, we included 1227 pati ents with ischemic stroke from the PAIS trial. Missing 
data on hypertension (3.1%) were stati sti cally imputed; all other baseline variables and outcomes were 
complete. For the external validati on of the model predicti ng mRS at three months, we included, 1657 
ischemic stroke pati ents from the PRACTISE study. Sixty-eight pati ents with missing data on mRS at 
three months were excluded, resulti ng in an external validati on sample of 1589 pati ents. Other missing 
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data (0.6%) were stati sti cally imputed. Additi onally, we externally validated the model for functi onal 
outcome at three months in, 2125 ischemic stroke pati ents from the PASS study. Eighteen pati ents with 
missing data on the mRS at three months were excluded, resulti ng in an external validati on sample of 
2107 pati ents. Other missing data (0.4%) were stati sti cally imputed.
 In all three studies, most pati ents (55–58%) were male and the mean age was around 70 years 
(Table 3.1). The three populati ons are comparable concerning baseline characteristi cs, except for ti me 
from stroke onset to inclusion (PAIS and PRACTISE had a smaller ti me window compared to PASS), 
previous stroke (33% in PASS vs. 20% in the other trials) and diabetes (20% in PASS vs. 15–17% in PAIS 
and PRACTISE). The number of pati ents with poor outcome (mRS 3–6) was lower in PASS compared to 
PAIS and PRACTISE (Appendix 3.A). In PAIS, this is reﬂ ected in the substanti al proporti on of pati ents with 
favorable outcome on the BI at discharge (Appendix 3.A).
Table 3.1. Baseline characteristi cs of the included pati ents from the PAIS, PRACTISE and PASS studies
PAIS (n = 1227) PRACTISE (n = 1589) PASS (n = 2107)
Male sex 675 (55%) 872 (55%) 1212 (58%)
Age in years (mean, sd) 70.1 (13.4) 70.6 (13.4) 71.9 (12.5)
Time from onset to CT in hours 
(median, IQR)
3.0 (1.8-5.9) 2.0 (1.4-3.0) NA
NIHSS (median, IQR) 6.0 (3.0-11.0) 5.0 (3.0-12.0) 5.0 (3.0-9.0)
Diabetes mellitus 181 (15%) 266 (17%) 423 (20%)
Previous ischemic stroke 245 (20%) 318 (20%) 698 (33%)
Atrial fi brillati on 190 (16%) 290 (18%) 326 (16%)
Hypertension 601 (49%)a 811 (51%) 1154 (55%)
Current smoking 380 (31%) 374 (24%) 524 (25%)
NIHSS, Nati onal Insti tutes of Health Stroke Scale; IQR, interquarti le range; NA, not available; PRACTISE, Promoti ng Acute 
Thrombolysis in Ischemic StrokE; PASS, Preventi ve Anti bioti cs in Stroke Study; PAIS, Paracetamol (Acetaminophen) In Stroke.
a38 missings.
Model development in PAIS
The relati on between age as a conti nuous variable and the log odds of disability (BI) in the development 
data was non-linear and intensifi ed when age was above 60 years (Appendix 3.B). Because of this non-
linearity, we considered diff erent age eff ects for pati ents older vs. younger than 60 years. 
 Of the variables considered, age per decade above 60, NIHSS per point and diabetes were the 
strongest predictors of BI at discharge, both in univariable (data not shown) and multi variable analysis 
(Table 3.2) and were included in the model for disability at discharge. The internally validated ordinal 
AUC was 0.76 (95%CI 0.75–0.79). Age per decade above 60, NIHSS per point, diabetes, previous stroke 
and atrial fi brillati on were the strongest predictors of mRS at three months, both in univariable (data 
not shown) and multi variable analysis (Table 3.2) and were included in the fi nal model for mRS at three 
months. The internally validated ordinal AUC was 0.75 (95%CI 0.74–0.77).
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External validati on in PRACTISE and PASS
In PRACTISE, the DSS-3 months had an ordinal AUC of 0.74 and an AUC for the cutoff  mRS ≥ 3 of 
0.81 (95% CI 0.81–0.84) (Appendix 3.C). The model predicted 49.4% poor outcome (mRS ≥ 3); whereas 
the observed probability of poor functi onal outcome was 45.2%. The calibrati on slope was 1.022 and 
the intercept was -0.238, indicati ng that the model’s predicti ons of poor outcome were systemati cally 
higher than the observed probability of poor outcome (Figure 3.1A).
 In PASS, the DSS-3 months had an ordinal AUC of 0.69 and an AUC for the cutoff  mRS ≥ 3 of 0.81 
(95% CI 0.81–0.83) (Appendix 3.C). The predicted probability of poor outcome was 48.6%, compared to 
an observed probability of poor functi onal outcome of 38.5%. The calibrati on slope was 1.058 and the 
intercept was -0.555, indicati ng that the model’s predicti ons of poor outcome were systemati cally too 
high (Figure 3.1B). This overesti mati on was higher than in PRACTISE.
The internal and external validati on in the complete cases (PAIS n=1227, PRACTISE n=1581, PASS 
n=2098) yielded similar results (not shown).
 The lower discriminati ve ability of the DSS-3 months in the external validati on cohorts was largely 
explained by a less heterogeneous case-mix compared to the development cohort. This is illustrated 
by small diff erences between the development AUC and casemix-corrected AUCs (Appendix 3.C). The 
lower discriminati ve ability in PASS compared to PAIS and PRACTISE was due to both case-mix and 
diff erences in predictor eff ects (relati vely large diff erence between AUC in external validati on and case-
mix-corrected AUC in PASS).
 The fi nal DSS-3 months was developed on the combined data of all three cohorts (n=4923). 
The model had an ordinal AUC of 0.73 and an AUC for the cutoff  mRS ≥ 3 of 0.81 (95% CI 0.81–0.83) 
(Appendix 3.C).
 The fi nal models are presented as the DSS score chart (Table 3.3, and simplifi ed to fi ve outcome 
classes in Figure 3.2), with higher scores indicati ng worse outcome. For example, a pati ent of 70 years 
with an NIHSS of 13 and a history of previous stroke and diabetes has a DSS-discharge score of 8 and a 
predicted probability of 17% for BI 19–20 at discharge and a DSS-3 months score of 13 and a predicted 
probability of 76% for mRS ≥ 3 at three months (Appendix 3.D).
The Dutch Stroke Score for predicti ng disability and functi onal outcome aft er ischemic stroke
- 57 -
3
Table 3.3. DSS score chart based on ordinal analysis of the BI and mRS. A higher score indicates a worse outcome 
(lower predicted BI and higher mRS)
Variable Points for predicti ng BI at discharge Points for predicti ng  mRS score at 3 months
Age
    <60
    60-70
    70-80
    80-90
    90+
0
1
2
3
4
0
2
4
6
8
NIHSS
    0
    1-4
    5-15
    16-20
    21-42
0
1
5
10
15
0
1
5
10
15
Diabetes 1 2
Previous stroke - 2
Atrial fi brillati on - 1
Total 0-20 0-28
BI, Barthel Index; mRS, modifi ed Rankin Scale; NIHSS, Nati onal Insti tutes of Health Stroke Scale; DSS, Dutch Stroke 
Score.
Figure 3.1. Calibrati on plots of the DSS-3 months in (A) PRACTISE and (B) PASS.
DSS, Dutch Stroke Score; PRACTISE, PRomoti ng ACute Thrombolysis in Ischemic StrokE; PASS, Preventi ve Anti bioti cs 
in Stroke Study. 
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Figure 3.2. DSS score charts simplifi ed to fi ve outcome classes of the (A) BI at discharge and (B) mRS at three months. 
Legend of (A): Dark red=0, Red=1–9, Orange=10–14, Yellow=15–18, Green=19–20 and legend of (B): Dark red=6, 
Red=4–5, Orange=3, Yellow=2, Green=0–1.
DSS, Dutch Stroke Score; BI, Barthel Index; mRS, modifi ed Rankin Scale. 
Discussion
We propose the DSS, consisti ng of two simple predicti on models for disability (BI) at discharge and 
functi onal outcome (mRS) at three months aft er acute ischemic stroke based on clinical informati on 
available on admission. The DSS-discharge consists of three variables: age per decade above 60 years, 
NIHSS per point and diabetes. The DSS-3 months additi onally includes previous stroke and atrial 
fi brillati on. Both models showed reasonable performance in internal and external validati on.
Relati on with previous literature
Previously, several models to esti mate the probability of unfavourable outcome aft er stroke have been 
developed, with a high variability in endpoints, ti me between symptom onset and assessment of the 
variables, and pati ent populati ons. Literature reviews have shown that many of these predicti on models 
have methodological shortcomings that limit their use for early discharge planning. For instance, 
assessment of predictors multi ple days aft er stroke onset18,19 and the use of a dichotomous outcome 
such as mortality.20-26 In additi on, previously developed models were not validated, and hence their use 
in clinical practi ce is limited.8,27
 One tool has been developed specifi cally to predict unfavorable discharge desti nati on from the 
hospital stroke unit. Functi onal disability, poor sitti  ng balance, depression, cogniti ve disability and old age 
were identi fi ed as predictors of poor discharge outcome.10 However, this model was only applicable for 
decision-making at 7–10 days post stroke. Moreover, this study had some methodological shortcomings, 
including dichotomisati on of predictors, a small sample size and dichotomisati on of the outcome.
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Implicati ons of study ﬁ ndings
Predicti on models in acute stroke are useful to inform pati ents and relati ves on prognosis and identi fy 
pati ents at risk for poor outcome before treatment decisions are made.7 On populati on level, predicti on 
models can be used for adjustment when comparing quality of care for stroke pati ents across insti tuti ons. 
Additi onally, predicti on models could be relevant in design and analysis of randomised controlled 
trials, e.g. for covariate adjustment.28,29 Further, predicti on of functi onal outcome may contribute to 
discharge planning. If functi onal outcome is expected to be poor, contextual factors, such as housing 
circumstances, fi nancial problems and whether or not a pati ent is living alone, become more important.
 We developed the DSS to be used by stroke unit nurses during the fi rst day aft er admission. In 
clinical practi ce, the NIHSS is mostly scored shortly aft er the administrati on of alteplase. Therefore, we 
did not add treatment with alteplase as a covariable to our analysis. Recently, intra-arterial treatment 
administered within six hours aft er stroke onset has been shown benefi cial in pati ents with a proximal 
intracranial arterial occlusion.30 However, the majority (90%) of acutely admitt ed ischemic stroke pati ents 
sti ll receives intravenous alteplase as only treatment. Therefore, the DSS is potenti ally suitable for use 
in present neurovascular practi ce. To facilitate discharge planning in endovascular-treated pati ents, a 
next step could be to update the models by including treatment (thrombolysis, thrombectomy or both) 
as a predictor. Moreover, no imaging or laboratory tests are required for clinicians to be able to use 
the DSS, which allows bedside use of the models early aft er admission. The DSS score chart can be 
easily incorporated in clinical practi ce since it consists of a few readily obtainable clinical variables at 
admission. Stroke unit nurses will be able to score all variables, including the NIHSS, provided that they 
are well trained and certi fi ed. 
 The DSS-discharge sti ll needs to be externally validated to give reliable esti mates on model 
performance and study generalisability.
 At external validati on, the discriminati ve ability of the DSS-3 months was generally lower than 
in the development sample. Discriminati on was bett er in PRACTISE compared to PASS, both for the 
ordinal analysis of the mRS and for three diff erent cutoff s of the mRS (Appendix 3.C). These higher 
AUCs were partly explained by diff erences in case-mix, as reﬂ ected in the case-mix-corrected AUCs. 
In additi on, the predictor eff ects were slightly stronger in PRACTISE than in PASS. These diff erences in 
regression coeffi  cients were most evident for diabetes and previous stroke, and could be explained by 
discrepancies in predictor defi niti ons. For instance, in PASS, previous stroke comprised both Transient 
Ischemic Att ack (TIA) and ischemic stroke, while in PRACTISE only ischemic stroke was considered. This 
implicates that the DSS-3 months is valid, but the defi niti ons of the predictors should be identi cal to 
those in the development cohort.
 The reasonable discriminati ve ability of the DSS-3 months was associated with an overall 
overesti mati on of the probability of poor outcome. This overesti mati on was higher in PASS compared 
to PRACTISE, which might be due to the diff erence in outcome distributi on between these cohorts 
(lower proporti on of pati ents with poor outcome in PASS). This diff erence is most likely caused by the 
exclusion of pati ents with imminent death and neurological deteriorati on in PASS. The overesti mati on 
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of the probability of poor outcome implies that the DSS-3 months needs updati ng (e.g. adjustment of 
the intercept [recalibrati on]) before it is suitable for individualised predicti ons in clinical practi ce.
Strengths and limitati ons
Strengths of this study are the internal and (parti al) external validati on of the DSS, and the large size of the 
development and two independent validati on cohorts. Even though many models have been developed 
for predicti on of outcome aft er stroke, the large sample size and the aim of contributi ng to effi  cient 
discharge planning makes that our study has added value compared to already existi ng evidence. Also, 
we predicted outcomes over the whole range from no symptoms to death. Furthermore, we used two 
well-known and widely implemented outcome measures for functi onal outcome in our models. The 
BI is a reliable and valid scale to measure ADL.31 Since discharge desti nati on (parti ally) depends on the 
pati ent’s ability to carry out ADL, the BI is a suitable outcome for our model. Additi onally, we selected 
potenti al predictors based on the literature and clinical knowledge. This is preferred over selecti on 
based on the data as the latt er may result in overfi tti  ng (model perfect for the development data but 
performing poor in new pati ents.12 The robustness of our approach is represented in the reasonable 
performance of the models in internal and external validati on.
 Several limitati ons of our study need to be considered. We included only hospitalised pati ents with 
an ischemic stroke in our analysis. Consequently, our chart does not apply for pati ents with intracerebral 
hemorrhage. Further, the development and validati on cohorts originated from randomised controlled 
trials conducted in the Netherlands, potenti ally limiti ng the generalisability of the chart. To evaluate 
the performance of the models beyond the Dutch setti  ng, external validati on in observati onal data 
from setti  ngs with a diff erent healthcare system confi gurati on is necessary. However, the Dutch stroke 
populati on is representati ve for stroke populati ons in developed countries. Moreover, our external 
validati on cohorts consist of unselected, prospecti vely included pati ents, originati ng from hospitals 
representati ve in size, geographic distributi on and frequency of stroke treatment procedures. We were 
able to externally validate the DSS-3 months, but not the DSS-discharge as no data on BI at discharge 
were available. Also, discharge policy is variable between and within diff erent healthcare systems, 
which makes it a diffi  cult outcome for predicti on purposes. However, these diff erences in discharge 
ti ming resemble the variati on in clinical practi ce. Additi onally, in the fi eld of rehabilitati on, predicti ng 
functi onal outcome in terms of the mRS has limitati ons. Important aspects that can contribute to the 
level of disability and the need for rehabilitati on (e.g. pain, communicati on, cogniti on) are not enti rely 
covered by the mRS.32 However, the mRS is a widely used outcome measure in stroke management.
 The prognosti c performance of the DSS aft er validati on could be classifi ed as sati sfactory. This 
does not disqualify the usefulness of the models for clinical practi ce, because in general, multi variable 
predicti on models are able to incorporate and accurately weigh more factors than a human mind.33
Nevertheless, the results should always be regarded as a mere recommendati on and should be placed 
in the context of the personal circumstances, needs and wishes of the pati ent. Other factors that are 
worth considering when planning pati ents’ discharge are the presence of social support, cogniti ve 
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disability, the therapeuti c needs of the pati ent and the expected future residence desti nati on (e.g. 
home or nursing facility). 
Conclusion
The DSS has sati sfactory performance in predicti ng BI at discharge and mRS at three months in ischemic 
stroke pati ents. If further validated, the DSS may contribute to effi  cient stroke unit discharge planning 
alongside pati ents’ contextual factors (e.g. social support, housing circumstances and cogniti ve 
disability) and therapeuti c needs.
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Appendix
Appendix 3.A. Outcome distributi on of (A) the BI at discharge in PAIS and (B) the mRS at three months in PAIS, 
PRACTISE and PASS.
Appendix 3.B. Non-linear relati on between age and the log odds of higher BI at discharge aft er acute ischemic stroke 
in PAIS. 
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Appendix 3.D. Details of the (A) DSS-discharge and (B) DSS-3 months. 
The probability of each of the outcome categories is calculated according to the logisti c formula: 1/(1 + exp-LP), in 
which LP stands for linear predictor. 
A. To calculate the probability P on each of the fi ve BI categories: 
Slope Barthel for age<60 = nihss*-0.213 + 6*-0.468 + diabetes*-0.496 
Slope Barthel for age>60 = nihss*-0.213 + age per decade*-0.468 + diabetes*-0.496 
LP(Barthel 19-20) = Slope + 4.91 
LP(Barthel 15-18) = Slope + 5.45 - Slope + 4.91 
LP(Barthel 10-14) = Slope + 6.14 - Slope + 5.45 
LP(Barthel 1-9) = Slope + 7.66 - Slope + 6.14 
LP(Barthel 0) = 1 - Slope + 7.66 
B. To calculate the probability P on each of the fi ve mRS categories: 
Slope Rankin for age<60 = nihss*0.182 + 6*0.495 + diabetes*0.410 + previous stroke*0.249 + atrial fi brillati on*0.212 
Slope Rankin for age>60 = nihss*0.182 + age per decade*0.495 + diabetes*0.410 + previous stroke*0.249 + atrial 
fi brillati on*0.212 
LP(Rankin 6) = Slope + -4.68 
LP(Rankin 4-5) = Slope + -3.76 - Slope + -4.68 
LP(Rankin 3) = Slope + -2.93 - Slope + -3.76 
LP(Rankin 2) = Slope + -1.89 - Slope + -2.93 
LP(Rankin 0-1) = 1 - Slope + -1.89
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AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICA-
TION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HE-
MATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION 
ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES 
PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HY-
POXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT 
OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE 
TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT 
CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPI-
DURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM 
LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS 
DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL 
INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE 
AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION 
LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRIL-
LATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMA-
TIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD 
ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLO-
GICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR 
EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOG-
LOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE 
HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE 
ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSI-
ON TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACH-
NOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE 
NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION 
MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA 
HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM 
SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS 
STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA 
HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT 
OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE 
TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT 
CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPI-
DURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM 
LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS 
DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL 
INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE 
AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION 
LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRIL-
LATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMA-
TIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD 
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Abstract
Outcome prognosti cati on in traumati c brain injury (TBI) is important but challenging due to 
heterogeneity of the disease. The aim of this systemati c review is to present the current state-of-the-
art on prognosti c models for outcome aft er moderate and severe TBI and evidence on their validity. 
We searched for studies reporti ng on the development, validati on or extension of prognosti c models 
for functi onal outcome aft er TBI with Glasgow Coma Scale (GCS) ≤12 published between 2006-2018. 
Studies with pati ents aged ≥14 years and evaluati ng a multi variable prognosti c model based on 
admission characteristi cs were included. Model discriminati on was expressed with the area under the 
receiver operati ng characteristi c curve (AUC), and model calibrati on with calibrati on slope and intercept. 
We included 58 studies describing 67 diff erent prognosti c models, comprising the development of 42 
models, 149 external validati ons of 31 models and 12 model extensions. The most common predictors 
were GCS (motor) score (n=55), age (n=54) and pupillary reacti vity (n=48). Model discriminati on varied 
substanti ally between studies. The Internati onal Mission for Prognosis and Analysis of Clinical Trials 
(IMPACT) and Corti coid Randomisati on Aft er Signifi cant Head injury (CRASH) models were developed on 
the largest cohorts (8,509 and 10,008 pati ents, respecti vely) and were most oft en externally validated 
(n=91), yielding AUCs ranging between 0.65-0.90 and 0.66-1.00, respecti vely. Model calibrati on was 
reported with a calibrati on intercept and slope for 7 models in 53 validati ons, and was highly variable. In 
conclusion, the discriminatory validity of the IMPACT and CRASH prognosti c models is supported across 
a range of setti  ngs. The variati on in calibrati on, reﬂ ecti ng heterogeneity in reliability of predicti ons, 
moti vates conti nuous validati on and updati ng if clinical implementati on is pursued.
PROSPERO registry number: CRD42016052100
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Introducti on
Traumati c brain injury (TBI) is a major cause of injury-related death and disability.1 It is a disease with a 
considerable economic impact, oft en aff ecti ng the working populati on.2 Pati ents with TBI show substanti al 
variati on in injury mechanism, pathology, clinical severity and prognosis. Due to the heterogeneity of 
the disease, predicti on of functi onal outcome aft er TBI is challenging. Outcome prognosti cati on is 
important to assist clinicians in providing reliable informati on to pati ents and relati ves, to guide clinical 
management and trial design, and to give insight in quality of care by comparing observed and expected 
outcomes.3 Many prognosti c models for functi onal outcome aft er moderate and severe TBI have been 
developed and validated, but their methodological quality was described as poor in reviews performed 
in 2006 and 2008.4, 5
  Over the past decade, new prognosti c models for moderate and severe TBI have been developed 
and existi ng models have been externally validated and extended in new datasets. The questi on 
remains whether the quality of the currently available models justi fi es further implementati on in 
clinical practi ce. For instance, when informing a relati ve of a pati ent with severe TBI in the intensive care 
unit on prognosis, the physician might want to use a prognosti c model to communicate the chance of 
recovery within the next six months. But can the use of this prognosti c model be recommended in this 
setti  ng and for this pati ent? The aim of this systemati c review is to present the current state-of-the-art 
on prognosti c models for outcome aft er moderate and severe TBI and to review their performance at 
internal and external validati on.
Methods
This systemati c review was conducted and reported in line with the Preferred Reporti ng Items for 
Systemati c Reviews and Meta-Analyses (PRISMA) Statement.6 The protocol of this systemati c review has 
been registered on PROSPERO (registrati on number 2016: CRD42016052100) and can be accessed at: 
htt p://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016052100.
Literature search
We performed a literature search in Embase, Medline Ovid, Web of Science, Cochrane Central, PsychInfo 
Ovid and Google Scholar to identi fy arti cles published between January 1st 2006 and November 12th 
2018 reporti ng on the development, validati on or extension of models predicti ng outcome aft er 
moderate and severe TBI. We used search terms on the following topics: brain or head injury, predicti on 
or prognosis, model, and mortality/survival or recovery (Appendix 4.A). Studies evaluati ng prognosti c 
models in moderate and severe TBI published before 2006 were already incorporated in previous 
systemati c reviews.4,5 For comparison of model performance at internal versus external validati on, 
the development studies of models published before 2006 reporti ng a performance measure were 
retrieved manually.7-12
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Eligibility criteria
Studies were eligible if they reported on the development, validati on and/or extension of multi variable 
prognosti c models for functi onal outcome in pati ents aged ≥ 14 years with moderate and severe TBI. 
We included original arti cles that were published in English language between 2006 and 2018. Studies 
that enrolled both adults and children were included when >80% of the subjects was adult or when 
adults and children were analyzed and reported separately. Moderate or severe TBI was defi ned as a 
Glasgow Coma Scale (GCS) score ≤ 12.13 When a study only reported inclusion of pati ents with moderate 
or severe TBI without defi ning this in terms of GCS, it was assumed that moderate referred to GCS 9-12 
and severe referred to GCS 3-8. In case of a populati on including TBIs of all severiti es, the study was 
included when the data of pati ents with moderate and severe TBI were incorporated in the analyses 
(as regards the Corti coid Randomisati on Aft er Signifi cant Head injury [CRASH] model) or analyzed 
separately. Studies that evaluated model performance in specifi c subgroups of pati ents (diff erent age 
groups, pati ents that underwent neurosurgery) were also included. The predictors used in the models 
had to be based on pati ent data obtained in the fi rst 24 hours aft er injury (on hospital admission), 
because early outcome predicti on is important to provide informed expectati ons to relati ves and to 
aid early inclusion of pati ents in clinical trials. Moreover, we wanted to enable comparison between 
diff erent prognosti c models within this review as well as between this study and previous literature.4 No 
limitati ons existed concerning outcome measurement provided that functi onal outcome was measured 
between 14 days and 24 months aft er injury. We excluded reviews and qualitati ve studies, studies 
confi ned to the rehabilitati on setti  ng, studies that focused on pati ents with mild TBI (defi ned as GCS 
13-15) and studies that focused on single predictors instead of a model containing multi ple predictors.
  One investi gator (S.A.D.) carried out the literature search and assessed studies for eligibility on 
ti tle and abstract, and subsequently on full text. In case of doubt, a second investi gator (K.A.F.) was 
involved. Disagreements were resolved by discussion or by consultati on with a third (senior) investi gator 
(H.F.L.).
Data extracti on
We used a data extracti on form based on the Criti cal Appraisal and Data Extracti on for Systemati c 
Reviews of Predicti on Modeling Studies (CHARMS) checklist.14 One investi gator (S.A.D.) extracted the 
data from the included studies, and a random check (20%) was performed by a second investi gator 
(K.A.F.). To ensure consistency of the data extracti on, the data extracti on form was tested on two 
studies by both investi gators. The random check showed no discrepancies.
  For all studies, data on study design, study populati on and sample size, outcome measure and 
scale used (e.g. functi onal outcome according to the Glasgow Outcome Scale [Extended], GOS[E]) and 
ti ming of outcome assessment was collected. For each prognosti c model described in the included 
studies, we extracted data on the following topics: type of model (e.g. regression analysis, decision tree), 
internal or external validati on and model performance. Model performance can be expressed in terms 
of discriminati on (ability of the model to disti nguish between pati ents with good and poor outcome) 
and calibrati on (agreement between observed and predicted probabiliti es). A common measure for 
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discriminati on is the area under the receiver operati ng characteristi c curve (AUC or C-stati sti c). The 
AUC ranges from 0.5 (no discriminati ve ability) to 1 (perfect discriminati on). Calibrati on is oft en tested 
with the Hosmer-Lemeshow goodness-of-fi t test or assessed by a calibrati on slope and calibrati on 
intercept.15 The calibrati on slope describes the eff ect of the predictors in the validati on sample and 
should be equal to 1. The intercept indicates whether predicti ons are systemati cally too high or too low, 
and should ideally be zero.16
  If one study reported on multi ple prognosti c models or multi ple stages of prognosti c modeling 
(e.g. development and validati on), data extracti on was performed separately for each model or stage. 
We classifi ed prognosti c models as separate models when they included a diff erent set of prognosti c 
variables. Modifi cati ons of existi ng prognosti c models at external validati on due to missing predictor 
data were not defi ned as separate models, nor were models with identi cal predictors but for diff erent 
outcome measures (e.g. mortality and functi onal outcome) or outcomes measured at diff erent ti me 
points. However, when prognosti c models consisted of identi cal predictors but were developed on 
diff erent cohorts with re-esti mati on of model parameters, we did consider them as independent 
models rather than as validati on studies. 
  Model performance in terms of discriminati on and calibrati on was summarized according to AUC, 
calibrati on intercept and calibrati on slope weighted for the square root of study sample size. Analyses 
were performed with R soft ware version 3.3.1 (R Foundati on for Stati sti cal Computi ng, Vienna, Austria).
Results
The literature search identi fi ed 3246 unique studies, of which 3158 were excluded based on ti tle and 
abstract. Of the 88 full texts screened, 58 studies met the eligibility criteria and were included in this 
review (Figure 4.1). Data of the 58 studies were collected between 1984 and 2017 (Appendix 4.B). Sample 
sizes ranged from 4117 to 10,008 pati ents.18 The included studies described the development, validati on 
or extension of 67 diff erent prognosti c models (Appendix 4.B). This comprised the development of 
42 models, 149 external validati ons of 31 models and 12 model extensions (Figure 4.1). Half of the 
studies (n=29, 50%) evaluated multi ple models in one study (Appendix 4.B). The most frequently used 
predictors were GCS (motor) score (n=55), age (n=54) and pupillary reacti vity (n=48) (Figure 4.2). 
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Figure 4.1. Preferred Reporti ng Items for Systemati c Reviews and Meta-Analyses (PRISMA) ﬂ ow diagram of selected 
arti cles.
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Table 4.1. Summary of characteristi cs of development, validati on and extension of models for moderate and severe 
traumati c brain injury
Characteristi cs Development (n=42) External validati on (n=149) Extension (n=12)
No. of models 42 31 12
Median number of pati ents (IQR) 700 (381-1466) 409 (290-890) 342 (160-534)
Type of model
Regression analysis
Classifi cati on tree
Otherab
40 (94)
1 (3)
1 (3)
142 (95)
7 (5)
-
12 (67)
-
4 (33)
Internal validati on NA
Apparent
Cross-validati on
Bootstrapping
Split sample
15 (36)
6 (14)
11 (26)
13 (31)
4 (33)
-
8 (67)
3 (25)
Performance measures
Calibrati on
    Plot
    Goodness of fi t 
    Slope
    Intercept
    Otherc
Discriminati on
    Accuracy rate
    Sensiti vity/specifi city
    ROC/AUC
    Otherd
15 (36)
36 (86)
2 (5)
2 (5)
2 (5)
1 (8)
2 (5)
32 (76)
13 (31)
80 (54)
77 (52)
53 (36)
53 (36)
7 (5)
6 (4)
4 (3)
142 (95)
39 (26)
1 (8)
10 (83)
5 (42)
5 (42)
3 (25)
-
-
11 (92)
8 (67)
IQR, interquarti le range, ROC, receiver operati ng characteristi c curve, AUC, area under the receiver operati ng 
characteristi c curve
aE.g. Bayesian methods, discriminant analysis, machine learning
bOne study compared fi ve diff erent stati sti cal approaches on the same cohort: logisti c regression, decision tree, 
neural network, Bayesian methods and discriminant analysis.27 
cE.g. Calibrati on belt
dE.g. Nagelkerke R2, Brier score
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Model development and internal validati on
Nineteen studies described the development of 42 prognosti c models (1-8 models per study).18-36
Cohorts for model development were mostly single center and prospecti ve, with a median sample 
size of 700 pati ents (Appendix 4.B and Table 4.1). Moderate or severe TBI was defi ned according to 
the GCS score in all cohorts. All models had either mortality or unfavorable outcome according to the 
GOS(E) as outcome measure, assessed between 14 days and one year aft er trauma (Appendix 4.B). For 
the vast majority of models, unfavorable outcome was defi ned as GOS 1-3 or GOSE 1-4 (Appendix 4.B). 
Age, GCS (motor) score and pupils were the most frequently used predictors (Figure 4.2). Common 
radiological characteristi cs were traumati c subarachnoid hemorrhage or intraventricular hemorrhage 
(19 models), presence of hematoma (14 models), compression of cisterns and third ventricle (15 
models) and Marshall or Rott erdam computed tomography (CT) classifi cati on (9 models). The most 
oft en used physiological predictor was hypotension (17 models). Several laboratory predictors were 
studied, among which glucose, hemoglobin and coagulopathy (Figure 4.2). Other less frequently used 
predictors included sex, mechanism of injury, ethnic group, and cerebral perfusion pressure (CPP) 
(Figure 4.2). Biomarkers, e.g. S100 astroglial calcium-binding protein B (S100B) and glial fi brillary acidic 
protein (GFAP), were only included in one newly developed model (Figure 4.2). Most models were 
developed with logisti c regression (n=40, 94%) and internally validated with apparent or split-sample 
validati on (Table 4.1). An AUC for internal validati on was reported for 32 models (76%). The AUCs for 
the models for mortality ranged from 0.71 to 0.94, with a mean weighted AUC of 0.84. The models for 
unfavorable outcome showed AUCs ranging from 0.67 to 0.98 (mean weighted AUC 0.82).
External validati on
In 49 studies, 149 external validati ons of newly developed (n=17) or existi ng (n=14) prognosti c models 
were described (1-10 models per study).17-19, 22, 25, 29-31, 33, 34, 36-74 The external validati on cohorts had a 
median sample size of 409 pati ents, and were oft en multi center (n=27, 56%) and prospecti ve (n=37, 
77%) (Table 4.1 and Appendix 4.B). The defi niti on of moderate and severe TBI was mostly based on GCS 
score, but someti mes other criteria were used (e.g. loss of consciousness and Abbreviated Injury Scale 
≥ 2) (Appendix 4.B). Five studies only included pati ents with severe TBI who underwent decompressive 
craniectomy.17, 40, 48, 49, 72 The ti me of outcome assessment according to the GOS(E) was six months in 
most studies (n=36, 75%), and ranged between hospital discharge and 18 months (Appendix 4.B). The 
models at external validati on included more physiological variables due to validati on of several existi ng 
Intensive Care severity scores (e.g. Acute Physiology And Chronic Health Evaluati on II, Sepsis-related 
Organ Failure Assessment score) (Figure 4.2). For each external validati on, at least one performance 
measure was reported. Model calibrati on was most frequently expressed with a calibrati on plot 
(54%) or the Hosmer-Lemeshow goodness-of-fi t test (52%) (Table 4.1). For 25 external validati ons, no 
measure of model calibrati on was reported. In 95% of the external validati ons, model discriminati on 
was expressed in terms of an AUC (Table 4.1).
            showed substanti al variati on (Figure 4.3). The AUCs at external validati on ranged between 
0.61-0.99 (mean weighted AUC 0.80) for the models for mortality, and between 0.66-1.00 (mean 
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weighted AUC 0.77) for the models for unfavorable outcome. We further focused on models with a 
reported AUC at internal validati on and one or more external validati ons (n=20). Discriminati ve ability 
was slightly poorer at external validati on compared to internal validati on, with a mean AUC diff erence 
of -0.013 (p=0.086 by paired t-test) for predicti on of mortality and -0.017 (p=0.031) for unfavorable 
outcome. 
  Model calibrati on, reported with a calibrati on intercept and slope, was summarized for the 
models that were externally validated once or more (7 models in 53 validati ons, Figure 4.4). We 
observed substanti al variati on in the agreement between observed and predicted probabiliti es. The 
mean weighted calibrati on intercept was -0.28 (range -3.3-0.93) for the models for mortality, and 
-0.019 (range -5.7-2.4) for the models for unfavorable outcome. This indicates that both mortality and 
unfavorable outcome were generally lower than expected. The mean weighted calibrati on slopes were 
1.1 (range 0.42-2.3) and 0.88 (range 0.57-2.5) for mortality and unfavorable outcome respecti vely. The 
values at the extremes of the ranges for calibrati on slope and intercept were mainly due to selecti on 
of specifi c populati ons with moderate and severe TBI, such as pati ents who underwent decompressive 
craniectomy or TBI defi ned according to the Abbreviated Injury Scale.48, 67
 The Internati onal Mission for Prognosis and Analysis of Clinical Trials (IMPACT) and CRASH models 
were most frequently externally validated (n=91). The mean weighted AUCs were 0.79 (mortality) 
and 0.77 (unfavorable outcome) for the IMPACT models (range 0.65-0.90), and 0.82 (mortality) and 
0.78 (unfavorable outcome) for the CRASH models (range 0.66-1.00) (Figure 4.3 and Table 4.2). In 
total 51 external validati ons reported calibrati on with an intercept and slope. These 51 validati ons 
showed overesti mated risks by the IMPACT and CRASH models for mortality and underesti mated risks 
for unfavorable outcome (Figure 4.4 and Table 4.2). The more complex IMPACT and CRASH models, 
for example including CT characteristi cs, showed only modest improvement in discriminati ve ability 
(Appendix 4.C), and calibrati on remained highly variable (Figure 4.4). Comparison of the performance 
of the IMPACT and CRASH models with other models, such as Hukkelhoven and Nijmegen, was not 
feasible given the limited number of validati ons of these other models (Table 4.2).
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Model extensions
In fi ve studies, 12 extensions of the IMPACT and CRASH prognosti c models were assessed.41, 44, 51, 57, 58
The median sample size of the extension cohorts was 342 pati ents (Table 4.1). Moderate and severe 
TBI pati ents were selected based on GCS, except for one cohort consisti ng of consecuti ve TBI pati ents 
requiring intracranial pressure monitoring.44 Outcomes were assessed between one week and six 
months (Appendix 4.B). Most studies reported model discriminati on with an AUC (n=11, 92%) and 
calibrati on with the Hosmer-Lemeshow goodness-of-fi t test (n=10, 83%) (Table 4.1). The extensions 
included several serum and cerebrospinal ﬂ uid biomarkers, extracranial injury, coagulati on parameters 
or dynamic predictors containing informati on on the fi rst 24 hours of the clinical course (Acute 
Physiology And Chronic Health Evaluati on II score, intracranial pressure and mean arterial pressure) 
(Figure 4.2). Performance of the extended models in terms of both discriminati on and calibrati on 
improved somewhat compared to the original versions of the models. The mean AUC increase at model 
extension was 0.013 (p=0.18 by paired t-test) for models for mortality and 0.10 (p=0.026) for models 
for unfavorable outcome. Calibrati on was not evaluated or showed no improvement.41, 44, 51, 57, 58 None of 
the extended models was externally validated.
Discussion
We systemati cally reviewed 58 papers describing the development, validati on or extension of 67 
diff erent multi variable prognosti c models for functi onal outcome in moderate and severe TBI. We 
identi fi ed 149 external validati ons of prognosti c models. The IMPACT and CRASH models currently 
dominate the fi eld of prognosti c modeling in moderate and severe TBI. External validati ons of these 
models showed substanti al variati on in performance: overall moderate to good discriminati on, but 
highly variable calibrati on.
Strengths and limitati ons
This systemati c review is based on a comprehensive literature search resulti ng in a large number of 
prognosti c models and validati on studies in the fi eld of moderate and severe TBI. A novel feature 
compared to previous systemati c reviews on this topic is that improvements in prognosti c research in TBI 
now permit inclusion of a substanti al number of external validati on studies. However, some limitati ons 
should be considered. We did not consider models for which the outcomes (mortality or unfavorable 
outcome) were measured at diff erent ti me points as separate models. Similarly, models with identi cal 
predictors but for diff erent outcome measures were not defi ned as separate models. This may have 
caused an underesti mati on of the number of prognosti c models for moderate and severe TBI. Another 
factor that might have unjustly reduced the number of models is the exclusion of studies that were 
not published in English language. Additi onally, most studies in this systemati c review were conducted 
in middle and high income countries. Therefore, our results might not be generalizable to low income 
countries. Finally, comparing model calibrati on between diff erent models and setti  ngs was diffi  cult due 
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to variati on in, or even absence of, calibrati on measures. Model calibrati on was reported in terms of 
an intercept and slope for only seven models. Our summary of model calibrati on might therefore not 
reﬂ ect the overall ability of the currently available models to provide predicti ons in individual pati ents.
Comparison with previous literature
Previous systemati c reviews on prognosti c models in moderate and severe TBI mainly focused on 
their methodological quality. Several recommendati ons were proposed to improve methodology and 
reporti ng of prognosti c models.4, 5 The prognosti c models evaluated in the current systemati c review 
showed advancements in reporti ng and stati sti cal approaches, especially regarding external validati on. 
Models were externally validated in independent cohorts and most validati on studies reported 
appropriate model performance measures in terms of discriminati on and calibrati on.15 However, 
measures for discriminati on are sti ll more frequently reported than calibrati on measures. Moreover, 
although the Hosmer-Lemeshow goodness-of-fi t test for model calibrati on is no longer recommended 
due to lack of power and interpretability, this was sti ll used in more than half of the validati ons. The lack 
of adequate calibrati on measures is remarkable, since poor calibrati on implies that the predicti ons will 
be misleading when used in clinical practi ce. This may lead to harmful decision making.75
Model development and predictors
Aft er publicati on of the previous systemati c reviews, several new prognosti c models for outcome 
predicti on aft er moderate and severe TBI have been developed. Especially the introducti ons of the 
IMPACT and CRASH models have been important to confi rm the core predictors for unfavorable 
outcome aft er moderate and severe TBI obtained at admission: older age, less responsive pupils and 
lower GCS (motor) score.18, 31 Although these baseline predictors included in the IMPACT and CRASH 
models only explain around 35% of the variance in outcome, more complex models with additi onal 
predictors collected within 24 hours may not lead to substanti al improvements in model performance.3
This is supported by our observati on that performance of the IMPACT and CRASH models showed only 
modest improvement in discriminati ve ability by adding CT characteristi cs, physiological and laboratory 
variables obtained within the fi rst 24 hours, both at internal and external validati on (Figure 4.3 and 
Appendix 4.C). However, prognosti c esti mates will be refi ned during the course of the disease, as may 
be considered in dynamic predicti on models.76 Any prognosti c model should only be considered an 
additi on to clinical experience.
  In line with previous recommendati ons, other recently developed models introduced several 
new predictors (e.g. CPP, ethnic group, mechanism of injury, biomarkers).3 However, many of these 
predictors were only included in a few models and not yet externally validated (Figure 4.2). Therefore, it 
remains diffi  cult to assess the added value of these models and predictors. Further research is essenti al, 
especially external validati on.
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External validati on
We found a large number of external validati ons in contemporary series. The IMPACT and CRASH 
models were externally validated most extensively. Model performance at external validati on was 
on average close to performance at internal validati on. Performance at external validati on may best 
reﬂ ect the models’ discriminati ve ability when applied in clinical practi ce.77 The discriminati ve ability at 
external validati on was mostly around 0.8, with one very small study even reporti ng an implausible AUC 
value of 1 for the CRASH CT model for unfavorable outcome.74 Calibrati on varied highly among diff erent 
models and studies. The variability in discriminati ve performance and calibrati on slopes is most likely 
att ributable to diff erences in measurement of predictors or selecti on of the validati on populati on.78
For instance, a few studies investi gated model performance in more homogeneous subgroups such 
as pati ents with decompressive craniectomy.17, 40, 48, 49, 72 We also observed a substanti al number of 
variati ons (i.e. diff erences in included predictors) on IMPACT and CRASH at external validati on (Appendix 
4.D), mostly due to discrepancies in predictor defi niti ons or unavailability of predictor data.18, 31, 38, 61, 62, 
64, 68 Further, ti ming of outcome measurement varied substanti ally across diff erent studies. Although 
most models were designed for outcome predicti on at six months aft er injury, model performance 
was assessed in cohorts with outcome data available up to 18 months aft er injury.48 Heterogeneity 
in baseline risk was noted according to calibrati on-in-the-large (intercept diff erences). This variability 
might be att ributed to diff erences in distributi ons and eff ects of unmeasured covariates and is therefore 
oft en diffi  cult to explain. The substanti al heterogeneity in model performance across diff erent setti  ngs 
indicates that models need to be recalibrated for each new setti  ng before implementati on in clinical 
practi ce is warranted.
Model extension
Highly variable model performance may be problemati c when introducing the models to a specifi c 
clinical setti  ng. Several stages have been identi fi ed in updati ng prognosti c models, ranging from 
updati ng the intercept to additi on of predictors.16 There has been extensive research into the additi onal 
prognosti c value of baseline biomarkers for TBI.79 However, extending the IMPACT and CRASH models 
with markers of coagulati on or serum and cerebrospinal ﬂ uid biomarkers (S100B and GFAP) barely 
improved model performance in the few studies that have been performed.41, 58 Because TBI is a 
heterogeneous disease with a highly variable clinical course, adding new informati on as it becomes 
available over ti me or including factors that predict treatment response may be more promising to 
improve outcome predicti on.3 Extending the currently available models with such dynamic predictors 
has been uncommon so far, and yielded variable improvement in model performance.44, 57 External 
validati on of these extended models is lacking. Possibiliti es for updati ng the IMPACT and CRASH models 
are currently being evaluated in various studies, including the Collaborati ve European NeuroTrauma 
Eff ecti veness Research in Traumati c Brain Injury (CENTER-TBI) study, Transforming Research and Clinical 
Knowledge in TBI (TRACK-TBI) dataset and Collaborati ve REsearch on ACute Traumati c Brain Injury in 
intensiVe Care Medicine in Europe (CREACTIVE).80-82 Given the highly variable calibrati on, updati ng of 
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the baseline risk esti mate (the intercept in the regression model) should be considered. Also, machine 
learning techniques are currently gaining interest and might be helpful for dynamic predicti on.
Implementati on in clinical practi ce
The availability of a large number of prognosti c models for functi onal outcome aft er moderate and 
severe TBI suggests that outcome predicti on is considered relevant for clinical practi ce. However, despite 
previous recommendati ons, none of the available models have been implemented in TBI guidelines. 
Their use in clinical practi ce is limited.3 This might partly be explained by the lack of evidence-based 
treatment opti ons in TBI,83 limiti ng the use of prognosti c models to select pati ents for individualized 
management. Previous studies evaluati ng the percepti ons of physicians on uti lizati on of the IMPACT 
calculator in clinical practi ce showed that approximately half of the clinicians involved in TBI care was 
aware of its existence. Of those, only 50% occasionally used the model in clinical practi ce.84, 85 Factors 
limiti ng clinical use of the IMPACT calculator comprised mistrust in the IMPACT development data, 
uti lizati on for research purposes only, ti me needed to gather the data required to complete the online 
tool, and concern about misinterpretati on of prognosti c esti mates by pati ents and their families.84, 85
However, the IMPACT calculator was reported to be useful for reducing variability between physicians 
with diff erent levels of clinical experience.85
  Model discriminati on, although variable, was adequate in most studies. The lack of implementati on 
can therefore not be explained by poor discriminati ve ability. Moreover, models do not necessarily need 
high discriminati ve performance to be accepted in clinical practi ce. Examples are the Hypertension, 
Abnormal Renal/Liver Functi on, Stroke, Bleeding History or Predispositi on, Labile INR, Elderly, Drugs/
Alcohol Concomitantly (HAS-BLED, AUC 0.65) and Congesti ve heart failure, Hypertension, Age, 
Diabetes mellitus, Prior Stroke or TIA or Thromboembolism (CHA2DS2-VASc, AUC 0.61) models that 
are commonly applied in neurovascular practi ce, and the extensively used Gail breast cancer models 
(pooled AUCs between 0.55-0.75).86-88 Compared to these widely implemented tools, the models for 
outcome aft er moderate and severe TBI perform very well (weighted mean AUCs of 0.80 and 0.76 for 
mortality and unfavorable outcome, respecti vely).
  Model calibrati on, on the other hand, showed substanti al heterogeneity between diff erent 
setti  ngs. The adequate discriminati ve ability and highly variable calibrati on may indicate that the 
models perform well at group level, but cauti on is required when using them to provide predicti ons for 
individual pati ents in a specifi c clinical setti  ng.
  Based on the main fi ndings of this systemati c review, we provided a set of recommendati ons 
regarding stati sti cal evaluati on and implementati on of prognosti c models in moderate and severe TBI 
(Table 4.3). 
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Table 4.3. Recommendati ons on (stati sti cal) evaluati on and implementati on of prognosti c models for moderate and 
severe TBI
•   Conti nuous validati on and updati ng of prognosti c models is required to judge generalizability and 
transportability to other TBI populati ons.
•   Calibrati on reﬂ ects the ability of the prognosti c model to provide reliable predicti ons and should thus be 
reported at every external validati on.
•   The currently available prognosti c models for moderate and severe TBI discriminate well between low 
risk and high risk pati ents.
•   Cauti on is required when providing predicti ons for pati ents in a specifi c clinical setti  ng.
•   Prognosti c models for moderate and severe TBI may need to be recalibrated for each new setti  ng before 
implementati on in clinical practi ce is warranted.
Conclusion
The IMPACT and CRASH prognosti c models have been developed on the largest datasets and have 
adequate discriminati ve ability across a range of setti  ngs. The reliability of predicti ons is highly variable. 
We recommend implementati on of these models in clinical practi ce, provided that they have been 
validated or updated for the specifi c clinical setti  ng. 
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Appendix
Appendix 4. A. Search strategy
Date search: November 12, 2018
Database Search algorithm
Embase.
com 
(‘traumati c brain injury’/exp OR ‘brain injury’/de OR ‘head injury’/de OR ‘acquired brain 
injury’/de OR (‘nervous system injury’/de AND brain/exp) OR (((trauma* OR injur* OR 
damage*) NEAR/3 (brain* OR cerebral* OR head OR cranial* OR intracranial*)) OR tbi):ab,ti ) 
AND (((model/de OR ‘mathemati cal model’/de OR ‘disease model’/de) AND (‘prognosis’/de 
OR ‘predicti on’/de OR ‘mortality’/de OR ‘survival’/de OR  fatality/de OR ‘convalescence’/de 
OR ‘predicti ve validity’/de )) OR ‘nomogram’/de OR (((prognos* OR predict* OR mortal* OR 
convalescen* OR recover*  OR surviv* OR fatal*) NEAR/6 (model*)) OR nomogram*):ab,ti ) 
NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Lett er]/lim OR 
[Note]/lim OR [Editorial]/lim) AND [english]/lim
Medline Ovid (“Brain Injuries”/ OR exp “Brain Hemorrhage, Traumati c”/ OR “Craniocerebral Trauma”/ OR 
“Head Injuries, Closed”/ OR “Head Injuries, Penetrati ng”/ OR (“Trauma, Nervous System”/ 
AND exp brain/) OR (((trauma* OR injur* OR damage*) ADJ3 (brain* OR cerebral* OR 
head OR cranial* OR intracranial*)) OR tbi).ab,ti .) AND (((exp “Models, Stati sti cal”/ OR 
exp “Models, Theoreti cal”/) AND (“prognosis”/ OR exp “mortality”/ OR “mortality”.xs. OR 
survival/ OR “Fatal Outcome”/ OR “Convalescence”/ )) OR “Nomograms”/ OR (((prognos* OR 
predict* OR mortal* OR convalescen* OR recover*  OR surviv* OR fatal*) ADJ6 (model*)) OR 
nomogram*).ab,ti .) NOT (exp animals/ NOT humans/) NOT (lett er OR news OR comment OR 
editorial OR congresses OR abstracts).pt. AND english.la.
PsycINFO Ovid (“Traumati c Brain Injury”/ OR exp “Brain Damage”/ OR “Head Injuries”/ OR (((trauma* OR 
injur* OR damage*) ADJ3 (brain* OR cerebral* OR head OR cranial* OR intracranial*)) OR 
tbi).ab,ti .) AND (((“Models”/ ) AND (“prognosis”/ OR exp “Death and Dying”/ OR “Mortality 
Rate”/  )) OR “Nomograms”/ OR (((prognos* OR predict* OR mortal* OR convalescen* OR 
recover*  OR surviv* OR fatal*) ADJ6 (model*)) OR nomogram*).ab,ti .) NOT (exp animals/ 
NOT humans/) NOT (lett er OR news OR comment OR editorial OR congresses OR abstracts OR 
books).pt. AND english.la.
Cochrane central ((((trauma* OR injur* OR damage*) NEAR/3 (brain* OR cerebral* OR head OR cranial* OR 
intracranial*)) OR tbi):ab,ti ) AND ((((prognos* OR predict* OR mortal* OR convalescen* OR 
recover*  OR surviv* OR fatal*) NEAR/6 (model*)) OR nomogram*):ab,ti ) 
Web of science  TS=(((((trauma* OR injur* OR damage*) NEAR/2 (brain* OR cerebral* OR head OR cranial* 
OR intracranial*)) OR tbi)) AND ((((prognos* OR predict* OR mortal* OR convalescen* OR 
recover*  OR surviv* OR fatal*) NEAR/5 (model*)) OR nomogram*)) NOT ((animal* OR rat OR 
rats OR mouse OR mice OR murine OR cat OR cats OR feline OR dog OR dogs OR canine OR 
sheep OR ovine OR cow OR bovine OR catt le OR horse OR equin* OR pig OR swine OR porcine 
OR monkey* OR primate* OR gerbil* OR rabbit* OR rodent*) NOT (human* OR pati ent*))) 
AND DT=(arti cle) AND LA=(english)
Google scholar “brain|cerebral|head|cranial|intracranial trauma|injury|injuries|damage”|tbi 
“prognosis|prognosti c|predicti ve|survival model|models”|” 
model|models*mortality|convalescence|recovery|fatality|fatal”|nomogram|nomograms
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Appendix 4.D. Overview of predictors included in 67 models for moderate and severe traumati c brain injury 
(including 12 modifi cati ons of IMPACT and CRASH)
Model no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Demographics
Age
Gender
Ethnic group
X X X X X X X X X
X
X
X
X
X
X X
Clinical
GCS score
GCS motor score
Pupils
AIS/ISS/MEI
Limb movement
Mechanism of injury
NACA score
X
X
X
X
X X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physiological
Hypoxia
Hypotension
Mean arterial pressure
Intracranial pressure
Temperature
Heart rate
Respiratory rate
PaO2
FiO2
Systolic blood pressure
Cerebral perfusion pressure
Mechanical venti lati on
Urine output
Arrhythmia
X
X
X
X X X X
X
X
X
X
Radiology
CT classifi cati on
Midline shift 
Cisterns/third ventricle
tSAH/IVH
Hematoma
Lesions
Fourth ventricle
Contusion
Basal skull fracture
Intracranial mass eff ect
X
X
X
X
X
X
X
X
Xa
X
X
X
Xa
X
X
X
Xa
X
X
X
Xa
X
X
X
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Model no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Laboratory
Glucose
Hemoglobin
Coagulopathy
Sodium
Creati nine
Potassium
White blood cell count
Hematocrit
pH
Bilirubin
Platelet count
INR/PT
Biomarkers
D-dimer
Calcium
Blood urea nitrogen
Bicarbonate
X
X
X
X
X
X
X
X
X X
X
X
Other
Chronic health status
Type of admission
Metastati c cancer
Cirrhosis
Acute renal failure
Chronic renal failure
Cerebrovascular incident
Cardiopulmonary resuscitati on 
prior admission
Gastrointesti nal bleed
Proven infecti on
Vasoacti ve drug
Total 6 3 3 3 3 7 4 10 14 5 11 15 3 5 8
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Appendix 4.D. conti nued
Model no. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Demographics
Age
Gender
Ethnic group
X X X X X X X X X X
Clinical
GCS score
GCS motor score
Pupils
AIS/ISS/MEI
Limb movement
Mechanism of injury
NACA score
X X
X X X X
X
X
X
X
X
X
X
X
X
X
Physiological
Hypoxia
Hypotension
Mean arterial pressure
Intracranial pressure
Temperature
Heart rate
Respiratory rate
PaO2
FiO2
Systolic blood pressure
Cerebral perfusion pressure
Mechanical venti lati on
Urine output
Arrhythmia
X X X X X
X
X
X
Radiology
CT classifi cati on
Midline shift 
Cisterns/third ventricle
tSAH/IVH
Hematoma
Lesions
Fourth ventricle
Contusion
Basal skull fracture
Intracranial mass eff ect
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
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Model no. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Laboratory
Glucose
Hemoglobin
Coagulopathy
Sodium
Creati nine
Potassium
White blood cell count
Hematocrit
pH
Bilirubin
Platelet count
INR/PT
Biomarkers
D-dimer
Calcium
Blood urea nitrogen
Bicarbonate
Xb
X
X
X
X
X
X
X
X
Other
Chronic health status
Type of admission
Metastati c cancer
Cirrhosis
Acute renal failure
Chronic renal failure
Cerebrovascular incident
Cardiopulmonary resuscitati on 
prior admission
Gastrointesti nal bleed
Proven infecti on
Vasoacti ve drug
Total 2 4 2 5 3 2 6 5 3 5 6 6 10 12 4
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Appendix 4.D. conti nued
Model no. 31 32 33 34 34-
m1
34-
m2
35 35-
m1
35-
m2
35-
m3
36 36-
m1
37 37-
m1
37-
m2
Demographics
Age
Gender
Ethnic group
X X X X X X X X X X X X X
Clinical
GCS score
GCS motor score
Pupils
AIS/ISS/MEI
Limb movement
Mechanism of injury
NACA score
X
X X
X X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physiological
Hypoxia
Hypotension
Mean arterial pressure
Intracranial pressure
Temperature
Heart rate
Respiratory rate
PaO2
FiO2
Systolic blood pressure
Cerebral perfusion pressure
Mechanical venti lati on
Urine output
Arrhythmia
X
X
X
X
X
X
X
X
Radiology
CT classifi cati on
Midline shift 
Cisterns/third ventricle
tSAH/IVH
Hematoma
Lesions
Fourth ventricle
Contusion
Basal skull fracture
Intracranial mass eff ect
X
X
X
Xa
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
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Model no. 31 32 33 34 34-
m1
34-
m2
35 35-
m1
35-
m2
35-
m3
36 36-
m1
37 37-
m1
37-
m2
Laboratory
Glucose
Hemoglobin
Coagulopathy
Sodium
Creati nine
Potassium
White blood cell count
Hematocrit
pH
Bilirubin
Platelet count
INR/PT
Biomarkers
D-dimer
Calcium
Blood urea nitrogen
Bicarbonate
X
Other
Chronic health status
Type of admission
Metastati c cancer
Cirrhosis
Acute renal failure
Chronic renal failure
Cerebrovascular incident
Cardiopulmonary resuscitati on 
prior admission
Gastrointesti nal bleed
Proven infecti on
Vasoacti ve drug
Total 10 5 6 4 4 3 9 6 5 7 3 2 8 8 6
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Appendix 4.D. conti nued
Model no. 37-
m3
37-
m4
37-
m5
37-
m6
38 38-
m1
38-
m2
39 40 41 42 43 44 45 46
Demographics
Age
Gender
Ethnic group
X X X X X X X
X
X 
X
X
X
X X X
Clinical
GCS score
GCS motor score
Pupils
AIS/ISS/MEI
Limb movement
Mechanism of injury
NACA score
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Xd
Xd
X
Xd
Xd
X
X
X
X
X
X
X X
Physiological
Hypoxia
Hypotension
Mean arterial pressure
Intracranial pressure
Temperature
Heart rate
Respiratory rate
PaO2
FiO2
Systolic blood pressure
Cerebral perfusion pressure
Mechanical venti lati on
Urine output
Arrhythmia
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X X
X
X
X
X
X
X
X
Radiology
CT classifi cati on
Midline shift 
Cisterns/third ventricle
tSAH/IVH
Hematoma
Lesions
Fourth ventricle
Contusion
Basal skull fracture
Intracranial mass eff ect
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X X
X
X
X
X
X
X
X
X
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Model no. 37-
m3
37-
m4
37-
m5
37-
m6
38 38-
m1
38-
m2
39 40 41 42 43 44 45 46
Laboratory
Glucose
Hemoglobin
Coagulopathy
Sodium
Creati nine
Potassium
White blood cell count
Hematocrit
pH
Bilirubin
Platelet count
INR/PT
Biomarkers
D-dimer
Calcium
Blood urea nitrogen
Bicarbonate
X
X
X
X
X
X
X X
X
X
X
X
X
X
Other
Chronic health status
Type of admission
Metastati c cancer
Cirrhosis
Acute renal failure
Chronic renal failure
Cerebrovascular incident
Cardiopulmonary resuscitati on 
prior admission
Gastrointesti nal bleed
Proven infecti on
Vasoacti ve drug
X
Total 6 7 7 5 10 9 8 12 12 5 4 3 3 4 14
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Appendix 4.D. conti nued
Model no. 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61
Demographics
Age
Gender
Ethnic group
X X X X X X X X X X X X X
Clinical
GCS score
GCS motor score
Pupils
AIS/ISS/MEI
Limb movement
Mechanism of injury
NACA score
X X
X
X
X X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physiological
Hypoxia
Hypotension
Mean arterial pressure
Intracranial pressure
Temperature
Heart rate
Respiratory rate
PaO2
FiO2
Systolic blood pressure
Cerebral perfusion pressure
Mechanical venti lati on
Urine output
Arrhythmia
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Xe
Xe
Xe
Xe
Xf
Xf
Radiology
CT classifi cati on
Midline shift 
Cisterns/third ventricle
tSAH/IVH
Hematoma
Lesions
Fourth ventricle
Contusion
Basal skull fracture
Intracranial mass eff ect
X
X
X X
X X
X
X
X
X
X
X
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Model no. 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61
Laboratory
Glucose
Hemoglobin
Coagulopathy
Sodium
Creati nine
Potassium
White blood cell count
Hematocrit
pH
Bilirubin
Platelet count
INR/PT
Biomarkers
D-dimer
Calcium
Blood urea nitrogen
Bicarbonate
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Other
Chronic health status
Type of admission
Metastati c cancer
Cirrhosis
Acute renal failure
Chronic renal failure
Cerebrovascular incident
Cardiopulmonary resuscitati on 
prior admission
Gastrointesti nal bleed
Proven infecti on
Vasoacti ve drug
X
X X
X
X
X
X
X
X
X 
X
X
X
X
X 
X X X
Total 17 7 7 15 13 6 4 5 4 16 21 23 22 23 14
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Model no. 62 63 64 65 66 67
a-e
Total 
n (%)
Demographics
Age
Gender
Ethnic group
X X X X X X 54 (82)
5 (8)
2 (3)
Clinical
GCS score
GCS motor score
Pupils
AIS/ISS/MEI
Limb movement
Mechanism of injury
NACA score
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
28 (42)
27 (42)
48 (73)
13 (19)
6 (10)
4 (6)
1 (1)
Physiological
Hypoxia
Hypotension
Mean arterial pressure
Intracranial pressure
Temperature
Heart rate
Respiratory rate
PaO2
FiO2
Systolic blood pressure
Cerebral perfusion pressure
Mechanical venti lati on
Urine output
Arrhythmia
Xf
Xf
X
X
X
X
X
X
X
X
12 (19)
25 (40)
8 (13)
7 (11)
5 (8)
6 (10)
6 (6)
8 (13)
3 (5)
4 (3)
1 (2)
3 (5)
2 (3)
1 (2)
Radiology
CT classifi cati on
Midline shift 
Cisterns/third ventricle
tSAH/IVH
Hematoma
Lesions
Fourth ventricle
Contusion
Basal skull fracture
Intracranial mass eff ect
X
X
X
X
X
X
X
X
X
X
X
X
16 (26)
11 (16)
17 (26)
27 (44)
21 (34)
11 (16)
2 (3)
3 (5)
1 (2)
2 (3)
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Model no. 62 63 64 65 66 67
a-e
Total 
n (%)
Laboratory
Glucose
Hemoglobin
Coagulopathy
Sodium
Creati nine
Potassium
White blood cell count
Hematocrit
pH
Bilirubin
Platelet count
INR/PT
Biomarkers
D-dimer
Calcium
Blood urea nitrogen
Bicarbonate
X
X
X
X
X
X
X
X
X
X
X
X
Xg
10 (16)
10 (16)
4 (6)
7 (11)
9 (15)
5 (8)
5 (8)
4 (6)
4 (6)
3 (5)
4 (6)
3 (5)
2 (3)
2 (3)
2 (3)
1 (2)
1 (2)
Other
Chronic health status
Type of admission
Metastati c cancer
Cirrhosis
Acute renal failure
Chronic renal failure
Cerebrovascular incident
Cardiopulmonary resuscitati on prior admission
Gastrointesti nal bleed
Proven infecti on
Vasoacti ve drug
5 (8)
3 (5)
2 (3)
2 (3)
1 (2)
1 (2)
1 (2)
1 (2)
1 (2)
1 (2)
1 (2)
Total 15 11 12 12 13 6
GCS, Glasgow Coma Scale; tSAH, traumati c subarachnoid hemorrhage; IVH, intraventricular hemorrhage; CT, 
computed tomography; AIS, Abbreviated Injury Scale; ISS, Injury Severity Score; MEI, major extracranial injury; PaO2, 
parti al arterial pressure of oxygen; INR, internati onal normalized rate; PT, prothrombin ti me; pH, potenti al hydrogen; 
FiO2, fracti on of inspired oxygen; NACA, Nati onal Advisory Committ ee for Aeronauti cs
aEDH and SDH 
bGFAP and S-100B peak concentrati on
cPre- and post-resuscitati on
dSix individual predictors within ISS
e19 dynamic predictors related to ICP and MAP 
f11 dynamic predictors related to ICP and MAP
gCombinati ons of 3 diff erent biomarkers
AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICA-
TION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HE-
MATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION 
ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES 
PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HY-
POXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT 
OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE 
TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT 
CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPI-
DURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM 
LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS 
DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL 
INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE 
AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION 
LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRIL-
LATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMA-
TIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD 
ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLO-
GICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR 
EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOG-
LOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE 
HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE 
ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSI-
ON TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACH-
NOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE 
NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION 
MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA 
HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM 
SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS 
STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA 
HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT 
OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE 
TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT 
CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPI-
DURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM 
LOCATION ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS 
DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL 
INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE 
AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION 
LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRIL-
LATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMA-
TIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD 
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4.1
Dear Editor:
With great interest we read the recent study by Walker and colleagues on the development of a 
prognosti c model to predict long-term functi onal outcomes for adult pati ents with moderate and 
severe traumati c brain injury (TBI).1 The authors used a large prospecti ve multi -center cohort of pati ents 
with TBI receiving inpati ent rehabilitati on, representati ve for clinical practi ce in the United States. 
Prognosti c modeling for outcome aft er TBI in the rehabilitati on setti  ng could help set expectati ons and 
plan treatments in those pati ents who are in inpati ent rehabilitati on aft er sustaining a TBI. We noted, 
however, several methodological shortcomings that necessitate a cauti ous interpretati on of fi ndings 
from this study.
  First, the authors seem to have excluded or removed pati ents with the outcomes death or 
vegetati ve state from the analysis, arguing that including these would not have added much signifi cant 
informati on. Obviously, leaving out these pati ents introduces some bias toward bett er outcome. 
Moreover, it is unknown in advance which pati ents will die or remain vegetati ve, and hence use of the 
model in clinical practi ce is impossible.
  Second, the authors performed a complete case analysis by removing all pati ents with missing 
Glasgow Outcome Scale scores or a missing covariate from the analysis. Systemati c diff erences between 
pati ents with missing data and pati ents with complete data could cause bias. A soluti on for this problem 
that is now widely implemented in clinical research is a multi ple imputati on procedure, where missing 
values are substi tuted with plausible values based on correlati ons with covariates and with outcome 
variables.2
  Third, the authors claim that a decision tree model is the best method to defi ne a prognosti c 
model in this context. Thorough methodological research has shown quite subopti mal performance of 
decision trees for modeling prognosis in TBI and other medical domains, however.3,4 Studies comparing 
diff erent modeling strategies concluded that logisti c regression analysis is the preferred method to 
develop a prognosti c model for outcomes of TBI.3 A key prognosti c characteristi c such as age is then 
dealt with in a natural, conti nuous way rather than creati ng arti fi cial groupings.
  Fourth, the authors state that they demonstrated a reasonable predicti ve accuracy of themodel. 
Indeed, a randomsplit sample is an independent test for the model, but cannot be considered as external 
validati on. To assess generalizability of the model, validati on is required with meaningful geographic or 
temporal splitti  ng.5
  Remarkably, the authors cite a systemati c review that includes all the above menti oned 
recommendati ons for improvement of methodological quality in prognosti c models in TBI.6 Moreover, 
promising prognosti c models for functi onal outcome aft er moderate and severe TBI have been 
developed over the last decade, including the Internati onal Mission for Prognosis and Analysis of Clinical 
Trials (IMPACT) and Corti coid Randomisati on Aft er Signifi cant Head injury (CRASH) models.7,8 Relevant 
admission characteristi cs included in these models, such as pupillary reacti vity and extracranial injury, 
unfortunately were not incorporated in the current analyses.
  In conclusion, we observe multi ple methodological shortcomings in both development and 
validati on of the proposed prognosti c tool. In additi on, important advances in prognosti c modeling in 
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TBI over the last decade should be considered. Applicati on of the proposed model in pati ents with TBI 
in inpati ent rehabilitati on can only be recommended aft er sati sfactory performance is shown in fully 
independent external validati on studies with adequate design.
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AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICA-
TION MAJOR EXTRACRANIAL INJURY HYPOXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HE-
MATOMA HEMOGLOBIN GLUCOSE AMOUNT OF SUBARACHNOID BLOOD ANEURYSM LOCATION 
ANEURYSM SIZE HYPERTENSION LACTATE TREATMENT AGE NEUROLOGICAL STATUS DIABETES 
PREVIOUS STROKE ATRIAL FIBRILLATION CT CLASSIFICATION MAJOR EXTRACRANIAL INJURY HY-
POXIA HYPOTENSION TRAUMATIC SAH EPIDURAL HEMATOMA HEMOGLOBIN GLUCOSE AMOUNT 
OF SUBARACHNOID BLOOD ANEURYSM LOCATION ANEURYSM SIZE HYPERTENSION LACTATE 
TREATMENT AGE NEUROLOGICAL STATUS DIABETES PREVIOUS STROKE ATRIAL FIBRILLATION CT 
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Abstract
Objecti ve: External validati on of prognosti c models is crucial but rarely done. Our aim was to externally 
validate a prognosti c model to predict 60-day case fatality aft er aneurysmal subarachnoid hemorrhage 
developed from the Internati onal Subarachnoid Aneurysm Trial in a retrospecti ve unselected cohort of 
subarachnoid hemorrhage pati ents.
Design: The model’s predictors were age, aneurysm size, Fisher grade, and World Federati on of 
Neurological Surgeons grade. Two versions of the model were validated: one with World Federati on of 
Neurological Surgeons grade scored at admission and the other with World Federati on of Neurological 
Surgeons grade at treatment decision. The outcome was 60-day case fatality. Performance of the 
model was assessed by studying discriminati on, expressed by the area under the receiver operati ng 
characteristi c curve, and calibrati on.
Setti  ng: University hospital.
Pati ents: We analyzed data from 307 consecuti ve aneurysmal subarachnoid hemorrhage pati ents 
admitt ed between 2007 and 2011 (validati on cohort).
Interventi ons: None.
Measurements and main results: The observed 60-day case fatality rate was 30.6%. Discriminati on 
was good, and diff ered between the model with World Federati on of Neurological Surgeons grade at 
treatment decision (area under the receiver operati ng characteristi c curve, 0.89) and at admission 
(area under the receiver operati ng characteristi c curve, 0.82). Mean predicted probabiliti es were lower 
than observed: 17.0% (model with World Federati on of Neurological Surgeons grade at admission) and 
17.7% (model with World Federati on of Neurological Surgeons grade at treatment decision).
Conclusions: The model discriminated well between pati ents who died or survived within 60 days. 
In additi on, we found that using World Federati on of Neurological Surgeons grade at moment of 
treatment decision of the ruptured aneurysm improved model performance. However, since predicted 
probabiliti es were much lower than observed probabiliti es, the Internati onal Subarachnoid Aneurysm 
Trial predicti on model needs to be adapted to be used in clinical practi ce.
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Introducti on
Aneurysmal subarachnoid hemorrhage (aSAH) is associated with signifi cant morbidity and mortality.1,2
Although the case fatality rate has decreased, mortality is sti ll around 35%.2,3
  Reliable predicti on of short-term mortality risk is useful to inform pati ents and relati ves on 
prognosis and select pati ents at risk for poor outcome before therapeuti c decisions are made, both 
in clinical practi ce and in interventi on studies.4-6 In additi on, outcome predicti on may be important in 
benchmarking quality of care. Several prognosti c factors can be combined in a prognosti c model to 
calculate the risk of a specifi c endpoint for an individual pati ent.7 For aSAH, various prognosti c models 
have been developed.4,5 However, to date no prognosti c model for aSAH has found its way into clinical 
practi ce. This might be explained by methodological problems with the development of these models; 
typically too many predictors are tested for the number of outcome events in datasets, leading to 
overfi tt ed models with limited generalizability and overopti misti c esti mates of model performance.4 To 
reveal the performance of predicti on models in new datasets, external validati on is a crucial step, but 
is rarely done.4-8 Finally, applicati on in clinical practi ce is further hampered by the necessity to adapt 
predicti on models to specifi c clinical setti  ngs that in additi on may rapidly change over ti me, for instance, 
when new therapies are introduced.9
  A recent prognosti c model, predicti ng 60-day case fatality aft er aSAH using data from the 
Internati onal Subarachnoid Aneurysm Trial (ISAT),9 has shown reasonable performance.4,5 The objecti ve 
of this study is to externally validate the ISAT predicti on model in an independent cohort.
Methods
Study design and populati on
In this retrospecti ve cohort study, we included consecuti vely admitt ed aSAH pati ents to the Erasmus 
MC, University Medical Center, Rott erdam, The Netherlands. Pati ents were identi fi ed through a hospital 
registry and were admitt ed between October 2007 and October 2011. All aSAH pati ents were routi nely 
managed at an ICU. 
 Inclusion criteria were 1) 18 years or older, 2) admitt ed to hospital less than or equal to 28 days 
aft er ictus, 3) SAH, proven by CT or cerebrospinal ﬂ uid spectrophotometry, and 4) ruptured intracranial 
aneurysm as the presumed cause. Exclusion criteria were 1) explicit objecti on by the subject to view the 
medical data, and 2) missing data on 60-day case fatality. The study protocol was approved by the local 
medical ethics committ ee.
Derivati on cohort
The predicti on model was based on pati ents included in the Internati onal Subarachnoid Aneurysm Trial 
(ISAT; n = 2,143), which compared the safety and effi  cacy of endovascular coiling with neurosurgical 
clipping.9 The ISAT predicti on model included the predictors age, maximum lumen size of the 
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ruptured aneurysm, Fisher grade, and World Federati on of Neurological Surgeons (WFNS) grade at 
randomizati on.5 The model aimed to predict case fatality at 60 days. The model performed reasonably 
at internal validati on with an area under the curve (AUC) of 0.70.5
Validati on cohort: data collecti on and outcome
The following data were collected: age, sex, Fisher grade, WFNS grade at admission, locati on of ruptured 
aneurysm, and aneurysm treatment mode. Assessment of Fisher grade10 and maximum lumen size (in 
millimeters, on CT angiography or digital subtracti on angiography) of the ruptured aneurysm was done 
by an interventi onal neuroradiologist (P.A.B.). Because the ISAT predicti on model used WFNS grade11
at ti me of randomizati on for coiling or clipping, we additi onally assessed WFNS grade at treatment 
decision regarding suitability for coiling or clipping, which was deemed a proxy for the moment of 
randomizati on in ISAT. 
 The outcome was 60-day case fatality, which was collected from our electronic pati ent record. When 
these data were not available, a lett er to the general practi ti oner was sent for retrieval of this informati on.
Discriminati on and calibrati on
The external validity of the ISAT predicti on model was assessed in terms of discriminati on and 
calibrati on. Discriminati on refers to how well the model disti nguishes between those who die within 
60 days and those who survive. Discriminati on was assessed by calculati ng the AUC of the receiver 
operati ng curve (ROC). The discriminati ve power of a model may be inﬂ uenced by diff erences in case-
mix between the derivati on and validati on cohort.12 In a populati on with a prognosti cally homogeneous 
case-mix, it will be more diffi  cult to disti nguish between pati ents with good or poor outcome than in a 
heterogeneous populati on. To take this into account, we calculated the case-mix-corrected AUC. The 
case-mix-corrected AUC indicates the discriminati ve power of a model, under the assumpti on that the 
predictor eff ects are fully correct for the validati on populati on. It was calculated by simulati ng new 
outcome values for all pati ents in the validati on dataset, based on the predicted risks for each pati ent 
calculated by the prognosti c model.12
 Calibrati on refers to the agreement between predicted and observed probabiliti es. Calibrati on was 
assessed graphically in a calibrati on graph, and expressed as the calibrati on slope and an intercept. The 
calibrati on slope describes the eff ect of the predictors in the validati on sample versus in the derivati on 
sample. Ideally, the calibrati on slope is equal to 1. The intercept indicates whether predicti ons are 
systemati cally too high or too low, and should ideally be zero.
Stati sti cal analyses
Pati ent baseline characteristi cs are presented as medians (interquarti le range [IQR]) or frequencies 
(percentage). The associati on of the predictors with 60-day case fatality was assessed with univariable 
and multi variable logisti c regression analyses. Associati ons were expressed as odds rati os (ORs) and 
95% CIs. For adequate comparison of the prognosti c eff ects for Fisher grade, we converted the ISAT 
reference category for this variable from grade 1 to grade 4 by recalculati ng the ORs and the 95% CIs.
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 Two versions of the model were validated: one with WFNS grade at admission and the other with 
WFNS grade at treatment decision.
 The main analysis was performed on the enti re cohort. A sensiti vity analysis was performed 
by excluding pati ents in whom either coiling or clipping had not been performed, pati ents who died 
within 48 hours aft er admission, and pati ents who had emergency decompressive craniotomy because 
of impending herniati on due to intracerebral hematoma. The remaining pati ents were considered to 
approximate the original ISAT populati on.
The stati sti cal analyses were performed using SPSS (Stati sti cal Package for Social Sciences, version 
22; IBM Corporati on, Armonk, NY) and R soft ware (R Foundati on for Stati sti cal Computi ng, Vienna, 
Austria). Missing values in the validati on cohort were stati sti cally imputed using a multi ple imputati on 
method with the AregImpute functi on in R stati sti cal soft ware. Complete case analyses were done for 
comparison with the imputed analyses. The calibrati on plots were created with an adapted version of 
the val.prob functi on from the rms library in the R package. 
Results
Study populati on
We retrieved 410 pati ents with aSAH. Reasons for exclusion are shown in Appendix 5.A. Thirteen 
pati ents with missing data on case fatality were excluded. The main reason for loss to follow-up was 
transfer of pati ents to another hospital. We performed analyses on 307 pati ents (96%), of whom 94 
pati ents (30.6%) died within 60 days. In the dataset with four independent variables (i.e., age, aneurysm 
lumen size, Fisher grade, and WFNS grade) and one outcome variable per pati ent, 47 of 1,228 data 
points (3.8%) were missing and stati sti cally imputed in the validati on sample. The highest percentage of 
missings was in the variables lumen size (11.7%) and Fisher grade (3.3%). 
 The distributi on of demographic data and prognosti c variables of both the validati on cohort and the 
ISAT derivati on populati on are shown in Table 5.1. In total, 93 pati ents (30%) did not receive aneurysm 
treatment. Among these, 41 died less than 48 hours, 32 died between 48 hours and 60 days, and 20 
survived more than 60 days. The decision whether or not to treat the aneurysm was based on local clinical 
guidelines (Appendix 5.B). The Fisher grades and WFNS grades were signifi cantly higher in the validati on 
cohort than the ISAT sample. 
 The median ti me between SAH and randomizati on in the ISAT derivati on cohort was 2 days 
(coiling: IQR, 1–4; range, 0–26 and clipping: IQR, 1–5; range, 0–28). In the validati on cohort, the median 
ti me between SAH and treatment decision was 1 day (IQR, 0–3; range, 0–25). The median interval 
between the moment of assessment of WFNS grade at admission and WFNS grade at ti me of treatment 
decision was 1 day (IQR, 0–2; range, 0–22). There was no stati sti cally signifi cant diff erence between 
WFNS grade at admission and WFNS grade at ti me of treatment decision in the unselected cohort (n 
= 307; p = 0.69, Wilcoxon signed rank test); in the cohort of pati ents who met the original ISAT criteria 
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(i.e., were clipped or coiled), WFNS grade at admission diff ered from WFNS grade at treatment decision 
(n = 211; p = 0.04, Wilcoxon signed rank test) (Appendix 5.C).
Prognosti c eﬀ ects
In the validati on cohort, the strongest univariable predictor of case fatality was WFNS grade at ti me of 
treatment decision (WFNS grade 4: OR, 6.95; 95% CI, 2.30–21.01 and WFNS grade 5: OR, 299.20; 95% 
CI, 83.53–1071.74) (Table 5.2). WFNS grade was also the strongest predictor in the ISAT populati on. 
Associati ons of both age and lumen size with 60-day case fatality were similar in derivati on and 
validati on cohort. No pati ents with Fisher grade 1 and 2 died within 60 days in the validati on cohort. 
The prognosti c eff ects of WFNS grade in the multi variable analysis showed the same trend as in the 
univariable analysis (Table 5.2).
Table 5.1. Baseline characteristi cs of pati ents in the Internati onal Subarachnoid Aneurysm Trial development cohort 
and in the Rott erdam validati on cohort
Characteristi cs Measure or category Internati onal Subarachnoid 
Aneurysm Trial derivati on 
cohort (n=2,143)
Rott erdam 
validati on cohort 
(n=307)
pa
Ageb (yr) 52 (44-60) 56 (47-66) <0.001
Maximum lumen size 
aneurysm (mm)
Total available 2128 (100%)
5.0 (4.0-7.0)
271 (88%)
6.0 (4.8-8.1)
<0.001
Fisher grade, n (%) Total available
1
2
3
4
2128 (100)
114 (6)
360 (17)
902 (42)
752 (35)
297 (97)
7 (2)
7 (2)
62 (21)
221 (75)
<0.001
World Federati on of 
Neurological Surgeons grade, 
n (%)
Total available
1
2
3
4
5
6 (not assessable)
2128 (100)
1324 (62)
546 (26)
133 (6)
74 (4)
20 (1)
31 (1)
306 (99)
115 (38)
62 (20)
6 (2)
50 (16)
73 (24)
NA
<0.001
Sex, n (%) Total available
Female
Male
2128 (100)
1339 (63)
789 (37)
307 (100)
200 (65)
107 (35)
0.450
Treatment, n (%) Total available
Coil 
Clip
None
2128 (100)
1062 (50)
1066 (50)
NA
307 (100)
153 (50)
61 (20)
93 (30)
<0.001
Locati on ruptured aneurysm, 
n (%)
Total available
Anterior circulati on
Posterior circulati on
None
2128 (100)
2070 (97)
58 (3)
NA
307 (100)
210 (68)
77 (25)
20 (7)
<0.001
NA, not applicable. 
ap were calculated by Mann-Whitney U test, chi-square test, or Fisher exact test. 
bMedian (interquarti le range).
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Model performance
Assessment of discriminati ve ability of the model in all pati ents (n = 307) including WFNS grade at ti me 
of treatment decision showed an AUC of 0.89 (Figure 5.1A). When WFNS grade at admission was used, 
the AUC was 0.82 (Figure 5.1B), indicati ng less opti mal discriminati on. 
 The model with WFNS grade at admission predicted 17.0% 60-day case fatality, and the model 
with WFNS grade at ti me of treatment decision 17.7%, whereas the observed case fatality was 30.6%. 
The calibrati on slopes were 1.417 for the model with WFNS grade at admission, and 1.959 for WFNS 
grade at ti me of treatment decision. The intercepts were 1.502 and 2.248, respecti vely, indicati ng 
that the model’s predicti ons of case fatality were systemati cally lower than observed case fatality. 
When WFNS grade at ti me of treatment decision was used as a predictor, this overall underesti mati on 
increased. In pati ents with low observed case fatality risk (≤ 20%) (Figure 5.2A), the calibrati on plot 
shows adequate agreement between predicted and observed 60-day case fatality. The model was also 
tested in the nonimputed dataset (only complete cases, n = 266), which showed similar results (not 
shown). 
 Sensiti vity analysis in pati ents similar to the original ISAT populati on (n = 211) showed reasonable 
calibrati on and discriminati on in the model with WFNS grade at ti me of treatment decision (AUC = 
0.72; calibrati on slope, 0.916) (Figure 5.2). The model with WFNS grade at admission showed lower 
discriminati ve ability between survivors and nonsurvivors (AUC = 0.65; calibrati on slope, 0.599). 
Intercepts were –0.423 for the model with WFNS grade at ti me of treatment decision and –1.031 for 
WNFS at admission. This indicates an overall overesti mati on of case fatality in this selecti on of pati ents, 
which decreased when using WFNS grade at ti me of treatment decision.
 For both versions of the predicti on model, discriminati on was bett er in the unselected validati on 
cohort, which was largely explained by a more heterogeneous case-mix, compared with the cohort of 
pati ents who met the original ISAT selecti on criteria. This is indicated by a small diff erence between 
case-mix–corrected AUCs of the two cohorts: the case-mix–corrected AUCs in the unselected cohort (n 
= 307) were 0.77 for WFNS grade at treatment decision and 0.76 for WFNS grade at admission, versus 
0.74 (WFNS grade at treatment decision) and 0.73 (WFNS grade at admission) in the cohort that met 
the original ISAT selecti on criteria.
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Figure 5.1. Calibrati on plots of the model with (A) World Federati on of Neurological Surgeons (WFNS) grade at ti me 
of treatment decision and (B) WFNS grade at admission in the unselected Rott erdam validati on cohort (n = 307). 
C, area under the receiver operati ng characteristi c (ROC) curve, SAH, subarachnoid hemorrhage. 
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Figure 5.2. Calibrati on plots of the model with pati ents clipped or coiled aft er considerati on for both treatment 
modaliti es (similar to original Internati onal Subarachnoid Aneurysm Trial [ISAT] inclusion criteria, n = 211) with (A) 
World Federati on of Neurological Surgeons (WFNS) grade at ti me of treatment decision and (B) WFNS grade at 
admission. 
C, area under the receiver operati ng characteristi c (ROC) curve, SAH, subarachnoid hemorrhage. 
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Discussion
This study is the fi rst to externally validate a prognosti c model for SAH based on data from ISAT to predict 
60-day case fatality. External validati on yielded a discriminati ve performance superior to the derivati on 
setti  ng, suggesti ng generalizability. However, predicted probabiliti es were lower than observed 60-day 
case fatality, implicati ng relati vely poor calibrati on. An important secondary fi nding was that ti ming of 
WFNS grade assessment inﬂ uenced model performance. 
 A recent systemati c review showed that the ISAT predicti on model has reasonable performance 
and good design compared with other SAH predicti on models.4 The most commonly used predictors 
in this review were age, WFNS grade, Fisher grade, and aneurysm size.4 These variables are easily 
obtainable at admission, facilitati ng a prognosti c esti mate early in the disease course. However, we 
found greater predicti ve ability of the model with WFNS grade at ti me of treatment decision compared 
with WFNS grade at admission. This fi nding is in line with a previous study demonstrati ng that WFNS 
grade obtained at admission was inferior to WFNS grade aft er admission.13 This indicates that including 
a change over ti me may help to improve model performance.13,14 This seems especially true for aSAH, 
which is characterized by variable clinical course.14-16 However, the ideal ti ming of obtaining predictors 
does depend not only on model performance but also on the ti ming of various treatments, based on 
such predictors (e.g., immediately aft er admission or later). 
 Assessing the performance of a prognosti c model and interpreti ng its clinical relevance is 
complex.8 We aimed to investi gate the generalizability of the ISAT model by testi ng it in an unselected 
cohort within a diff erent setti  ng (observati onal cohort vs randomized controlled trial) and case-mix 
(more severely aff ected pati ents). In principle, a model is generalizable to populati ons comparable to the 
development data, based on the data (i.e., comparability of mean age, severity) or on clinical judgment 
(are populati ons expected to be comparable between center A and B). However, generalizability is not 
by defi niti on limited to populati ons comparable to the development setti  ng; model esti mates may 
also be valid in broader populati ons. External validati on is useful to see whether the model can be 
used in diff erent setti  ngs. Thus the diff erences between derivati on and validati on cohorts are more an 
advantage than a limitati on of our study.
 We found higher AUCs in the heterogeneous validati on populati on than described in both the 
derivati on cohort and the sensiti vity analysis in pati ents who were clipped or coiled. The higher AUCs 
reﬂ ect the less restricti ve enrollment criteria: the greater the heterogeneity, the bett er the model can 
disti nguish pati ents with or without the outcome of interest. Discriminati ve ability of the ISAT predicti on 
model in our cohort remained adequate (well over 0.70) aft er correcti ng for the more heterogeneous 
case-mix. This fi nding suggests that the model might be applicable for prognosti c classifi cati on of future 
aSAH pati ent populati ons. 
 The good discriminati ve ability of the model is accompanied by an overall underesti mati on of 
case fatality, especially in pati ents with high case fatality risk. This fi nding is partly explained by the 
fact that pati ents who died early are included in our cohort (13% of our pati ents died < 48 hr), but 
not in ISAT. Furthermore, the modest performance of the model in pati ents with a case fatality risk 
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greater than 20% is in line with the higher proporti on of poor-grade pati ents in the validati on cohort. 
It is indeed common that RCTs—as ISAT—typically include lower risk pati ents. When risk esti mates 
are used for clinical decision making, reliable absolute risk esti mates are needed. Therefore, a model 
with good agreement between observed and predicted probabiliti es (calibrati on) is required.17 For 
clinical practi ce, this implicates that the ISAT predicti on model needs to be updated in more recent 
data and for specifi c setti  ngs. Specifi cally, we would recommend adjustment of the intercept of the 
model such that the overall mean predicted probability is equal to the observed overall outcome 
frequency (recalibrati on). A second step in updati ng the model would be reesti mati on of the regression 
coeffi  cients of the predictors in the model. Whether such updati ng is needed should be decided based 
on external validati on results, the comparability of the development and validati on setti  ng based on 
clinical knowledge, and the number of pati ents in the development setti  ng. For example, one would 
not decide to completely refi t a model based on a small validati on set when the development sample 
was very large. A general message is that existi ng prognosti c models should always be considered and 
validated instead of developing new models.
 Strengths of this study are external validati on in an unselected populati on of aSAH pati ents, 
reﬂ ecti ng real-life clinical practi ce and replicati on of predictors and outcome.5 Several limitati ons of 
our study need to be considered. First, since the validati on cohort consisted of ICU managed aSAH 
pati ents, model performance may not apply to non-ICU pati ents. Second, this study is a single-center 
study and external validity of the ISAT model needs to be confi rmed. Third, there was a small number 
of missing outcomes in the unselected cohort, but sensiti vity analyses accounti ng for missing outcomes 
did not diff er (results not shown). Finally, we only had case fatality at 60 days and not functi onal status. 
Although 60-day case fatality is a very robust outcome, long-term disability is a more relevant outcome 
for pati ents and should be included in future prognosti c studies. 
 Outcome predicti on in individual aSAH pati ents remains diffi  cult due to the variable clinical course 
and multi ple treatment opti ons.18 Our fi ndings might indicate that acute phase variables are not ideal 
predictors in diseases with variable clinical course, in contrast to neurologic diseases with a less variable 
course.19 To improve outcome predicti on, including dynamic variables over ti me in future models may 
benefi t performance. Additi onally, we could focus on predictors with a higher prognosti c value. Since 
Fisher grade has subopti mal interobserver variability,20-23 the use of other grading scales for blood on 
CT may further improve model performance.20,24,25 Importantly, future prognosti c models on mortality 
should include data on causes of death and withdrawal of care practi ces to further scruti nize external 
validity of such models.
Conclusions 
Validati on of existi ng models should always be taken as a starti ng point in prognosti c model 
development. This external validati on study confi rms generalizability of the ISAT prognosti c model 
in terms of discriminati on, in an independent unselected cohort of more severely aff ected aSAH 
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pati ents. In additi on, WFNS grade at treatment decision for the ruptured aneurysm benefi tt ed model 
performance. However, predicted probabiliti es were lower than observed case fatality, illustrati ng 
the need for conti nuous external validati on and updati ng over ti me and to specifi c setti  ngs before 
implementati on in clinical practi ce.
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Appendix 5.A. Flowchart clarifying pati ent ﬂ ow according to in- and exclusion criteria
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Appendix 5.B. Management guideline with regard to acutely treat or not (yet) treat ruptured intracranial aneurysm 
in Erasmus Medical Center during period of study (validati on cohort):
The decision whether or not to treat the aneurysm of individual pati ents was made based on the local 
multi disciplinary clinical guidelines in our university hospital. These guidelines state that no endovascular or 
neurosurgical aneurysm treatment immediately aft er SAH is considered in pati ents with WFNS grade 5 who 
do not improve aft er resuscitati on within the ﬁ rst 24 hours and/or CSF drainage in case of hydrocephalus 
(excluding those who have a space occupying ICH with impending herniati on necessitati ng emergency 
decompression craniotomy).
The combinati on of early deaths and the adherence to these local clinical guidelines explain why 30% of our 
cohort did not receive aneurysm treatment.
With regard to poor grade pati ents on admission:
In severely aﬀ ected pati ents (i.e. those with WFNS 5 or even those with (parti ally) absent brainstem 
reﬂ exes aft er resuscitati on), we adhere to a policy of treatment at the ICU (including CSF drainage in case 
of hydrocephalus) of at least 24 hours aft er the ictus during which ti me the course of the neurological 
examinati on and level of consciousness will guide our multi -disciplinary decision to stay on acti ve treatment 
or to stop treatment because of infaust prognosis or consider organ donati on in potenti al organ donors.
We acknowledge the fact that pati ents aft er SAH may eventually improve aft er successful resuscitati on 
even when brain stem reﬂ exes are initi ally absent.
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Appendix 5.C. Histogram showing the signifi cantly diff erent distributi on of WNFS on admission and WFNS at ti me of 
treatment decision among pati ents clipped or coiled aft er considerati on for both treatment modaliti es (original ISAT 
selecti on criteria). Wilcoxon Signed Ranks test, p = 0.04.
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5.1
To the Editor:
With great interest, we read the study by van Donkelaar et al,1 which describes the development and 
validati on of the SAFIRE (size of the aneurysm, age, Fisher grade, World Federati on of Neurosurgical 
Societi es aft er resuscitati on) grading scale to predict functi onal outcome aft er aneurysmal subarachnoid 
hemorrhage (aSAH). Indeed, early identi fi cati on of aSAH pati ents at risk for poor functi onal outcome 
is important for clinical decision making. However, is the development of a new prognosti c model the 
most logical approach, given the contemporary evidence on outcome predicti on in aSAH?
 Several cross-validated or externally validated prognosti c models for mortality and functi onal 
status aft er aSAH exist.2–5 Although the generalizability and transportability of prognosti c models to 
other populati ons can only be established aft er a conti nuous process of model validati on and updati ng, 
existi ng models should always be taken into account to prevent development of multi ple models 
with unknown generalizability. For instance, poor calibrati on of the ISAT (Internati onal Subarachnoid 
Aneurysm Trial) model in a single-center aSAH populati on implied that the model should be updated,3
not discarded. According to van Donkelaar et al,1 the currently available prognosti c models lack accuracy 
and generalizability, but this was not fully tested in their own data. Instead of developing a new model, 
validati on and updati ng of available prognosti c models for aSAH would have been preferred.3
 Additi onally, it is not evident that this study provides novel insights for clinicians and researchers 
in the fi eld of aSAH. The authors state that the SAFIRE grading scale excels in simplicity.1 However, the 
fi nal predictors of this prognosti c model (age, World Federati on of Neurological Surgeons grade, Fisher 
grade, and aneurysm size) are identi cal to those in the ISAT model.2 The potenti al limitati on of the ISAT 
model that World Federati on of Neurological Surgeons grade was assessed at randomizati on, which is 
not clinically applicable, has been addressed in a previous external validati on.3 The SAHIT (Subarachnoid 
Hemorrhage Internati onal Trialists) prognosti c models that were developed on >10 000 pati ents from 
multi ple randomized clinical trials and observati onal studies,4 were deemed by the authors to be complex 
and confusing for use in clinical practi ce.1 But these SAHIT models with increasing complexity (core: age, 
hypertension and World Federati on of Neurological Surgeons grade; neuroimaging: core+Fisher grade, 
aneurysm locati on, and size; full: neuroimaging+aneurysm treatment)4 facilitate insight in the added 
value of new predictors and allow clinicians to predict outcome depending on the clinical situati on (eg, 
before or aft er imaging). Moreover, model simplicity is merely a matt er of model presentati on: when 
the regression equati on of a prognosti c model is available, a risk score or nomogram can easily be 
developed.4
 In conclusion, the proposed SAFIRE grading scale resembles existi ng prognosti c models for clinical 
outcome aft er aSAH in terms of predictors, performance, and simplicity and does, therefore, not seem 
to contribute to current knowledge. External validati on and updati ng of existi ng prognosti c models 
should always be considered before development of a new model. This is especially relevant in a disease 
like aSAH for which a variety of neurological and imaging grading scales are being used worldwide, while 
core predictors of clinical outcome have been established.
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Abstract
Object: Diff erences in clinical outcomes between centers and countries may reﬂ ect variati on in pati ent 
characteristi cs, diagnosti c and therapeuti c policies or quality of care. The purpose of this study was 
to investi gate the presence and magnitude of between-center and between-country diff erences in 
outcome aft er aneurysmal subarachnoid hemorrhage (aSAH).
Methods: We analyzed data from 5972 aSAH pati ents enrolled in randomized clinical trials of 3 diff erent 
treatments from the Subarachnoid Hemorrhage Internati onal Trialists (SAHIT) repository including data 
from 179 centers and 20 countries. We used random eff ects logisti c regression adjusted for pati ent 
characteristi cs and ti ming of aneurysm treatment to esti mate between-center and between-country 
diff erences in unfavorable outcome, defi ned as Glasgow Outcome Scale score of 1-3 (severe disability, 
vegetati ve state or death) or modifi ed Rankin Scale score of 4-6 (moderately severe disability, severe 
disability or death) at three months. Between-center and between-country diff erences were quanti fi ed 
with the median odds rati o (MOR), which can be interpreted as the rati o of odds of unfavorable outcome 
between a typical high-risk and a typical low-risk center or country.
Results: The proporti on of pati ents with unfavorable outcome was 27% (n=1599). We found substanti al 
between-center diff erences (MOR = 1.26, 95% CI 1.16-1.52), which could not be explained by pati ent 
characteristi cs and ti ming of aneurysm treatment (adjusted MOR = 1.21, 95% CI 1.11-1.44). We 
observed no between-country diff erences (adjusted MOR = 1.13, 95% CI 1.00-1.40). 
Conclusions: Clinical outcomes aft er aSAH diff er between centers. These diff erences could not be 
explained by pati ent characteristi cs or ti ming of aneurysm treatment. Further research is needed to 
confi rm the presence of diff erences in outcome aft er aSAH between hospitals in more recent data and 
to investi gate potenti al causes.
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Introducti on
Despite advances in treatment, functi onal outcome aft er aneurysmal subarachnoid hemorrhage (aSAH) 
remains poor.1, 2 The combinati on of a relati vely young age of onset and poor clinical outcomes makes 
aSAH a disease with major individual and economic impact.3 The main evidence-based treatment 
recommendati ons in aSAH include endovascular coil embolizati on in pati ents with a ruptured 
aneurysm eligible for both endovascular coiling and neurosurgical clipping, administrati on of oral 
nimodipine and maintenance of euvolemia to prevent delayed cerebral ischemia (DCI), and drainage of 
cerebrospinal ﬂ uid in pati ents with hydrocephalus.4 However, many other interventi ons to prevent or 
treat complicati ons in aSAH are less evidence-based.4, 5 Also, discrepancies have been found between 
centers regarding clinical practi ce and adherence to guidelines for aSAH,6, 7 suggesti ng diff erences in 
diagnosti c and therapeuti c policies between centers and countries that may contribute to variati ons in 
observed case-fatality rates across regions.1
  Between-center and between-country diff erences in outcome can be caused by random variati on 
or by center-, country- or pati ent-related factors (e.g. diff erences in country economic status or severity 
of aSAH), but they may also reﬂ ect diff erences in processes of care including diagnosti c and therapeuti c 
policies and adherence to guidelines (quality of care). Insight into between-center or between-country 
diff erences in outcome may facilitate research evaluati ng the comparati ve eff ecti veness of structures 
and processes of care in aSAH (e.g. organizati onal structures, individual treatment interventi ons), and 
may consequently contribute to improvement in quality of care. We aimed to investi gate the presence 
and magnitude of between-center and between-country diff erences in clinical outcome aft er aSAH. 
Methods
Study populati on
The Subarachnoid Hemorrhage Internati onal Trialists (SAHIT) repository contains data on more 
than 15,000 SAH pati ents from 10 randomized clinical trials (RCTs) and 11 observati onal studies or 
registries. For the present study, we used data from multi center studies of 3 diff erent treatments: the 
Intraoperati ve Hypothermia for Aneurysm Surgery Trial (IHAST), Magnesium Sulfate in Aneurysmal 
Subarachnoid Hemorrhage (MASH I and II) trials, and trials of ti rilazad mesylate in pati ents with 
aneurysmal subarachnoid hemorrhage (ti rilazad trials),8-12 including a total of 6036 pati ents. The other 
studies in the SAHIT database could not contribute to the esti mati on of between-center and between-
country diff erences, either because they were single-center studies (and therefore no disti ncti on could 
be made between study eff ect and center or country eff ect) or because no informati on on center or 
country was available in the SAHIT database. Details on the development of the SAHIT repository and 
the included studies have been reported previously.13 The SAHIT database was approved by the research 
ethics board at St Michael’s Hospital, Toronto, Canada. Pati ents previously consented to the use of their 
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data for future related studies, and all data for the current study were anonymized. Therefore, neither 
approval from an insti tuti onal review board nor informed consent was required.
Primary outcome measure
The RCTs used either the Glasgow Outcome Scale (GOS)8-10 or modifi ed Rankin Scale (mRS) score11, 12 at 
3 months for functi onal outcome. We therefore defi ned our primary outcome measure as functi onal 
outcome according to the GOS or mRS score at 3 months, combined into a composite endpoint by 
dichotomizing both outcomes into favorable (GOS score 4-5 or mRS score 0-3) versus unfavorable (GOS 
score 1-3 or mRS score 4-6).
Between-center and between-country diﬀ erences
We used random eff ects (multi level) logisti c regression to esti mate diff erences in functi onal outcome 
aft er aSAH between centers and countries in order to be able to account for random variati on due 
to small sample sizes per center or country and for diff erences in pati ent characteristi cs and process 
measures. In a random eff ects model, fi xed eff ects are esti mated for pati ent and process characteristi cs, 
and random eff ects are esti mated for the eff ect of center and country. The random eff ects model 
assumes a normal distributi on of the random eff ects. The variance of the random eff ects ( 2) esti mated 
in the random eff ects logisti c regression model is a measure for the unexplained between-center or 
between-country diff erences, independent of both random variati on (chance) and pati ent and process 
characteristi cs as included in the model. Since between-center and between-country diff erences may 
inﬂ uence each other, we used one random eff ects logisti c regression model with both center and 
country as random eff ects (Appendix 7.A). 
  To facilitate interpretati on of the between-center or between-country diff erences and allow 
for a direct comparison with the eff ect size (odds rati os) of pati ent characteristi cs, we calculated the 
median odds rati o (MOR) with 95% confi dence interval (CI).14, 15 For each pair of pati ents from diff erent 
centers or countries, an odds rati o was computed between a pati ent from the center or country with 
the highest risk for unfavorable outcome and a pati ent from the center or country with the lowest risk 
for unfavorable outcome. The MOR represents the median value of the distributi on of these odds rati os 
for unfavorable outcome for all pairs of pati ents in our dataset. The MOR is calculated based on the 2 
esti mated in the random eff ects model, using the following formula: MOR = exp(√ [2 x 2] x Φ-1[0.75]), 
where Φ corresponds to the cumulati ve distributi on functi on of the normal distributi on with mean 0 
and variance 1. Hence, Φ–1(0.75) is the 75th percenti le.14, 15 If there are no unexplained between-center 
or between-country diff erences, 2 = 0 and MOR = 1.
   The random eff ects logisti c regression model was considered for both unadjusted between-
center and between-country diff erences, and for between-center and between-country diff erences 
adjusted for diff erences in pati ent and process characteristi cs (fi xed eff ects) between centers and 
countries. To enable comparison between the variance components of the unadjusted and adjusted 
models, we rescaled the variance of the adjusted models according to previously proposed methods.16
The pati ent characteristi cs included in the model were age, history of hypertension, World Federati on 
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of Neurosurgical Societi es (WFNS) grade, Fisher grade, aneurysm locati on (anterior cerebral artery 
aneurysms [including anterior communicati ng artery aneurysms], internal cerebral artery aneurysms 
[including posterior communicati ng artery aneurysms], middle cerebral artery aneurysms or posterior 
circulati on aneurysms [including vertebral and basilar artery aneurysms]), aneurysm size (≤12 mm, 13-
24 mm or ≥25 mm)17 and aneurysm treatment (clipping, coiling or none). These variables are known 
predictors of poor outcome aft er aSAH.17-20 Because recommendati ons on the ti ming of aneurysm 
treatment diff er between American and European guidelines, we additi onally adjusted for the process 
measure “ti me from aSAH to aneurysm treatment”.4, 21 All analyses were also adjusted for study as a 
fi xed eff ect because the overall outcome may vary across studies. Centers that parti cipated in multi ple 
studies were given the same center code across studies. We performed sensiti vity analyses in the 
centers that included more than 10 pati ents to evaluate the robustness of our results.
  Because the MOR is an overall measure for between-center and between-country diff erences, 
we also compared the eff ect esti mates for the individual centers and countries to identi fy the hospitals 
or countries with the highest and lowest risk of unfavorable outcome. The esti mated random eff ects 
(betas) for unfavorable outcome of the individual centers and countries were presented graphically by 
plotti  ng them with a 95% CI. 
  Stati sti cal analyses were performed with R soft ware version 3.3.1 (R Foundati on for Stati sti cal 
Computi ng, Vienna, Austria). Missing data were stati sti cally imputed using single imputati on (mice
package R). The CIs around the MOR were computed with the conﬁ nt.merMod functi on (lme4 package 
R). 
Results
Study populati on
We analyzed data from 5972 aSAH pati ents from 179 centers in 20 diff erent countries, aft er excluding 
pati ents with missing data on functi onal outcome (n=54) or unknown center (n=10). Missing data on 
history of hypertension (22%), Fisher grade (22%), aneurysm locati on (18%), aneurysm size (23%) and 
ti ming of aneurysm treatment (8%) were imputed. Unfavorable outcome at 3 months occurred in 1599 
pati ents (27%), and 872 pati ents (15%) died. The pati ents’ median age was 53 years (interquarti le 
range [IQR] 44-62). A total of 1132 pati ents (19%) had a poor WFNS grade (4 or 5) at admission (Table 
7.1). The number of included pati ents per center ranged from 1 to 846 (Figure 7.1A). The majority of 
pati ents were from the US (n=1765, 30%) or from one of 14 countries in Europe (n=3155, 53%). Other 
parti cipati ng countries were Canada (n=536), Australia (n=344), New Zealand (n=142), Chile (n=21) and 
Mexico (n=9) (Figure 7.1B). The centers located in the US parti cipated in the IHAST and ti rilazad studies. 
The United Kingdom was the only country that contributed to the studies of all 3 treatments (Appendix 
7.B). Pati ent characteristi cs, such as age, history of hypertension and poor WFNS or Fisher grade at 
admission, were predicti ve of unfavorable outcome (Appendix 7.C).
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Table 7.1. Descripti ve stati sti cs of the studies in the SAHIT repository used for analysis of between-center and 
between-country diff erences
IHAST MASH I & II Tirilazad
Study period 2000-2003 2000-2011 1991-1997
Original publicati on Todd et al (2005)10 Van den Bergh et al 200511
Dorhout Mees et al 201212
Kassell et al (1996)9 
Haley et al (1997)8 
Pati ents, n 1000 1484 3488
Centers, n 30 9 148
Countries, n 7 3 19
Conti nents Europe
North America
Oceania
Europe
South America
Europe
North America
Oceania
Age in years, median (IQR) 52 (43-60) 56 (48-65) 51 (42-62)
History of hypertension, 
n (%)a
398 (40) 57 (4) 1124 (33)
Initi al WFNS grade, n (%)
1
2
3
4
5
660 (66)
289 (29)
51 (5)
0 (0)
0 (0)
728 (49)
346 (23)
64 (4)
218 (15)
127 (8)
1265 (36)
1028 (29)
408 (12)
346 (10)
441 (13)
Fisher grade, n (%)b
1
2
3
4
54 (5)
342 (34)
474 (47)
130 (13)
1 (0)
22 (1)
43 (3)
141 (10)
330 (9)
451 (13)
2271 (66)
414 (12)
Aneurysm locati on, n (%)c
ACA/ACoA
ICA/PCoA
MCA
Pst circ (incl BA & VA)
391 (39)
318 (32)
206 (21)
84 (8)
190 (13)
117 (8)
89 (6)
61 (4)
1243 (36)
1019 (29)
695 (20)
469 (13)
Aneurysm size, n (%)d
≤12 mm
13-24 mm
≥25 mm
878 (88)
94 (9)
24 (3)
143 (10)
14 (1)
2 (1)
2549 (73)
785 (23)
126 (4)
Aneurysm treatment
Clipping
Coiling
None
1000 (100)
0 (0)
0 (0)
551 (37)
735 (50)
198 (13)
3151 (90)
0 (0)
337 (10)
Time from aSAH to aneurysm 
treatment in days, median (IQR)
2.0 (1.0-4.0) 1.0 (1.0-2.0) 1.4 (1.0-1.8)
Outcome at 3 mos, n (%)e
Unfavorable
Mortality
144 (14)
61 (6)
398 (27)
234 (16)
1057 (30)
577 (17)
ACA, anterior cerebral artery; ACoA, anterior communicati ng artery; BA, basilar artery; circ, circulati on; ICA, internal 
cerebral artery; MCA, middle cerebral artery; PCoA, posterior communicati ng artery; pst, posterior; VA, vertebral artery.
aMASH 1276 missing
bMASH 1277 missing. In the MASH trials, the Hijdra score was used to measure the amount of subarachnoid blood.
cMASH 1027 missing
dMASH 1325 missing
eOutcome was based on 3-month GOS scores for IHAST and the ti rilazad studies and 3-month mRS scores for the 
MASH trials.
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Figure 7.1. Observed number of pati ents (A) per center in one of 179 centers, with numbers varying from 1 to 846 
(median 20; IQR 11-37) and (B) per country in one of 20 countries, with numbers varying from 9 to 1765 (median 
109; IQR 31-334).
Between-center diﬀ erences
We found between-center diff erences in functi onal outcome, both before and aft er adjustment for 
pati ent characteristi cs and ti me to aneurysm treatment (MOR = 1.26, 95% CI 1.16-1.52, and adjusted 
MOR = 1.21, 95% CI 1.11-1.44, respecti vely) (Table 7.2). The MOR of 1.21 implies a median increase of 
21% in odds of unfavorable outcome if a pati ent was treated in a hospital with higher risk of unfavorable 
outcome. This order of magnitude is comparable to the eff ect of hypertension or aneurysm size larger 
than 12 mm (Appendix 7.C). While between-center diff erences were substanti al in the ti rilazad trials 
(adjusted MOR = 1.22, 95% CI 1.10-1.46), we found no between-center diff erences beyond random 
variati on, pati ent characteristi cs and ti ming of aneurysm treatment in the IHAST (adjusted MOR = 1.00, 
95% CI 1.00-1.02) and MASH studies (adjusted MOR = 1.00, 95% CI 1.00-1.50) (Table 7.2).
  The eff ect esti mates for unfavorable outcome in individual centers were subject to substanti al 
uncertainty (Figure 7.2A), making it diffi  cult to identi fy individual centers that perform bett er or worse 
than others.
Between-country diﬀ erences
No between-country diff erences were observed in the unadjusted (MOR = 1.14, 95% CI 1.00-1.43) 
and adjusted (adjusted MOR = 1.13, 95% CI 1.00-1.40) analyses (Table 7.2 and Figure 7.2B). Between-
country diff erences beyond random variati on, pati ent characteristi cs and ti ming of treatment were 
absent in the IHAST (adjusted MOR = 1.00, 95% CI 1.00-1.02) and the MASH studies (adjusted MOR = 
1.00, 95% CI 1.00-1.38) and nonsignifi cant in the ti rilazad trials (adjusted MOR = 1.14, 95% CI 1.00-1.46) 
(Table 7.2).
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   Sensiti vity analyses with only centers that included 10 or more pati ents yielded similar between-
center and between-country diff erences (Appendix 7.D).
Figure 7.2. Diff erences between (A) centers and (B) countries in unfavorable outcome, adjusted for age, history of 
hypertension, WFNS, Fisher grade, aneurysm locati on, aneurysm size and ti me from SAH to aneurysm treatment in 
a random eff ects model. The circles indicate the random eff ects for the individual centers (betas), and the size of the 
circle refers to the number of pati ents in each center. The lines reﬂ ect the 95% confi dence interval.
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Table 7.2. Between-center and between-country diff erences in the total database (n=5972) and within studies.
Unfavorable 
outcome
n (%)
Unadjusted Adjusteda
Between-center 
diff erencesb Ƭ2 MOR (95% CI) Ƭ2 MOR (95% CI)
Totalc (n=5972) 1599 (27) 0.062 1.26 (1.16-1.52) 0.045 1.21 (1.11-1.44)
IHAST (n=1000) 144 (14) 0.000 1.00 (1.00-1.53) 0.000 1.00 (1.00-1.02)
MASH (n=1484) 398 (27) 0.050 1.23 (1.00-1.85) 0.000 1.00 (1.00-1.50)
Tirilazad (n=3488) 1057 (30) 0.074 1.28 (1.15-1.60) 0.047 1.22 (1.10-1.46)
Between-country 
diff erencesd
Totalc (n=5972) 1599 (27) 0.021 1.14 (1.00-1.43) 0.016 1.13 (1.00-1.40)
IHAST (n=1000) 144 (14) 0.000 1.00 (1.00-1.69) 0.000 1.00 (1.00-1.02)
MASH (n=1484) 398 (27) 0.000 1.00 (1.00-1.70) 0.000 1.00 (1.00-1.38)
Tirilazad (n=3488) 1057 (30) 0.038 1.20 (1.05-1.58) 0.020 1.14 (1.00-1.46)
aAdjusted for age, hypertension, WFNS grade, Fisher grade, aneurysm locati on, aneurysm size, aneurysm treatment 
and ti me from aSAH to aneurysm treatment.
bAdjusted for country as a random eff ect.
cModels in the total database were adjusted for study.
dAdjusted for center as a random eff ect.
Discussion
We analyzed data from a large internati onal repository of aSAH pati ents and observed substanti al 
between-center diff erences in functi onal outcome that could not be explained by random variati on, 
diff erences in pati ent characteristi cs or ti ming of aneurysm treatment. We observed no stati sti cally 
signifi cant between-country diff erences.
   Previous studies have reported substanti al between-center diff erences in other neurological 
diseases. Large between-center diff erences in outcome were found in a study in traumati c brain injury 
(TBI), based on more than 15,000 pati ents from both RCTs and observati onal studies.22 The between-
center diff erences in our study were similar to those reported in TBI (comparable variances).22 Another 
example is the considerable between-center variability in functi onal outcome that was observed in 
pati ents enrolled in the Tinzaparin in Acute Ischemic Stroke Trial (TAIST).23 In aSAH, only a few studies 
have reported on between-center or between-country diff erences in outcome.24, 25 Moreover, studies 
that evaluated between-center and between-country variability generally used fi xed eff ect models, 
while random eff ects logisti c regression is preferred to bett er take into account clustering of pati ents, 
especially with a small number of pati ents per center or country.26 The present study confi rms the 
previously reported absence of between-center diff erences in outcome aft er aSAH within the IHAST 
study, but contradicts prior analyses by showing that between-center diff erences in outcome do exist 
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within the Tirilazad trials.24, 25 Our results were based on a large repository and we used advanced stati sti cal 
methods accounti ng for diff erences due to random variati on and pati ent or process characteristi cs. 
  Between-center diff erences in clinical outcomes aft er aSAH persisted aft er adjustment for pati ent 
characteristi cs and ti ming of aneurysm treatment. Other factors that might explain between-center 
diff erences are residual confounding and registrati on bias. However, these factors are unlikely to 
account for our results. We adjusted for known prognosti c factors for outcome aft er aSAH as well as 
for ti me from aSAH to aneurysm treatment. This reduced the risk for residual confounding, although 
we acknowledge that data on several other factors that might inﬂ uence outcome (e.g. withdrawal of 
life-sustaining measures or severity of underlying systemic illness) were unavailable. Also, our analyses 
were performed on multi ple RCTs with high-quality data. Altogether, diff erences in unfavorable outcome 
between centers might be best explained by diff erences in diagnosti c and therapeuti c policies or quality 
of care. We observed no stati sti cally signifi cant between-country diff erences, suggesti ng that hospitals 
with similar pati ent outcomes are not clustered within one country.
  Diff erences in outcome aft er aSAH between centers due to diff erent treatment policies or quality 
of care are undesirable. However, because of limited evidence regarding treatment strategies and 
diff erences in adherence to guidelines,4-6 it is expected that diagnosti c and therapeuti c policies for aSAH 
vary between centers and countries. This has been confi rmed in previous studies.27-29 In our study, the 
causality between variati on in treatment policies or quality of care (other than ti ming of aneurysm 
treatment) and observed outcome diff erences could not be verifi ed. We are therefore unable to present 
recommendati ons for current clinical practi ce. However, gaining insight into outcome diff erences 
between centers and countries is an important fi rst step to evaluate practi ce variati on and eventually 
improve clinical outcomes aft er aSAH. Our results provide the opportunity to perform comparati ve 
eff ecti veness research relati ng diff erences in structures and processes of care in aSAH between centers 
to diff erences in outcome. In TBI, such comparati ve eff ecti veness research is currently being conducted 
in a large prospecti ve observati onal study.30
  Assessing the performance of individual hospitals and countries is challenging since the esti mates 
for specifi c centers and countries are subject to substanti al uncertainty. Because the eff ect of chance 
increases with a decrease in the number of treated pati ents or outcomes,31 a recommendati on for 
future comparati ve eff ecti veness research is to focus on suffi  cient numbers of pati ents per center or 
country. 
  We found that between-center diff erences were substanti al in the ti rilazad trials, but were absent 
in the more recent IHAST and MASH trials. The ti rilazad trials included more centers than the IHAST and 
MASH trials (Appendix 7.B), which increases the stati sti cal power to identi fy diff erences in outcome. 
Moreover, progress has been made in diagnosti c and therapeuti c management since publicati on of 
the ti rilazad trials and prognosis aft er aSAH may therefore have improved. For instance, the ti rilazad 
studies and IHAST were (largely) conducted before publicati on of the Internati onal Subarachnoid 
Aneurysm Trial, so only 12% of the pati ents in our dataset underwent coil embolizati on. This and other 
factors related to the relati vely old data limit the generalizability of our results to the contemporary 
aSAH populati on. Unfortunately, the more recent observati onal studies in the SAHIT repository could 
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not contribute to the esti mati on of between-center and between-country diff erences, because they 
were conducted in a single center or informati on on center or country was not available in the SAHIT 
database.13 Given the evidence in aSAH and from related disease fi elds,7, 22, 32 we consider it unlikely that 
between-center diff erences in clinical outcomes aft er aSAH are no longer present in current clinical 
practi ce. Our results should however be confi rmed in a multi center prospecti ve cohort study.
  Some other limitati ons should be acknowledged. Our data are based on RCTs with strict 
inclusion criteria. This created a relati vely homogeneous study populati on, which might have caused 
an underesti mati on of the between-center and between-country diff erences. Further, the varying 
inclusion criteria (e.g. neurological conditi on on admission, ti me from onset of aSAH to inclusion) 
across the studies8-11 made it impossible to assess the previously studied eff ect of center-volume on 
outcome.33, 34 Informati on on other center- and country-specifi c aspects could not be retrieved due to 
the historic nature of the data, and the current center- and country-specifi c characteristi cs would not 
be applicable to the ti me when the data were collected for these studies. For example, the presence 
of neurocriti cal care teams has been associated with improved outcomes and inclusion of this factor in 
future observati onal studies would be very important.35-37 Finally, we were unable to assess the eff ect 
of ti me on outcome diff erences, because the inclusion periods of the trials were relati vely short, and 
only analyses on within-study ti me trends could be performed, since adjustment for study is required 
to disti nguish between ti me eff ect and study eff ect.
Conclusions
Clinical outcomes aft er aSAH diff er between centers. These diff erences could not be explained by 
random variati on, pati ent characteristi cs or ti ming of aneurysm treatment. Further research is needed 
to confi rm the presence of diff erences between hospitals with respect to outcome aft er aSAH between 
hospitals in more recent data and to investi gate potenti al causes, such as variati on in diagnosti c and 
therapeuti c policies or quality of care, in order to identi fy best practi ces and inform guidelines.
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Appendix
Appendix 7.A. Random eff ects logisti c regression model for between-center and between-country diff erences
Random eff ect logisti c regression with random intercepts for center and country
Logit (p(Yij = 1)) = β0 + β1 + β2 + (u0j + u0k + e0ijk)
With Yij the outcome for pati ent i in center j, β0 the intercept, β1 the pati ent and process characteristi cs, 
β2 the study, u0j the random intercept for center, u0k the random intercept for the country, and e0ijk the 
residuals. The random intercepts are assumed to be normally distributed with τ20j = var(u0j) and τ
2
0kj = 
var(u0k).
Appendix 7.B. Number of centers per country within each of the trials
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Appendix 7.C. Predictor eff ects for unfavorable outcome aft er aSAH in the multi variable logisti c regression model 
(‘fi xed eff ects model’)
Predictor OR (95% CI)
Age per decade 1.45 (1.37-1.54)
Hypertension 1.52 (1.29-1.78)
WFNS grade
1
2
3
4
5 
1.0 (reference)
1.83 (1.54-2.18)
4.58 (3.65-5.73)
5.98 (4.80-7.46)
12.73 (10.11-16.03)
Fisher grade
1
2
3
4
1.0 (reference)
1.27 (0.82-1.98)
2.01 (1.38-2.95)
1.97 (1.24-3.13)
Aneurysm locati on
ACA/ACoA
ICA/PCoA
MCA
Pst circ (incl BA & VA)
1.0 (reference)
0.84 (0.70-1.01)
0.68 (0.56-0.83)
1.04 (0.81-1.33)
Aneurysm size
≤ 12 mm
13-24 mm
≥ 25 mm
1.0 (reference)
1.33 (1.10-1.60)
1.54 (0.94-2.52)
Aneurysm treatment
Clipping
Coiling
None
1.0 (reference)
0.69 (0.53-0.89)
3.35 (2.66-4.22)
Time from aSAH to aneurysm treatment in days 1.01 (0.99-1.04)
ACA, anterior cerebral artery; ACoA, anterior communicati ng artery; BA, basilar artery; circ, circulati on; ICA, internal 
cerebral artery; MCA, middle cerebral artery; PCoA, posterior communicati ng artery; pst, posterior; VA, vertebral 
artery.
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Appendix 7.D. Sensiti vity analysis of between-center and between-country diff erences in centers with more than 
ten pati ents
Unfavorable outcome
n (%)
Unadjusted Adjusteda
Between-center 
diﬀ erencesb Ƭ2 MOR (95% CI) Ƭ2 MOR (95% CI)
Totalc (n=5757) 1537 (27) 0.064 1.26 (1.17-1.52) 0.042 1.21 (1.09-1.43)
IHAST (n=971) 137 (14) 0.000 1.00 (1.00-1.56) 0.000 1.00 (1.00-1.02)
MASH (n=1484) 398 (27) 0.050 1.23 (1.00-1.85) 0.000 1.00 (1.00-1.50)
Tirilazad (n=3302) 1002 (30) 0.076 1.29 (1.16-1.61) 0.020 1.14 (1.06-1.29)
Between-country 
diﬀ erencesd
Totalc (n=5757) 1537 (27) 0.023 1.15 (1.00-1.44) 0.020 1.14 (1.00-1.42)
IHAST (n=971) 137 (14) 0.000 1.00 (1.00-1.71) 0.000 1.00 (1.00-1.02)
MASH (n=1484) 398 (27) 0.000 1.00 (1.00-1.70) 0.000 1.00 (1.00-1.38)
Tirilazad (n=3302) 1002 (30) 0.041 1.21 (1.06-1.64) 0.012 1.11 (1.00-1.32)
aAdjusted for age, hypertension, WFNS grade, Fisher grade, aneurysm locati on, aneurysm size, aneurysm treatment 
and ti me from aSAH to aneurysm treatment.
bAdjusted for country as a random eff ect.
cModels in the total database were adjusted for study.
dAdjusted for center as a random eff ect.
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Abstract
Background and purpose: The uti lity-weighted modifi ed Rankin Scale (UW-mRS) has been proposed as 
a new pati ent-centered primary outcome in stroke trials. We aimed to describe uti lity weights for the 
mRS health states and to evaluate the stati sti cal effi  ciency of the UW-mRS to detect treatment eff ects 
in stroke interventi on trials.
Methods: We used data of the 500 pati ents enrolled in the MR CLEAN (Multi center Randomized 
Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Uti lity values 
were elicited from the EuroQol Group 5-Dimension Self-Report Questi onnaire assessed at 90 days aft er 
inclusion, simultaneously with the mRS. Uti lity weights were determined by averaging the uti liti es of 
all pati ents within each mRS category. We performed simulati ons to evaluate stati sti cal effi  ciency. The 
simulated treatment eff ect was an odds rati o of 1.65 in favor of the treatment arm, similar for all mRS 
cutoff s. This treatment eff ect was analyzed using 3 approaches: linear regression with the UW-mRS as 
outcome, binary logisti c regression with a dichotomized mRS (0–1/2–6, 0–2/3–6, and 0–4/5–6), and 
proporti onal odds logisti c regression with the ordinal mRS. The stati sti cal power of the 3 approaches was 
expressed as the proporti on of 10,000 simulati ons that resulted in a stati sti cally signifi cant treatment 
eff ect (p ≤0.05).
Results: The mean uti lity values (SD) for mRS categories 0 to 6 were: 0.95 (0.08), 0.93 (0.13), 0.83 (0.21), 
0.62 (0.27), 0.42 (0.28), 0.11 (0.28), and 0 (0), respecti vely, but varied substanti ally between individual 
pati ents within each category. The UW-mRS approach was more effi  cient than the dichotomous 
approach (power 85% versus 71%) but less effi  cient than the ordinal approach (power 85% versus 87%).
Conclusions: The UW-mRS as primary outcome does not capture individual variati on in uti lity values 
and may reduce the stati sti cal power of a randomized trial.
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Introducti on
The modifi ed Rankin Scale (mRS) is the most widely used primary outcome measure in trials for acute 
stroke interventi ons.1 2 The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death) measuring 
the degree of disability or dependence in everyday life.3 Previously, dichotomizing the mRS into dead 
or dependent (mRS, 3–6) versus independent (mRS, 0–2) was common, but this results in a reducti on 
in stati sti cal power to detect relevant treatment eff ects.4 Therefore, stati sti cal approaches preserving 
the ordinal nature of outcome measures, such as proporti onal odds logisti c regression, have been 
recommended for stroke and other neurological disorders.1,5-8
 Currently, the importance of incorporati ng quality of life (QoL) in outcome analysis in stroke trials 
is increasingly recognized.9-11 For the mRS to reﬂ ect both treatment eff ect and pati ent percepti on, the 
uti lity-weighted mRS (UW-mRS) has been proposed and used as primary end point.2,12,13 In the UW-mRS, 
uti liti es based on the EuroQol Group 5-Dimension Self-Report Questi onnaire (EQ-5D-3L) values are 
assigned to the mRS health states. Two prior studies reported uti lity weights for the mRS health states: 
1 representi ng the values of pati ents and 1 representi ng the values of clinicians. The uti lity weights that 
were proposed for the UW-mRS are based on these 2 studies.12 Compared with the ordinal mRS, the 
UW-mRS showed similar stati sti cal power to detect treatment eff ects in empirical data in a wide range 
of stroke trials.12 However, because in empirical data, the true treatment eff ect is unknown, the only 
valid method to assess stati sti cal power is simulati on. 
 We aimed to describe uti lity weights for the mRS health states and to evaluate the stati sti cal 
effi  ciency of the UW-mRS to detect treatment eff ects in stroke trials.
Methods
Study populati on
We used individual pati ent data of the 500 pati ents enrolled in the MR CLEAN (Multi center Randomized 
Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). MR CLEAN was 
a phase III, multi center randomized clinical trial, designed to evaluate whether intra-arterial treatment 
(within 6 hours of symptom onset) plus usual care would be more eff ecti ve than usual care alone in 
pati ents with acute ischemic stroke and a proximal arterial occlusion in the anterior cerebral circulati on. 
The primary outcome was the mRS at 90 days, and the secondary outcome was the EQ-5D-3L at 90 
days. In MR CLEAN, ethics approval was obtained from the local insti tuti onal review boards of the 
parti cipati ng centers, and writt en informed consent was obtained from pati ents or legal representati ves 
before randomizati on.14
Modiﬁ ed Rankin Scale
The mRS is a measure of functi onal outcome aft er stroke, evaluati ng the degree of disability or 
dependence in daily life. The scale is derived from clinical assessment by a trained nurse or a physician 
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and consists of 7 grades ranging from 0 (no symptoms) to 6, with 5 indicati ng severe disability and 6 
indicati ng death. A score of ≤2 indicates functi onal independence.4
Uti liti es
Uti liti es represent preferences for mRS health states and range from 0 (death) to 1 (perfect health). 
Uti lity values of poor outcome categories might even be negati ve, indicati ng that they are valued worse 
than death.15 In MR CLEAN, uti lity values were elicited using the EQ-5D-3L responses of pati ent, proxy, 
or healthcare provider assessed at 90 days aft er inclusion, simultaneously with the mRS. The EQ-5D-3L 
consists of 5 dimensions (mobility, self-care, usual acti viti es, pain/discomfort, and anxiety/depression) 
with 3 levels each (no problems, some problems, and extreme problems), thus defi ning 243 (35) disti nct 
health states.16 Converti ng the EQ-5D-3L responses into uti lity values was done according to the Dutch 
tariff —a countryspecifi c value set established based on the ti me trade-off  method.17 Pati ents who died 
before the follow-up interviews at 90 days received a uti lity value of zero. The uti lity values ranged from 
−0.33 to 1.00. We determined uti lity weights for each mRS category by averaging the derived uti liti es 
(including the negati ve values) of all pati ents within each mRS health state (eg, the uti lity weight for 
mRS=1 is the average of the uti liti es of all pati ents with mRS=1). Additi onally, we matched the uti lity 
values proposed by Chaisinanunkul et al,12 who collapsed mRS 5 to 6 by assigning a uti lity weight of zero 
to both categories, to our mRS values.
Simulati ons for stati sti cal eﬃ  ciency
Stati sti cal effi  ciency was evaluated based on simulati ons that uti lized the MR CLEAN database. For 
a single simulati on, 500 pati ents were sampled at random with replacement. For each pati ent, the 
predicted probability of each possible outcome on the 7-point ordinal mRS was modeled as a functi on 
of the baseline covariates. These covariates were identi cal to those in MR CLEAN and included age, 
stroke severity (Nati onal Insti tutes of Health Stroke Scale) at baseline, ti me from stroke onset to 
randomizati on, status with respect to previous stroke, atrial fi brillati on, diabetes mellitus, and occlusion 
of the internal caroti d artery terminus (yes/no).14
 Using these esti mated probabiliti es, an actual outcome in terms of an mRS or UW-mRS was 
simulated. Treatment (yes/no) was randomly assigned, and the simulated treatment eff ect was an odds 
rati o (OR) of 1.65 (β=0.5) in favor of the treatment arm, similar for all mRS cutoff s. We also evaluated 
a scenario with no treatment eff ect, by simulati ng a treatment eff ect of OR=1.0 (β=0). During this 
process, samples of 500 subjects were generated representi ng 250 pati ents from the control group and 
250 from the interventi on group, with a known treatment eff ect. This was then repeated 10,000×. 
 The data were analyzed by 3 diff erent stati sti cal approaches. First, we dichotomized the 90-day 
mRS in 3 diff erent ways of favorable versus unfavorable outcome: 0 to 1 versus 2 to 6, 0 to 2 versus 3 
to 6, and 0 to 4 versus 5 to 6. The treatment eff ect on the dichotomized mRS was determined using 
binary logisti c regression. Second, we used proporti onal odds logisti c regression for analysis of the 
treatment eff ect on the ordinal mRS. We fi tt ed a proporti onal odds logisti c regression model with the 
7-point ordinal mRS scale as outcome. The proporti onal odds model esti mates a common OR over all 
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health state transiti ons within the mRS. According to the proporti onal odds assumpti on, the common 
OR is an accurate reﬂ ecti on of the overall treatment eff ect if the ORs are the same for each health state 
transiti on. If there is agreement regarding the ordinality of the mRS, the common OR can be interpreted 
as a summary measure of treatment eff ect even if the proporti onal odds assumpti on is violated.18 Third, 
treatment eff ect on the UW-mRS was analyzed using linear regression, as proposed by Chaisinanunkul 
et al.12
 Each of the 3 approaches yielded either a signifi cant (P≤0.05) or a nonsignifi cant treatment eff ect 
(p >0.05, 2 sided). The power (or type 1 error in case of no treatment eff ect) of each stati sti cal approach 
was esti mated as the proporti on of the 10,000 analyses, which resulted in a stati sti cally signifi cant 
treatment eff ect.
 Associati ons were expressed as ORs or β with 95% confi dence intervals (CIs), averaged over 
all simulati ons. All analyses were performed unadjusted and adjusted for the prespecifi ed covariates 
identi cal to those menti oned above. Stati sti cal analyses were performed with R soft ware, version 
3.3.2 (R Foundati on for Stati sti cal Computi ng, Vienna, Austria). Missing data on ti me from stroke to 
randomizati on (0.4%) and level of vessel occlusion (0.2%) was stati sti cally imputed using simple 
imputati on (replacement by mean or mode, as applicable).
Results
Study populati on
All 500 parti cipants from the MR CLEAN trial were included in our analysis. The mRS at 90 days 
was available for all pati ents. The EQ-5D-3L assessments, and consequently the uti lity values, were 
available in 457 pati ents (including 108 pati ents who died before follow-up). In 43 pati ents (8.6%), mRS 
assessment could not be followed by an EQ-5D-3L assessment. In 192 pati ents (38%), the EQ-5D-3L was 
completed by a proxy.
 The total study populati on had a mean age of 65 years (SD, 14 years), and most pati ents (58%) 
were men (Table 8.1). The interventi on and control groups were similar in terms of baseline and 
treatment characteristi cs. The number of pati ents with poor outcome (mRS, 3–6) at 90 days was lower 
in the interventi on group than in the control group (Figure 8.1).
Uti lity weights
The mean uti lity values (SD) for mRS categories 0 to 6 were: 0.95 (0.08), 0.93 (0.13), 0.83 (0.21), 0.62 
(0.27), 0.42 (0.28), 0.11 (0.28), and 0 (0), respecti vely (Table 8.2). We observed substanti al variati on 
in uti lity values within each mRS category (Figure 8.2). Within MR CLEAN, the mean UW-mRS for the 
interventi on group was signifi cantly higher when compared with the control group (Table 8.2). 
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Outcome analysis in MR CLEAN
Ordinal analysis of the mRS showed improved functi onal outcomes in favor of the interventi on, 
consistent throughout all categories of the mRS except for death (adjusted common OR, 1.67; 95% CI, 
1.21–2.30) (Figure 8.1). The dichotomous approach led to slightly stronger treatment eff ects for cutoff s 
mRS 0 to 1 and 0 to 2 (adjusted OR, 2.07 [95% CI, 1.07–4.02] and 2.16 [95% CI, 1.39–3.38], respecti vely). 
The fact that the ORs were not equal for the diff erent cutoff s might imply that the proporti onal odds 
assumpti on did not hold perfectly in the empirical data. Linear analysis of the UW-mRS resulted in an 
adjusted β of 0.086 (95% CI, 0.033–0.131).
Figure 8.1. Distributi on of the modifi ed Rankin Scale at 90 days among interventi on and control groups
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Table 8.1. Baseline characteristi cs of the 500 pati ents in the MR CLEAN trial
Interventi on (n = 233) Control (n = 267)
Baseline variable Intra-arterial treatment plus 
usual care Usual care
Age, y; median (IQR) 65.8 (54.5-76.0) 65.7 (55.5-76.4)
Male sex 135 (58%) 157 (59%)
NIHSS score, median (IQR) 17 (14-21) 18 (14-22)
Previous ischemic stroke 29 (12%) 25 (9%)
Atrial fi brillati on 66 (28%) 69 (26%)
Diabetes mellitus 34 (15%) 34 (13%)
Prestroke mRS
    0
    1
    2
    >2
190 (82%)
21 (9%)
12 (5%)
10 (4%)
214 (80%)
29 (11%)
13 (5%)
11 (4%)
Treatment with IV alteplase 203 (87%) 242 (91%)
Time from stroke onset to start of IV alteplase, 
min; median (IQR)
85 (67-110) 87 (65-116)
Occlusion of the internal caroti d artery 
terminusa
59 (25%) 75 (28%)
Time from stroke onset to randomizati on, 
min; median (IQR)b
204 (152-251) 196 (149-266)
Time from stroke onset to groin puncti on, 
min; median (IQR)
260 (210-313) NA
IQR interquarti le range; IV, intravenous; mRS, modifi ed Rankin Scale; NA, not applicable; NIHSS, Nati onal Insti tutes 
of Health Stroke Scale.
aNo vessel imaging in 1 pati ent in the control group.
bData were missing for 2 pati ents in the interventi on group.
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Figure 8.2. Mean EuroQol Group 5-Dimension Self-Report Questi onnaire (EQ-5D-3L) uti lity values per modifi ed 
Rankin Scale (mRS) category in MR CLEAN (Multi center Randomized Clinical Trial of Endovascular Treatment for 
Acute Ischemic Stroke in the Netherlands)
Simulati ons
For all 3 prespecifi ed mRS dichotomizati ons, intra-arterial treatment was positi vely associated with 
bett er outcomes (adjusted OR, 1.66–1.68) (Table 8.3). The esti mated treatment eff ects were similar 
to the simulated (true) treatment eff ect of 1.65. When comparing the 3 diff erent mRS cutoff s, the 
stati sti cal effi  ciency for the cutoff  of mRS 0 to 2 versus 3 to 6 was highest (power 71% versus 62% for 
mRS 0–1 and 35% for mRS 0–4). This could be explained by an almost equal distributi on of pati ents 
among both categories for this cutoff  (Table 8.3).
 Ordinal analysis of the mRS esti mated an adjusted treatment eff ect of common OR=1.66 (95% 
CI, 1.41–1.95) (Table 8.3), similar to the dichotomous approach. However, the ordinal approach was 
stati sti cally more effi  cient (power 87% versus 71%).
 Linear regression analysis of the UW-mRS esti mated an adjusted benefi cial treatment eff ect of 
β=0.075 (95% CI, 0.027–0.125) (Table 8.3). The UW-mRS approach was stati sti cally less effi  cient in 
detecti ng treatment eff ects compared with the ordinal approach (power 85% versus 87%). Matching 
the uti liti es of Chaisinanunkul et al to the mRS values in MR CLEAN led to similar results (Table 8.2 
and Table 8.3). However, the assumpti ons of the linear model were not met because there was non-
normality of the residuals (Appendix 8.A).
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 In the simulati ons without a treatment eff ect, a proporti on of false-positi ves (type 1 error) of 
around 5% was esti mated for all 3 stati sti cal approaches (data not shown).
Table 8.2. Mean uti lity values per mRS category and mean UW-mRS in MR CLEAN and the study by Chaisinanunkul 
et al
No. of pati ents MR CLEAN Mean (SD) Chaisinanunkul et al12, mean uti lity values
mRS
    0 7 0.95 (0.08) 1.00
    1 36 0.93 (0.13) 0.91
    2 84 0.83 (0.21) 0.76
    3 87 0.62 (0.27) 0.65
    4 133 0.42 (0.29) 0.33
    5 45 0.11 (0.28) 0.00
    6 108 0.00 0.00
UW-mRS
Overall 500 0.45 (0.32) 0.40
Interventi on group 233 0.50 (0.33)a 0.46
Control group 267 0.41 (0.31) 0.36
MR CLEAN, Multi center Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands; mRS, modifi ed Rankin Scale; UW, uti lity weighted.
aMean uti lity for the interventi on group vs control group within MR CLEAN: P=0.002 (Mann-Whitney U test).
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Discussion
We evaluated the UW-mRS—a recently proposed pati ent-centered outcome measure in stroke. Our 
study, based on a Dutch stroke interventi on trial, showed that the UW-mRS does not capture the 
individual variati on in uti lity values within each mRS category. Moreover, our simulati ons revealed that 
the UW-mRS approach was more effi  cient in detecti ng treatment eff ects than dichotomous analysis of 
the mRS but less effi  cient than the ordinal approach.
 Widely used functi onal outcome measures in stroke interventi on trials, such as the mRS, 
have been extensively studied concerning their feasibility in measuring disability aft er stroke.19,20
Nevertheless, more att enti on has recently been aimed at incorporati ng pati ent-reported QoL in stroke 
outcome measures.10,11
 As part of this trend, the UW-mRS has been proposed as a new primary pati ent-centered outcome 
measure in acute stroke interventi on trials. In empirical data, the UW-mRS was equally stati sti cally 
effi  cient in detecti ng treatment eff ects compared with ordinal analysis of the mRS.12 Based on that 
study, the UW-mRS was recently used as the primary end point in the DAWN trial (Diff usion-Weighted 
Imaging or Computerized Tomography Perfusion Assessment With Clinical Mismatch in the Triage of 
Wake Up and Late Presenti ng Strokes Undergoing Neurointerventi on With Trevo),13 and it is expected 
that more trials will follow. However, the study by Chaisinanunkul et al was only based on analyses of 
empirical sets of data. Because the true treatment eff ect in empirical data is unknown and diff erent 
treatment eff ects on diff erent outcome measures could be caused by random variati on, the only valid 
method to assess the power of a stati sti cal approach is a simulati on study, as we performed. 
 Intuiti vely, pati ent-centered outcomes, such as the UW-mRS, are clinically useful because they 
concern pati entreported measures combined with the percepti on of the general public. These outcomes 
reﬂ ect pati ent percepti on and respect the nonequality of health state transiti ons on an ordinal scale. 
Nevertheless, averaging uti lity values for each mRS category does not reﬂ ect individual valuati on of 
these health states: all pati ents within 1 mRS category receive the same uti lity weight, irrespecti ve 
of their own valuati on of this health state (Figure 8.2). So, the UW-mRS is in fact a revaluati on of the 
mRS. Moreover, the uti lity distributi on with mRS=5 being worse than death for some pati ents does not 
support collapsing mRS categories 5 to 6 as proposed by Chaisinanunkul et al. To reﬂ ect true individual 
valuati on of health states, QoL instruments should rather be used as outcome. However, uti lity values 
derived from the EuroQol Group 5-Dimension Self-Report Questi onnaire may not cover the full range 
of limitati ons relevant to pati ents with stroke21 and may, therefore, overesti mate QoL in this group. 
An alternati ve would be to use uti lity values derived from QoL instruments designed specifi cally for 
pati ents with neurological disorders, such as Neuro-QoL.22 Nevertheless, because QoL depends on many 
external factors, it might introduce noise, making it less suitable as a primary outcome measure.23,24
 Our simulati ons revealed that the UW-mRS is not as stati sti cally effi  cient as ordinal analysis of 
the mRS and may, therefore, cause a reducti on in stati sti cal power when used in randomized trials. 
Chaisinanunkul et al12 analyzed the UW-mRS with a t test, implying a conti nuous outcome variable. We 
used linear regression, which is a comparable approach but allows for multi variable analysis. In theory, 
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linear analysis is expected to be more effi  cient than ordinal analysis when the assumpti ons of the linear 
model are met. A linear model assumes that the errors between observed and predicted values, that 
is, the residuals of the regression, are normally distributed. In our analyses, however, we found non-
normality of the residuals of the linear model for the UW-mRS. Because the UW-mRS remains a scale 
with 7 outcome categories, the assumpti on of normally distributed residuals can never be met. Non-
normality of the residuals might cause bias because of underesti mati on of the standard error.
 Therefore, the actual power of the UW-mRS approach will be even <85%. Ordinal analysis also 
makes an assumpti on (the proporti onal odds assumpti on), but it should be noted that the assumpti on 
of a normal distributi on of the residuals in a linear model is more diffi  cult to fulfi ll than the assumpti on 
of ordinality in proporti onal odds analyses. In line with theoreti cal expectati ons, the UW-mRS showed 
to be exactly as effi  cient as the mRS when it was analyzed with a proporti onal odds model (data not 
shown).
 Defi ning a benefi cial treatment eff ect in terms of the UW-mRS, and, therefore, clinical 
interpretability, might be diffi  cult. Treatment eff ect on the UW-mRS scale is expressed as a diff erence in 
mean UW-mRS between treatment and control groups.12 This diff erence can be converted into quality-
adjusted life-years (QALYs) gained or lost by a certain treatment.12,25 The QALY measure assumes that 
a year of life lived in perfect health is worth 1 QALY, and a year of life lived in a state less than perfect 
health is worth <1 QALY, proporti onal to its uti lity value (QALY=years of life×uti lity). QALYs can be used 
to calculate cost-eff ecti veness to select a certain interventi on for funding.26 Also, the QALY measure 
has been argued to be more intuiti ve to pati ents (healthy life-years gained) and, therefore, to improve 
communicati on of treatment eff ects.12,25 However, when not converted into QALYs, treatment eff ects 
expressed as uti lity diff erences remain diffi  cult to interpret. Moreover, clinicians and researchers are 
now used to working with the (common) OR.
 Ordinal outcome scales are also used in other neurological disorders besides stroke. Examples are 
the Glasgow Outcome Scale in traumati c brain injury and the Guillain-Barre syndrome disability score 
in Guillain-Barre syndrome.6,7,27 These ordinal outcomes could be transformed to pati ent-centered 
outcomes using uti lity values, similar to the UW-mRS. For
randomized trials in pati ents with other neurological diseases, such as traumati c brain injury and 
Guillain-Barre syndrome, our study might, therefore, also implicate that ordinal analysis
should remain the gold standard.
 Our study has several strengths. The simulati on study was based on data from the MR CLEAN trial, 
with relati vely broad inclusion criteria.14 As such, our fi ndings should be generalizable to future stroke 
trials. Furthermore, simulati on is the most adequate method to evaluate stati sti cal power. Also, we used 
uti lity values derived using the recommended ti me trade-off  method, which should be less prone to 
bias compared with other elicitati on methods.24
 Some limitati ons should also be acknowledged. As with all simulati on studies, we do not know how 
far our fi ndings may be extrapolated beyond the modeled situati ons. For instance, we only simulated 
a model with a uniform treatment eff ect across all mRS health state transiti ons, which, therefore, 
adheres perfectly to the proporti onal odds assumpti on. However, if the proporti onal odds assumpti on 
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would be violated, and treatment eff ect would not be uniform across the diff erent outcome categories, 
ordinal analysis would sti ll be the most effi  cient (6). Nevertheless, further validati on of our results is 
required. Finally, we used the EuroQol Group 5-Dimension Self-Report Questi onnaire assessed at 90 
days aft er inclusion, which reﬂ ects neither short-term QoL nor the fi nal health state. A bett er reﬂ ecti on 
of pati ent percepti on could be achieved by calculati ng QALYs based on multi ple QoL measurements in 1 
pati ent. Nevertheless, the aim of this study is not to describe QoL but to evaluate effi  ciency in detecti ng 
treatment eff ects.
 In conclusion, the UW-mRS has been received as a promising new pati ent-centered outcome in 
stroke research. However, the UW-mRS does not capture individual variati on in uti liti es within each mRS 
health state. Also, interpretati on of treatment eff ect on the UW-mRS scale might be more challenging 
than was fi rst suggested. Finally, clinicians and researchers should be aware of the reducti on in power 
compared with ordinal analysis of the mRS when they use the UW-mRS as outcome measure in acute 
stroke interventi on trials. More thorough evaluati on of the UW-mRS in terms of its added value, analyti c 
approach, and interpretati on is required. 
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Appendix 8.A. Q-Q plot to test normality of the residuals of the UW-mRS in simulati ons
Legend: Univariable linear model with UW-mRS as outcome and treatment eff ect as variable. (Standardized) 
residuals are the errors between observed and predicted values in a model. Theoreti cal quanti les are the residuals 
as theoreti cally expected when they are normally distributed. In a Q-Q plot, the residuals are normally distributed 
when they fall on the dashed line.
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8.1
In Response:
We thank Berry et al for starti ng this interesti ng discussion to criti cally assess the uti lity-weighted 
modifi ed Rankin Scale (UW-mRS) as outcome measure in stroke interventi on trials.1  Before responding 
to their comments, we want to point out that we were surprised by the descripti on of our analyses as 
misleading because it suggests deliberate tampering with results. We are grateful for the opportunity to 
counter the concerns raised and expect that our arguments will convince the readership of stroke, and 
hopefully Berry et al, that this qualifi cati on is enti rely inappropriate.
 Berry et al based their conclusion about the advantage of the UW-mRS over the ordinal mRS on 
a slight gain in stati sti cal power with multi nomial analysis. This stati sti cal approach is fundamentally 
ﬂ awed because it ignores the ordering of the mRS categories. The corresponding test stati sti c is the 
χ2 and its P value tests diff erences in distributi ons between mRS categories, independent of how 
these categories are valued. Therefore, the category death might as well be renamed blue, and the 
additi onal uti lity weights are useless. In additi on, multi nomial regression of the UW-mRS yields 1 odds 
rati o for each category, highly limiti ng interpretati on of the overall treatment eff ect. Although Berry et 
al promote this multi nomial approach in their lett er, in the DAWN trial (Diff usion-Weighted Imaging 
or Computerized Tomography Perfusion Assessment With Clinical Mismatch in the Triage of Wake Up 
and Late Presenti ng Strokes Undergoing Neurointerventi on With Trevo), they used an enti rely diff erent 
approach to analyze the UW-mRS: a (Bayesian normal dynamic) linear model.2
 The mRS analyzed with proporti onal odds (PO) logisti c regression does facilitate interpretati on 
of the overall treatment eff ect. The PO model assumes a similar treatment eff ect across all cutoff s of 
the scale. However, the dependence of the PO model on this proporti onality assumpti on should not be 
aggravated. As stated in our arti cle, if there is agreement on ordinality of the mRS, the common odds 
rati o can be interpreted as a summary
measure of treatment eff ect even if the PO assumpti on is violated.1,3 Therefore, testi ng for the PO 
assumpti on is redundant.
 We strongly disagree that assigning health values to the diff erent mRS categories is a feature 
of the UW-mRS. As clearly substanti ated in our arti cle, the UW-mRS does not capture the individual 
variati on in uti liti es within each mRS health state and does not add new informati on: it sti ll consists of 
7 ordered categories.1 Measuring quality of life in stroke trials is very important but should be done at 
individual level accounti ng for variati on between pati ents. In contrast with the remark by Berry et al, a 
treatment eff ect was observed on the EuroQol Group 5-Dimension Self-Report Questi onnaire (EQ-5D) 
in the MR CLEAN trial
(Multi center Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands) aft er including the deceased pati ents.1,4
 In conclusion, aft er the success of the DAWN trial, it might seem appealing to use the UW-
mRS as primary outcome in future stroke trials and Berry et al are clearly advocati ng their approach. 
However, we should not refrain from criti cally studying its added value in terms of stati sti cal accuracy 
and interpretability. As this added value appears to be absent, we sti ll recommend analyzing the mRS 
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with PO logisti c regression as a primary outcome measure in stroke trials. Individual variati on in quality 
of life should be measured as a secondary outcome using the EQ-5D or disease-specifi c instruments.
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9
General discussion 
The main objecti ve of this thesis was to identi fy pati ents at high risk for poor outcome aft er acute 
neurological diseases and to enhance knowledge on outcome variati on and stati sti cal effi  ciency of new 
outcome measures. An overview of the main fi ndings for the fi ve specifi c research questi ons posed in 
Chapter 1 can be found in Box 9.1. In this chapter, the main fi ndings will be discussed separately for 
outcome predicti on and outcome analyses, followed by implicati ons for clinical practi ce and policy, and 
recommendati ons for future research.
Box 9.1. Overview of main fi ndings per research questi on.
1. What characteristi cs are associated with poor outcome aft er acute neurological diseases?
Similar to previous studies, we observed that the main characteristi cs that are independently associated 
with poor outcome aft er acute neurological diseases are age and neurological status at hospital admission.
2. What is the methodological quality of existi ng prognosti c models in acute neurological diseases?
We identi fi ed a large number of external validati on studies of prognosti c models in moderate and severe 
traumati c brain injury. However, there are sti ll opportuniti es for improvement of the methodological quality 
of existi ng prognosti c models for functi onal outcome aft er acute neurological diseases. For instance, 
bootstrapping techniques were infrequently used at internal validati on and the importance of model 
calibrati on is oft en underesti mated.
3. Do these models provide reliable predicti ons for pati ents in speciﬁ c clinical setti  ngs? 
Providing reliable predicti ons for pati ents with acute neurological diseases in a specifi c clinical setti  ng 
remains challenging, and model performance across diff erent setti  ngs is highly variable. This may be 
problemati c when intending to apply prognosti c models in clinical practi ce.
4. What are the diﬀ erences in clinical outcomes between pati ents with aSAH in a range of internati onal 
hospitals, and can diﬀ erences be explained by variati on in case-mix?
We observed between-hospital variati on in clinical outcomes aft er aneurysmal subarachnoid hemorrhage. 
Random eff ects analyses revealed that between-hospital diff erences could not be explained by random 
variati on, pati ent characteristi cs and ti ming of aneurysm treatment.
5. What is the stati sti cal eﬃ  ciency of new outcome measures for acute neurological diseases?
Simulati ons showed that the uti lity-weighted modifi ed Rankin Scale (UW-mRS), a recently proposed 
pati ent-centered outcome measure for ischemic stroke, may reduce the power of clinical trials in detecti ng 
treatment eff ects. Further, the UW-mRS could complicate interpretati on of trial results. 
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Predicti on in acute neurological diseases
Characteristi cs associated with poor outcome
A fi rst step in prognosti c research is to identi fy characteristi cs associated with the outcome of interest. 
To facilitate early classifi cati on of disease severity and inclusion of pati ents in clinical trials, prognosti c 
factor research is oft en focused on characteristi cs that can be obtained early in the disease course, e.g. 
at hospital admission. 
 In line with previous literature,1, 2 we observed that age and the Nati onal Insti tutes of Health 
Stroke Scale (NIHSS) are the main drivers of prognosis aft er ischemic stroke (Chapter 3). In aneurysmal 
subarachnoid hemorrhage (aSAH), age and the World Federati on of Neurological Surgeons (WFNS) 
grade had the strongest associati on with mortality (Chapter 5). Age and WFNS are oft en included in 
prognosti c models for functi onal outcome aft er aSAH.3, 4 The most frequently included predictors in 
prognosti c models for functi onal outcome aft er moderate and severe traumati c brain injury (TBI) were 
age, the full Glasgow Coma Scale (GCS) or its motor component, and pupillary reacti vity (Chapter 4). 
These characteristi cs combined explain 35% of the variance in outcomes aft er moderate and severe 
TBI.5 These fi ndings indicate that similariti es seem to exist between ischemic stroke, aSAH and TBI 
in terms of prognosis. Age and neurological status at hospital admission are essenti al for adequate 
identi fi cati on of pati ents at high risk for poor clinical outcomes aft er acute neurological diseases.
 Several other admission characteristi cs were associated with poor clinical status aft er acute 
neurological diseases (Figure 9.1). Brain computed tomography (CT) characteristi cs related to the 
severity of intracranial lesions, such as the amount of subarachnoid blood in aSAH or presence of 
subdural or epidural hematoma in TBI, are also predicti ve of poor outcome (Chapters 4 and 5). In 
ischemic stroke, radiological characteristi cs such as the Alberta Stroke Program Early CT score (ASPECTS) 
and collateral score on CT angiography predict clinical outcome and have been included in prognosti c 
models.6-8 In aSAH, we observed that elevated serum lactate and glucose levels within the fi rst 24 hours 
aft er ictus were associated with delayed cerebral ischemia (DCI) related infarcti on and poor functi onal 
outcome (Chapter 2). Elevated glucose levels and other characteristi cs related to criti cal illness are 
also relevant for prognosis in TBI (Figure 9.1). However, only litt le prognosti c informati on was added 
when combining these CT and laboratory characteristi cs with age and neurological status in prognosti c 
models (Chapters 4 and 6). Leaving out additi onal admission characteristi cs in prognosti c models may, 
on the other hand, aff ect individual pati ent classifi cati on.
 The additi onal value of major extracranial injury for models predicti ng outcome in pati ents with 
moderate and severe TBI seems very limited (Chapter 6).9 This may be explained by an inverse relati on 
of major extracranial injury with TBI severity: the more severe the brain injury, the smaller appears 
the eff ect of extracranial injuries on clinical outcome. Also, the associati on between major extracranial 
injury and functi onal outcome may be inﬂ uenced by pati ent selecti on. Major extracranial injury has 
more prognosti c value in studies considering all trauma pati ents from ti me of injury, than in studies 
selecti ng pati ents based on presence of TBI who survived the early stage.10
 In our study on the associati ons between early lactate and glucose levels and poor outcome or 
delayed cerebral ischemia (DCI) aft er aSAH, lactate and glucose were associated with each of the two 
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outcome measures aft er adjustment for pati ent and imaging characteristi cs. However, when including 
both lactate and glucose in the multi variable model, only glucose was independently associated with 
DCI and only lactate was associated with poor outcome (Chapter 2). This fi nding emphasizes the 
importance of adjusti ng for all relevant prognosti c factors when analyzing potenti al prognosti c variables 
and outcomes. 
Figure 9.1. Overview of admission characteristi cs that are independently associated with poor clinical outcome 
aft er acute neurological diseases. NIHSS, Nati onal Insti tutes of Health Stroke Scale; WFNS, World Federati on of 
Neurological Surgeons; GCS, Glasgow Coma Scale; SAH, subarachnoid hemorrhage; CT, computed tomography.
aNot evaluated in this thesis for ischemic stroke.
Timing of predictor and outcome assessment
Variati on exists in ti ming of predictor assessment, which may aff ect associati ons between predictors 
and outcomes. Predictors obtained at hospital admission do not account for changes during the clinical 
course, such as neurological deteriorati on due to rebleeding of the aneurysm in aSAH. Assessment of 
prognosti c factors at a later stage may improve outcome predicti on. For instance, in line with results 
from a previous study,11 we observed that assessment WFNS at ti me of treatment decision improved 
discriminati ve ability of the Internati onal Subarachnoid Aneurysm Trial (ISAT) prognosti c model for 
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mortality aft er aSAH, when compared to assessment of WFNS at admission (Chapter 5). Characteristi cs 
obtained during the clinical course are gaining att enti on, but yielded variable improvement in 
performance of prognosti c models (Chapter 4). Variables obtained at hospital admission facilitate 
early predicti on of clinical outcomes, which may, for instance, facilitate starti ng the process of referring 
pati ents to rehabilitati on faciliti es or nursing homes soon aft er hospital admission (Chapter 3). 
 Timing of clinical outcome measurement is also highly variable across diff erent studies evaluati ng 
predictors or prognosti c models (Chapter 4).1, 12 Moreover, especially in aSAH, diff erent scales are 
used to measure functi onal outcome (e.g. modifi ed Rankin Scale [mRS] or Glasgow Outcome Scale 
[GOS]) and diff erences exist in cutoff s for favorable versus unfavorable outcome.13 Variati on in ti ming of 
predictor and outcome measurement may cause heterogeneity in predictor eff ects and performance of 
prognosti c models.
Methodological quality of prognosti c models
Although guidelines have been proposed to improve development and reporti ng of prognosti c models, 
a majority of the published models is not thoroughly developed or validated.14-17 Several systemati c 
reviews demonstrated opportuniti es for improvement of methodological quality of prognosti c models 
for functi onal outcome aft er ischemic stroke, aSAH and moderate and severe TBI.1, 3, 12, 18 Some main 
concerns were the small and selected cohorts used for model development, complete approach to 
handling of missing data, limited use of bootstrapping techniques for internal validati on, and the lack 
of external validati on studies. 
 Our systemati c review on prognosti c models in moderate and severe TBI demonstrated a good 
trend towards external validati on of existi ng prognosti c models. Within one decade, 31 prognosti c 
models were externally validated 149 ti mes (Chapter 4). Also, regression analyses were most frequently 
used for development of new models, which is in principle the preferred method for outcome predicti on 
in TBI (Chapter 4.1). However, methodological quality of prognosti c models could sti ll be improved. For 
instance, bootstrapping techniques for internal validati on were only applied in 25% of the developed 
models. Additi onally, model calibrati on at external validati on (i.e. agreement between observed and 
predicted outcome rates) was only assessed graphically in half of the validati ons (54%) (Chapter 4). Poor 
methodological quality of prognosti c models may reduce reliability of predicti ons for pati ents in specifi c 
clinical and research setti  ngs. Therefore, recommendati ons on model development and validati on 
remain current and relevant for future studies. 
 We provided examples on the development and validati on of prognosti c models for outcomes 
aft er acute neurological diseases. An overview of the main do’s and don’ts in prognosti c modeling 
resulti ng from this thesis is provided in Table 9.1. At model development, the specifi cati on and coding 
of predictors for the model is preferably based on literature and expert opinion (as done in Chapter 3).12, 
14, 19 Reliable esti mati on of model parameters requires suffi  cient sample size and is ideally performed 
with logisti c regression analyses (Chapters 4 and 4.1).19, 20 Concerning the handling of missing data, 
complete case analysis is sti ll regularly performed, although multi ple imputati on has been advocated 
for prognosti c research (Chapter 4.1). Finally, dichotomizati on of predictor and outcome variables 
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causes loss of informati on.21 Conti nuous predictors should therefore rather be included in the model as 
such, and ordinal or conti nuous outcome measures should be analyzed with proporti onal odds logisti c 
regression or linear regression, respecti vely.20
 Before applicati on in clinical practi ce, prognosti c models should be internally and externally 
validated.22 Evaluati ng model performance directly in the derivati on cohort (i.e. apparent validati on) 
may cause opti misti c esti mates of model performance. Random splitti  ng of the original sample into 
a derivati on and validati on cohort (i.e. split-sample validati on) is an ineffi  cient approach (Chapter 
4.1).14, 23 Therefore, recommended methods for internal validati on are cross-validati on or bootstrap 
resampling. With cross-validati on, a prognosti c model is developed on a part of the derivati on cohort 
and validated on the remaining pati ents. This process is repeated unti l all pati ents have been used for 
model validati on, and model performance is esti mated over all validati ons.19 A 10-fold cross-validati on 
uses 90% of the derivati on sample for development with validati on at 10%; repeated 10 ti mes.14 In 
the bootstrap procedure, random samples with replacement are drawn from the derivati on cohort, 
with sample size equal to that of the original cohort. The modeling steps are repeated in each of the 
bootstrap samples, and performance of the constructed models is additi onally evaluated in the original 
cohort. The diff erence in performance (i.e. opti mism) is subtracted from the apparent performance to 
indicate the expected model performance for future pati ents similar to the derivati on cohort (Chapter 
3).14, 19
 External validati on is important to judge the generalizability and transportability of prognosti c 
models to new populati ons, based on model discriminati on and calibrati on.14, 24 The area under the 
receiver operati ng characteristi c curve (AUC) is almost always used to report discriminati on between 
pati ents with and without the outcome of interest (Chapter 4). The AUC ranges between 0.5 (no 
discriminati on) to 1 (perfect discriminati on). Calibrati on is ideally assessed with a calibrati on graph, in 
which a 45-degree line with calibrati on slope 1 and intercept 0 indicates perfect agreement between 
observed and predicted outcome rates. In the current literature on prognosti c models, the importance 
of model calibrati on is oft en underesti mated (Chapter 4). Adequate model calibrati on is however crucial 
for adequately informing pati ents about their risks, and for decision support.14, 25 Ideally, a prognosti c 
model should be refi tt ed on development and validati on cohort combined to obtain the best esti mates 
of the regression coeffi  cients (Chapter 3).20
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Table 9.1 .Overview of do’s and don’ts for development and validati on of prognosti c models for acute neurological 
diseases resulti ng from this thesisa
DON’T DO
Model development
Use small cohorts Use a dataset with at least 100 events, or at least 10 
pati ents with the outcome of interest for each candidate 
predictor (10 events per variable)
Perform complete case analysis Multi ple imputati on
Dichotomize predictors or outcomes Include conti nuous predictors as such (e.g. age); analyze 
ordinal or conti nuous outcomes with proporti onal odds 
logisti c regression or linear regression, respecti vely
Use decision trees Logisti c regression
Model validati on - internal
Use apparent or split-sample approaches Use bootstrapping techniques or cross-validati on
Model validati on - external
Stop aft er internal validati on External validati on whenever possible
Forget model calibrati on Assess model calibrati on graphically (with intercept and 
slope) in additi on to model discriminati on
aStatements on all relevant recommendati ons for conducti ng and reporti ng prognosti c research have been 
published15, 16
 Validati on and updati ng of promising existi ng models is preferred over development of new 
models.26 Especially in the fi eld of acute neurological diseases, where the main predictors of clinical 
outcome have been confi rmed (Chapter 5.1). In our systemati c review on prognosti c models for 
functi onal outcome aft er moderate and severe TBI, we found that model discriminati on at external 
validati on is oft en good, but providing reliable predicti ons for individual pati ents (i.e. model calibrati on) 
remains challenging (Chapter 4). This was also observed in external validati on studies of the ISAT, 
Internati onal Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corti coid Randomisati on 
Aft er Signifi cant Head injury (CRASH) prognosti c models included in this thesis (Chapters 5 and 6) (Table 
9.2).27-29 Model performance at external validati on can be aff ected by several factors, including pati ent 
selecti on and defi niti on and measurement of predictors and outcomes.30 In the external validati on 
studies included in this thesis, the ISAT and IMPACT prognosti c models showed improved model 
discriminati on in broader, less selected cohorts (Chapters 5 and 6). Also, performance of prognosti c 
models for moderate and severe TBI is highly variable across diff erent setti  ngs (Chapter 4). These 
fi ndings underscore the need for model validati on and updati ng before implementati on in research or 
clinical practi ce.
 For models aimed at clinical decision making, a decision analysis is required beyond discriminati on 
and calibrati on.14 A decision analysis evaluates the consequences of applying the prognosti c model in 
a specifi c setti  ng, by balancing the relati ve importance of the benefi ts (true positi ves) and harms (false 
positi ves) of a clinical decision based on the model.31 If a decision analysis shows potenti al, the fi nal step 
is to perform an impact study. This includes evaluati ng whether care provided based on the model is 
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bett er than usual care, and determining the applicability in daily routi ne according to clinicians. These 
evaluati on steps have not been performed for the prognosti c models evaluated in this thesis, but are 
important to clarify whether or not a prognosti c model can be used in clinical practi ce.26
Table 9.2 .Overview of external validity of the ISAT model for aneurysmal subarachnoid hemorrhage and the IMPACT 
and CRASH models for traumati c brain injury evaluated in this thesis (Chapters 5 and 6, broadest pati ent selecti ons).
Prognosti c model Outcome Discriminati on 
AUC (95% CI)
Calibrati on
Observed versus predicted 
outcome rates
Aneurysmal SAH
(n = 307)
ISATa Mortality at 60 days 0.82 (-) 30.6% vs. 17.7%
Traumati c brain injury 
(GCS 3-14, n = 1742)
IMPACT core Mortality at 6 months 0.85 (0.83 to 0.87) 15% vs. 37%
Unfavorable outcome at 6 
months (GOSE 1-4)
0.80 (0.78 to 0.82) 43% vs. 46%
IMPACT extended Mortality at 6 months 0.88 (0.86 to 0.90) 15% vs. 34%
Unfavorable outcome at 6 
months (GOSE 1-4)
0.84 (0.82 to 0.86) 43% vs. 47%
IMPACT lab Mortality at 6 months 0.88 (0.86 to 0.90) 15% vs. 29%
Unfavorable outcome at 6 
months (GOSE 1-4)
0.84 (0.82 to 0.86) 43% vs. 44%
CRASH basic Mortality at 14 days 0.86 (0.83 to 0.88) 15% vs. 15%
Unfavorable outcome at 6 
months (GOSE 1-4)
0.82 (0.80 to 0.84) 43% vs. 43%
CRASH CT Mortality at 14 days 0.88 (0.86 to 0.90) 15% vs. 33%
Unfavorable outcome at 6 
months (GOSE 1-4)
0.84 (0.82 to 0.86) 43% vs. 56%
aOriginal model with World Federati on of Neurological Surgeons grade at hospital admission.
AUC, area under the receiver operati ng characteristi c curve; CI, confi dence interval; SAH, subarachnoid hemorrhage; 
GCS, Glasgow Coma Scale; IMPACT, Internati onal Mission on Prognosis and Analysis of Clinical Trials; GOSE, Glasgow 
Outcome Scale Extended; CRASH, Corti coid Randomisati on Aft er Signifi cant Head injury; CT, computed tomography.
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Applicati ons of prognosti c models 
Some main (potenti al) applicati ons for prognosti c models in research setti  ngs and clinical practi ce can 
be disti nguished (Table 9.3). 
Table 9.3. Overview of potenti al applicati ons of prognosti c models for acute neurological diseases 
Applicati ons Example in acute neurological diseases
Research
Inform clinical trial design Prognosti c targeti ng and covariate adjustment based on 
established predictors for clinical outcome for TBI could 
reduce required sample size for clinical trials32, 33
Provide insight in possible (and modifi able) causes 
for clinical outcomes
Markers of criti cal illness (e.g. elevated glucose levels, 
hypoxia, hypotension) are included in prognosti c models 
for moderate and severe TBI, giving insight in the systemic 
consequences of the brain injury
Clinical
Assist clinicians with communicati on regarding the 
disease course of individual pati ents 
Use of predicted probabiliti es provided by the IMPACT 
model to inform a relati ve of a pati ent with severe TBI in 
the intensive care unit on the chance of recovery within the 
next 6 months
Guide therapeuti c decisions for individual pati ents Prognosti c model to select pati ents with atrial fi brillati on at 
high risk for ischemic stroke for preventi ve treatment with 
anti coagulants34
Reducti on of heterogeneity in prognosti c esti mates 
across physicians
Use of a prognosti c score inﬂ uenced the prognosti c 
esti mates made by physicians in pati ents with intracerebral 
hemorrhage (e.g. more opti misti c prognosti c esti mates 
when the score indicated bett er prognosis)35
Improving quality of care Use established prognosti c models for case-mix adjustment 
in analyses on variati on in clinical outcomes aft er aSAH and 
TBI across hospitals and countries (Chapter 7)36, 37  
TBI, traumati c brain injury; aSAH, aneurysmal subarachnoid hemorrhage; IMPACT, Internati onal Mission on Prognosis 
and Analysis of Clinical Trials; CRASH, Corti coid Randomisati on Aft er Signifi cant Head injury.
 In the fi eld of acute neurological diseases, clinicians are involved in many publicati ons on 
prognosti c models. This implies that outcome predicti on is considered relevant for clinical practi ce. 
Most studies on clinical prognosti c models claim that the model predicti ons can assist clinicians 
with risk communicati ons concerning the disease course for (the relati ves of) individual pati ents.38
Predicti ons of clinical outcomes for individual pati ents with TBI based on clinical experti se alone may 
be too pessimisti c.39 Prognosti c models can incorporate a broad range of characteristi cs relevant for 
the subsequent clinical outcome, and may antagonize these views. Moreover, clinicians have indicated 
that the use of prognosti c models may assist in reducing heterogeneity in prognosti c esti mates across 
physicians.40, 41
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 However, in spite of the vast body of clinical research on prognosti c modeling, large-scale 
implementati on of prognosti c models in care for individual pati ents is not established. Multi ple barriers 
for implementati on of prognosti c models in clinical practi ce, in general as well as specifi cally for acute 
neurological diseases, can be identi fi ed (Box 9.2):
-  An important barrier is the lack of knowledge about existence of prognosti c models among 
clinicians. For the IMPACT prognosti c models, questi onnaires revealed that only 50% of clinicians 
knew about their existence.40, 42
-  Clinicians also indicated that they considered prognosti c models to be research tools, designed 
for populati ons and not for clinical decision making in individual pati ents.40 Further, prognosti c 
esti mates are diffi  cult to interpret and are therefore seen as misleading for individual pati ents and 
relati ves.26, 40 The mistrust in prognosti c models does however not seem to apply to all models and 
is not related to model performance, because several models with only moderate performance 
are frequently used in clinical practi ce.34, 43-45
-  Factors related to usability of a prognosti c model may also limit applicati on in clinical practi ce.26 
Prognosti c models oft en require computer support to calculate predicted probabiliti es of clinical 
outcomes.38 Moreover, in routi ne clinical practi ce, characteristi cs are considered that are not 
included in prognosti c models (e.g. comorbiditi es). Also, given the variety in neurological and 
imaging grading scales in acute neurological diseases, measurement of predictors may diff er 
across clinical setti  ngs. 
-  Changes in clinical practi ce, e.g. availability of new treatments or innovati ons in imaging 
techniques may change prognosis of individual pati ents.26 For instance, the Dutch Stroke Score, 
was developed on data that was collected before the introducti on of IAT (Chapter 3). Another 
example is the historic nature of the IMPACT development data. However, an eff ect of changes 
in clinical practi ce is not always observed at external validati on, as shown by the adequate 
performance of the IMPACT and CRASH models throughout the past decade (Chapters 4 and 6).
-  Finally, heterogeneity of the disease course and/or lack of evidence-based treatment opti ons may 
complicate applicati on of a prognosti c model in clinical practi ce. In acute neurological diseases, 
outcomes may be diff erent for pati ents with similar clinical and radiological characteristi cs.46
Additi onally, limited evidence exists on treatment for complicati ons related to aSAH and TBI 
that occur in the acute phase (e.g. DCI or raised intracranial pressure). A survey among clinicians 
revealed that the prognosti c esti mates provided by the IMPACT calculator have only litt le impact on 
(aggressiveness of) care of pati ents with TBI.42 Further, a RCT showed that documenti ng prognosis 
in the intensive care setti  ng had only limited impact on treatment decisions.47 Prognosti c models 
that do aff ect diagnosti c or therapeuti c decisions are more likely to be implemented in guidelines 
and/or clinical practi ce.34, 43-45 The prognosti c models evaluated in this thesis (ISAT, IMPACT and 
CRASH) are not (yet) recommended for clinical decision making.
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Box 9.2. Overview of barriers for applicati on of prognosti c models in clinical practi ce and potenti al soluti ons
Clinician related
- Lack of awareness regarding availability of prognosti c models
Soluti on: improve ‘marketi ng’, e.g. by designing and promoti ng online tools and apps
- Mistrust in prognosti c esti mates for individual pati ents:
 •  Prognosti c models are considered research tools designed for populati ons
 •  Interpretati on of prognosti c esti mates for individual pati ents is challenging
  Soluti on: provide clear guidance on the intended use of prognosti c models and their risk esti mates in 
clinical practi ce
Model related
- Limitati ons concerning usability:
 •  Computer support required to calculate predicted probabiliti es of outcome
 •  Characteristi cs that are considered in routi ne practi ce are not included in prognosti c models
 •  Ambiguous predictors or diff erences in predictor measurement across hospitals
  Soluti on: focus on simple models with easily obtainable characteristi cs that are preferably not subject 
to measurement variati on across diﬀ erent setti  ngs
-  Changes in clinical practi ce over ti me are not accounted for
Soluti on: externally validate prognosti c models in more recent data
Disease related
- Heterogeneous disease course
- Lack of evidence-based treatment opti ons
 Because of these barriers, prognosti c models are currently more seen as tools that may support 
clinicians to increase their confi dence in outcome prognosti cati on, than as crucial for changing 
prognosti c esti mates for individual pati ents based on clinical experience.41 Addressing the barriers from 
both research and clinical practi ce perspecti ves could enhance applicati on of prognosti c models in 
clinical practi ce. 
 Research should focus on simple models with easily obtainable characteristi cs. Additi onally, 
external validati on and updati ng of prognosti c models in recent data is important to address changes 
in clinical practi ce and provide reliable predicti ons for specifi c setti  ngs. In this thesis, examples have 
been provided for external validati on of the ISAT model in a cohort of aSAH pati ents admitt ed to the 
intensive care unit of our hospital, and the IMPACT and CRASH models in a large contemporary cohort 
of TBI pati ents across Europe (Chapters 5 and 6). Finally, decision analyses and impact studies should be 
performed to evaluate feasibility of implementati on in clinical practi ce. 
 From a clinical perspecti ve, the most fundamental aspect is to create awareness among 
clinicians regarding availability of prognosti c models, and provide clear guidance on the intended use 
of prognosti c models and their risk esti mates in clinical practi ce (as done in Chapter 6). It should be 
evident that applicati on of prognosti c models is merely meant to complement clinical judgement, not 
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to replace it. Further, when a prognosti c model has been externally validated extensively, variati on in 
model performance is commonly observed across diff erent setti  ngs. Therefore, validated prognosti c 
models should be implemented only if the model is expected to be applicable to the specifi c setti  ng and 
pati ent.14
Outcome analyses in acute neurological diseases
Diﬀ erences in clinical outcomes between hospitals and countries
Based on random eff ects modeling, we observed between-center diff erences in clinical outcomes aft er 
aSAH that could not be explained by random variati on, pati ent characteristi cs, and ti ming of aneurysm 
treatment (Chapter 7). Similar diff erences in clinical outcomes beyond case-mix have also been 
observed for pati ents with moderate and severe TBI.36 Also, other studies have identi fi ed diff erences 
between hospitals and countries in clinical outcomes aft er ischemic stroke and aSAH, but used other 
methodology.48-50
 Aft er establishing diff erences in clinical outcomes, the next step would be to relate this variati on in 
clinical outcomes to variati on in diagnosti c and treatment policies. For TBI, variati on in treatment policies 
was observed based on questi onnaires among physicians from multi ple centers across Europe.51-56
One way to evaluate the eff ect of diff erences in clinical practi ce on outcomes is to adjust for structure 
and process characteristi cs in random eff ects models. A decrease in between-center diff erences in 
clinical outcomes aft er adjustment may indicate that these factors aff ect clinical outcomes. Further, 
comparati ve eff ecti veness research (CER) can be performed to generate evidence on the benefi ts and 
harms of health care interventi ons (e.g. concerning therapeuti c policies or organizati on of care). By 
providing evidence-based recommendati ons for best clinical practi ce at individual and populati on level, 
CER has the potenti al to improve the quality and outcomes of care for pati ents with acute neurological 
diseases.57, 58
 However, the available data should facilitate evaluati on of potenti al causes for variati on in clinical 
outcomes. So far, random eff ects modeling for between-hospital variati on in clinical outcomes was 
performed on data from the Subarachnoid Hemorrhage Internati onal Trialists (SAHIT) repository and 
the IMPACT database (Chapter 7).36 Both data sources consist of a combinati on of multi ple RCTs, 
observati onal studies and hospital registries.59, 60 Data collecti on for the studies included in these 
repositories was not uniform, making it impossible to combine all data points for the included studies. 
Moreover, the SAHIT repository and IMPACT database were mainly designed for prognosti c research. In 
this way, meta-analyses on all studies combined are restricted due to loss of valuable data. For instance, 
we were unable to evaluate whether variati on in structure and process characteristi cs explained some 
of the between-center diff erences in clinical outcomes aft er aSAH. Also, to pool clinical outcomes, we 
had to dichotomize the outcome scales into favorable versus unfavorable because either the GOS or the 
mRS was used (Chapter 7). 
 The Nati onal Insti tute of Health (NIH) and the Nati onal Insti tute of Neurological Disorders and 
Stroke (NINDS) aim to sti mulate more uniform collecti on, coding and defi niti on of data points for 
clinical trials in acute neurological diseases through establishing common data elements (CDEs).61-64
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Standardizing names and defi niti ons of variables and agreement on methods for data framing may 
facilitate pooling and comparing data from diff erent studies. This may also reduce the variati on in 
measurement of predictors and outcomes that exists in the fi eld of acute neurological diseases.13, 
65 Additi onally, large observati onal cohort studies are required to confi rm presence of diff erences in 
clinical outcomes in more recent data, and to investi gate potenti al causes with CER. An example is 
provided by the Collaborati ve European NeuroTrauma Eff ecti veness Research in Traumati c Brain Injury 
(CENTER-TBI) study.66 This observati onal cohort of contemporary TBI pati ents facilitates adjustment for 
structure and process characteristi cs at hospital level in random eff ects models, and aims to provide 
recommendati ons for best clinical practi ce in TBI based on CER.
Stati sti cal eﬃ  ciency of new outcome measures
Introducti on of new outcome measures is common, with a current emphasis on measures other than 
functi onal outcome, such as pati ent-reported outcome measures (PROMs). PROMs reﬂ ect pati ents’ 
views on their symptoms, functi onal status and quality of life.67 New (pati ent-centered) outcome 
measures have to meet several requirements that should be evaluated before applicati on in clinical 
practi ce and research. One of these requirements concerns validity:  the degree to which a new 
outcome scale measures what we intend to measure.68 A specifi c aspect of validity is the stati sti cal 
effi  ciency of a new outcome measure to detect treatment eff ects. 
 We provided an example on a simulati on study evaluati ng the stati sti cal effi  ciency of a newly 
developed PROM for ischemic stroke: the uti lity-weighted mRS (UW-mRS). Before proper evaluati on of 
stati sti cal effi  ciency, the UW-mRS was used as a (co-)primary outcome in a clinical trial on IAT in pati ents 
with ischemic stroke presenti ng more than 6 hours aft er stroke onset.69 However, our simulati on study 
revealed that the UW-mRS approach was less effi  cient in detecti ng treatment eff ects than ordinal 
analysis of the mRS (Chapter 8). This fi nding underscores the importance of evaluati ng stati sti cal 
effi  ciency and interpretability of a new outcome measure before implementati on in research or clinical 
practi ce.
 By deriving mean uti lity weights for each mRS category, the UW-mRS remains an ordinal scale 
with 7 categories and does not add new informati on. Moreover, this approach does not account for 
individual variati on in uti liti es within each health state of the mRS (Chapters 8 and 8.1). A recent study 
confi rmed that substanti al variati on exists in uti lity values between and within mRS categories and over 
ti me post-stroke, which is not accounted for by the UW-mRS. Moreover, diff erences in methods used 
to derive uti lity values also cause variability in UW-mRS values,70 which complicates evaluati on and 
interpretati on of treatment eff ects. 
 The UW-mRS has been described as an “imperfect soluti on to an important problem.”70 In TBI, 
eff orts have been made to determine health state preference weights for the GOS. Only few preference 
weights with highly variable magnitude have been esti mated for the diff erent GOS categories. Several 
factors, such as age and comorbiditi es, aff ected the mean EuroQol Group 5-Dimension Self-Report 
Questi onnaire (EQ-5D) uti lity values per GOS category.71
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 The development of alternati ve measures that capture both functi onal outcome and quality of 
life is diffi  cult,58 and it remains uncertain whether implementati on of these outcome scales in research 
or clinical practi ce is achievable given the challenges associated with their validity.
Table 9.4. Pros (+) and cons (-) of using pati ent-reported versus functi onal outcome measures
Pati ent-reported outcome measure Functi onal outcome measure
+ Incorporates pati ent percepti on on 
physical and mental well-being
+ Objecti ve evaluati on of treatment eff ects
+ Reduces ﬂ oor and ceiling eff ects + Clinicians are used to interpretati on of 
treatment eff ects on odds or hazard rati o scale
+ Allows for individual variati on in clinical 
outcomes
+ Extensively studied and proven useful
- May reduce stati sti cal power to detect 
treatment eff ects
- May not be sensiti ve to subtle changes in 
clinical status (ﬂ oor and ceiling eff ects)
- May result in false-negati ve or false-
positi ve treatment eff ects 
- Does not include all domains relevant for the 
level of disability
- Complicates interpretati on of treatment 
eff ects
- Subject to interobserver variability
- Introduces noise because it is aff ected 
by external factors
Use of outcome measures in clinical practi ce and research
How should we primarily measure outcomes aft er acute neurological diseases in clinical practi ce 
and research setti  ngs? Functi onal outcome measures and PROMs each have their advantages and 
disadvantages (Table 9.4).
 For acute neurological diseases, functi onal outcome measures (e.g. mRS and GOS) are widely 
implemented in research setti  ngs and clinical practi ce. Functi onal outcome measures are simple, have 
been extensively studied and proven useful in detecti ng disability aft er acute neurological diseases.72, 73
They also facilitate objecti ve evaluati on of treatment eff ects on the odds or hazard rati o scale, which is 
currently common practi ce for clinicians and researchers. 
 Criti cism on functi onal outcome scales is that they are not granular enough to detect subtle but 
relevant changes in clinical status and do not include all domains that are important for the level of 
disability.58 Therefore, these outcome measures may be subject to ﬂ oor and ceiling eff ects, meaning 
that pati ents may score at the extreme ends of the distributi on despite relevant changes in clinical 
status.72 Slightly more detailed measures of functi onal outcome exist, such as the Barthel Index and the 
Glasgow Outcome Scale Extended (GOSE).73, 74 Functi onal outcome scales have also been criti cized for 
interobserver variability.75
 PROMs are increasingly popular and many studies regarding development of new PROMs or 
evaluati on of their clinical relevance have been published. The main reason that PROMs are strongly 
advocated, is that they may have the capacity to narrow the gap between pati ent and physician. 
They allow for individual variati on in clinical outcomes, and are therefore less sensiti ve to ﬂ oor and 
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ceiling eff ects than functi onal outcome measures. PROMs have many potenti al applicati ons, aimed at 
improving quality of care for individual pati ents as well as for healthcare systems.67, 76
 Some important limitati ons of generic and disease-specifi c PROMs should however be considered: 
-  As shown for the UW-mRS, PROMs may reduce stati sti cal power to detect treatment eff ects 
in clinical trials (Chapter 8). Lack of stati sti cal effi  ciency of an outcome measure could cause 
unnecessary pati ent inclusion in RCTs, which might cause delay in release of new treatments for 
acute neurological diseases. 
-  Further, evaluati on of treatment benefi t on PROMs may result in false-negati ve or false-positi ve 
treatment eff ects. For instance, the Multi center Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) showed a clear benefi t of IAT 
on the ordinal mRS in pati ents with ischemic stroke based on a proximal arterial occlusion in the 
anterior cerebral circulati on.77 However, IAT only had a limited eff ect on quality of life measured 
with the EQ-5D.78 Relying on a PROM as primary outcome measure could therefore wrongfully 
aff ect clinical management: when quality of life does only marginally improve, why would we sti ll 
perform IAT in ischemic stroke?
-  Also, PROMs may impede interpretati on of treatment eff ects. Concerning the UW-mRS, 
interpretati on of treatment eff ects expressed as diff erences in uti lity values or quality-adjusted 
life years (QALYs) is quite complex in research and clinical practi ce (Chapter 8).
-  Finally, the advantage of considering multi ple domains of daily functi oning also comes with a 
downside: most PROMs depend on external factors (i.e. not related to the specifi c disease or 
treatment). This ‘noise’ introduced by PROMs makes them less appropriate as effi  cacy measures 
for treatment (Chapter 8). Disease-specifi c PROMs may provide a soluti on in this regard, but 
a major disadvantage is that these PROMs cannot be compared with other disease groups or 
populati on norms.
 Therefore, PROMs are quite complex and there is currently not enough evidence to implement 
them in research and clinical practi ce as primary outcome measures. Two generic PROMs have been 
validated for many diseases: the EQ-5D and the Short-Form (SF-36).79, 80 In aSAH, there is however 
limited evidence for selecti on of suitable generic or disease-specifi c PROMs. None of the available 
PROMs complied with the standards for validity, and only one PROM was specifi cally developed for 
aSAH.81 For ischemic stroke, there is somewhat more evidence for both generic and stroke-specifi c 
PROMs, but the implementati on in research setti  ngs and clinical practi ce is sti ll lacking.82 The Quality 
of Life aft er Brain Injury (QOLIBRI) is a promising disease-specifi c PROM for TBI.83 Nevertheless, more 
should be done to evaluate the role of multi dimensional outcome measures in TBI research and clinical 
practi ce.58, 84
 In acute neurological diseases, PROMs are relevant since many pati ents experience impairments 
that aff ect both functi onal status and quality of life. However, PROMs have some important limitati ons 
and their impact on clinical practi ce sti ll needs to be established. Therefore, PROMs are currently not 
sensiti ve enough to be used as primary outcome measure in clinical trials or routi ne clinical practi ce.67
For now, treatment eff ects in clinical trials are sti ll recommended to be analyzed with functi onal scales 
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as primary outcome measures (Chapter 8).58, 85 Individual variati on in quality of life can be measured as 
a secondary outcome with validated generic or disease-specifi c scales (Chapters 8 and 8.1). Pati ents’ 
impairments on domains other than functi onal outcome should also be considered in clinical practi ce.
Limitati ons
The development data of the majority of prognosti c models evaluated in this thesis mainly originated 
from clinical trials (Chapter 3-6). The evaluati on of between-hospital variati on in clinical outcomes aft er 
aSAH was also based on data from multi center RCTs (Chapter 6). For prognosti c and outcomes research, 
observati onal cohorts are preferred. Moreover, these RCTs were conducted before the introducti on of 
some highly benefi cial interventi ons in ischemic stroke and aSAH (e.g. IAT and aneurysm coiling). These 
factors limit the generalizability of our results to contemporary pati ents with ischemic stroke or aSAH. 
Our fi ndings should therefore be interpreted with cauti on and should be validated in current setti  ngs. 
However, most ischemic stroke pati ents receive intravenous alteplase as only treatment (Chapter 3). 
Further, given the lack of evidence-based treatment opti ons and variati on in guidelines for treatment 
of aSAH, it is expected that between-center diff erences in clinical outcomes sti ll exist in current clinical 
practi ce (Chapter 6).
 The prognosti c models presented in this thesis consist of characteristi cs obtained within 24 
hours aft er hospital admission, but do not take into account changes in the clinical course. Therefore, 
characteristi cs obtained during the disease course or variables that predict treatment response may 
also be relevant. In routi ne clinical practi ce, variables such as improvement in neurological status 
and medical comorbiditi es are usually considered by clinicians, even if no model currently includes 
such variables. However, prognosti c models based on admission characteristi cs enable early disease 
classifi cati on and ti mely inclusion of pati ents in clinical trials. Further, model extension with dynamic 
predictors has not been widely investi gated and yielded variable improvement in model performance 
(Chapter 4).
Next steps in research and clinical practi ce
Based on our main fi ndings regarding predicti on and outcome analyses in acute neurological diseases 
and their interpretati on, specifi c recommendati ons on the next steps in future research and clinical 
practi ce can be summarized. 
Predicti on
-  Perform decision-analyti c evaluati ons and impact studies to get an impression of the clinical 
applicability of existi ng prognosti c models
-  Att empt updati ng of promising existi ng prognosti c models to enhance reliability of predicti ons for 
pati ents in a specifi c clinical setti  ng
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Outcome analyses
-  Reduce heterogeneity in defi niti ons and measurement of clinical characteristi cs and outcomes in 
acute neurological diseases by standardizing data collecti on through CDE
-  Relate between-hospital diff erences in clinical outcomes to variati on in clinical practi ce with CER 
in large datasets that allow for suffi  cient sample size per hospital to provide recommendati ons for 
best clinical practi ce
-  Use functi onal outcome scales to evaluate treatment eff ects in research and clinical practi ce and 
assess individual variati on in quality of life separately with validated scales (e.g. EQ-5D or SF-36)
-  Pursue development of multi dimensional outcome measures for acute neurological diseases, 
provided that their stati sti cal effi  ciency and interpretability are ensured
Overall conclusions
The aim of this thesis was to identi fy pati ents at high risk for poor outcome aft er acute neurological 
diseases and to enhance knowledge on outcome variati on and stati sti cal effi  ciency of new outcome 
measures. The core predictors to identi fy pati ents with acute neurological diseases at high risk for poor 
outcome are age and neurological status at hospital admission. Prognosti c models are increasingly 
externally validated, which is a crucial step before we start implementati on in clinical practi ce. Providing 
reliable predicti ons for individual pati ents with acute neurological diseases remains challenging, so 
validated prognosti c models should be applied in additi on to clinical experience and only if the model is 
expected to be applicable to the specifi c setti  ng and pati ent.
 Variati on between hospitals in clinical outcomes aft er aSAH exists and could not be explained by 
random variati on, case-mix and ti ming of aneurysm treatment. Our results need to be confi rmed in 
more recent data, ideally a large observati onal cohort study. Diff erences in clinical outcomes should be 
related to practi ce variati on in future (CER) studies, to provide evidence-based recommendati ons for 
best clinical practi ce.
 Pati ent-centered outcome measures may reduce the power of clinical trials in detecti ng treatment 
eff ects, and may complicate interpretati on of trial results. An example was provided for the UW-mRS 
in ischemic stroke. This fi nding underscores the importance of evaluati ng stati sti cal effi  ciency and 
interpretability of a new outcome measure before using it.
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Summary
Part I Introducti on
Most treatments and interventi ons in health care are aimed at opti mizing clinical outcomes. 
Measurement of clinical outcomes may serve diff erent purposes, such as outcome predicti on and 
outcome analyses. Clinical outcome predicti on involves the use of prognosti c factors or a prognosti c 
model for early identi fi cati on of pati ents at high risk for poor functi onal outcome in a specifi c clinical 
setti  ng. This may assist clinicians with treatment decisions, inclusion of pati ents in randomized clinical 
trials or benchmarking quality of care. Outcome analyses include examining variati on in outcomes 
across diff erent setti  ngs and determining the added value of new outcome measures. Variati on in 
clinical outcomes between hospitals and countries is present in many diseases, but is highly undesirable 
when caused by diff erences in management. Gaining insight in outcome diff erences across setti  ngs with 
random eff ects modeling creates the opportunity to evaluate practi ce variati on. Further, a trend exists 
towards new outcome measures incorporati ng both functi onal outcome and quality of life (pati ent-
reported outcome measures [PROMs]). New outcome measures should be stati sti cally effi  cient to 
obtain reliable esti mates of treatment eff ects in clinical trials, and should also facilitate interpretati on 
of treatment eff ects.
 Ischemic stroke, aneurysmal subarachnoid hemorrhage (aSAH) and traumati c brain injury (TBI) 
are acute neurological diseases with a heterogeneous disease course that are oft en associated with 
poor functi onal outcomes and reduced quality of life. This sti mulates measurement of clinical outcomes 
in terms of prognosis, variati on across setti  ngs and new assessment methods. 
The overall aim of this thesis was to identi fy pati ents at high risk for poor outcome aft er acute 
neurological diseases (Part II) and to enhance knowledge on outcome variati on and stati sti cal effi  ciency 
of new outcome measures (Part III). 
Specifi c research questi ons were: 
 1.    What characteristi cs are associated with poor outcome aft er acute neurological diseases?
 2.    What is the methodological quality of existi ng prognosti c models in acute neurological 
diseases?
 3.    Do these models provide reliable predicti ons for pati ents in specifi c clinical setti  ngs? 
 4.    What are the diff erences in clinical outcomes between pati ents with aSAH in a range of 
internati onal hospitals, and can these diff erences be explained by variati on in case-mix?
 5.    What is the stati sti cal effi  ciency of new outcome measures for acute neurological diseases?
Part II Predicti on
In Chapter 2, we performed a two-center retrospecti ve cohort study in 285 aSAH pati ents to evaluate 
the associati ons between maximum serum lactate and glucose levels measured within the fi rst 24 
hours aft er onset of aSAH, and delayed cerebral ischemia (DCI) or poor functi onal outcome (modifi ed 
Rankin Scale [mRS] 4-6). Aft er adjustment for pati ent and imaging characteristi cs, lactate and glucose 
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were independently associated with DCI and poor outcome with odds rati os between 1.17 and 1.56. 
Lactate and glucose were strongly related, and aft er inclusion of both parameters in the multi variable 
model, only glucose was independently associated with DCI and only lactate was associated with poor 
outcome. The role of early glucose and lactate in prognosti c models for outcome aft er aSAH and the 
associated pathophysiological mechanisms (e.g. relati on with sympatheti c stress) should be evaluated 
in future studies.
 Chapter 3 presents the development and validati on of prognosti c models for the Barthel Index 
(BI) at hospital discharge (Dutch Stroke Score [DSS]-discharge) and mRS at three months (DSS-3 months) 
aft er ischemic stroke. We analyzed individual pati ent data from three clinical trials, of which one served 
as development cohort (n=1227) and two as external validati on cohorts (n=1589 and n=2107). The DSS-
discharge included age, Nati onal Insti tutes of Health Stroke Scale (NIHSS) and diabetes as predictors, 
and showed reasonable discriminati on at internal validati on (area under the receiver operati ng 
characteristi c curve [AUC] of 0.76). The DSS-3 months consisted of age, NIHSS, diabetes, previous stroke 
and atrial fi brillati on, and yielded ordinal AUCs around 0.70 at internal and external validati on. However, 
model calibrati on showed that the DSS-3 months overesti mated the proporti on of poor outcome (mRS 
3-6) in the validati on cohorts. If further validated, the DSS may assist clinicians with effi  cient stroke unit 
discharge planning.
 Chapter 4 provides a systemati c overview of contemporary prognosti c models for functi onal 
outcome aft er moderate and severe TBI. We included 58 studies describing 67 unique prognosti c 
models. The most frequently included predictors were age, the full Glasgow Coma Scale or its motor 
component, and pupillary reacti vity. We observed that existi ng prognosti c models are increasingly 
externally validated (149 external validati ons of 31 models). However, methodological quality of 
prognosti c models for moderate and severe TBI could sti ll be improved. For instance, model calibrati on 
was reported graphically in only half of the validati ons (54%). The Internati onal Mission on Prognosis and 
Analysis of Clinical Trials (IMPACT) and Corti coid Randomisati on Aft er Signifi cant Head injury (CRASH) 
models were externally validated most extensively (n=91) and showed adequate discriminati ve ability 
across diff erent setti  ngs (mean weighted AUCs 0.77-0.82). However, the reliability of predicti ons was 
highly variable. This illustrates the need for conti nuous external validati on and updati ng of prognosti c 
models over ti me and to specifi c clinical setti  ngs.
 External validati on studies of prognosti c models for functi onal outcome aft er aSAH and moderate 
and severe TBI were presented in Chapters 5 and 6, respecti vely. The Internati onal Subarachnoid 
Aneurysm Trial (ISAT) model for 60-day mortality aft er aSAH consists of age, World Federati on of 
Neurological Surgeons grade, Fisher grade and aneurysm size as predictors. The ISAT model showed 
good discriminati ve ability in a retrospecti ve cohort of 307 aSAH pati ents admitt ed to the intensive care 
unit of the Erasmus University Medical Center (AUC 0.82). The IMPACT and CRASH models for mortality 
and unfavorable outcome (Glasgow Outcome Scale Extended 1-4) showed good discriminati on in a 
prospecti ve observati onal cohort of 1742 moderate and severe TBI pati ents across Europe (AUCs 0.80-
0.88). However, providing predicti ons for pati ents with aSAH and TBI in specifi c clinical setti  ngs remains 
diffi  cult.
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 Chapters 4.1 and 5.1 addressed some core methodological concepts of model development 
and validati on in acute neurological diseases. Adequate reporti ng of prognosti c research, taking 
into considerati on the available evidence in the fi eld, is crucial for the reliability and reproducibility 
of prognosti c models.  Importantly, the core clinical predictors of functi onal outcome aft er acute 
neurological diseases have been established. Therefore, validati on and updati ng of promising existi ng 
prognosti c models is preferred over the development of new models.
Part III Outcome analyses
In Chapter 7, random eff ects modeling was performed to evaluate between-hospital and between-
country variati on in clinical outcomes aft er aSAH. We analyzed data from 5972 aSAH pati ents treated at 
179 centers in 20 countries included in a large internati onal repository. We found substanti al between-
hospital variati on, that could not be explained by random variati on, pati ent characteristi cs or ti ming of 
aneurysm treatment (adjusted median odds rati o 1.21, 95% confi dence interval 1.11-1.44). There were 
no stati sti cally signifi cant between-country diff erences. Identi fying individual hospitals that performed 
bett er or worse than others was diffi  cult, because the individual random eff ect esti mates were subject 
to substanti al uncertainty. The data were relati vely old, and we were unable to evaluate the causality 
between observed outcome diff erences and variati on in treatment policies (other than ti ming of 
aneurysm treatment) or quality of care. Therefore, we could not provide recommendati ons for current 
clinical practi ce.
 A simulati on study evaluati ng the stati sti cal effi  ciency of the uti lity-weighted mRS (UW-mRS), a 
recently proposed pati ent-centered outcome measure in ischemic stroke, was presented in Chapter 
8. The simulati ons were based on individual pati ent data of 500 pati ents enrolled in a multi center 
clinical trial evaluati ng the eff ecti veness of intra-arterial treatment in ischemic stroke. Linear analysis of 
the UW-mRS was less effi  cient in detecti ng treatment eff ects than ordinal analysis of the mRS (power 
85% versus 87%). Moreover, the UW-mRS does not capture individual variati on in uti liti es within each 
mRS category, and may impede interpretati on of treatment eff ects. These fi ndings underscore the 
importance of studying the stati sti cal effi  ciency and interpretability of new pati ent-centered outcome 
measures, as outlined in Chapter 8.1.
Part IV Discussion
The main objecti ve of this thesis was to identi fy pati ents at high risk for poor outcome aft er acute 
neurological diseases and to enhance knowledge on outcome variati on and stati sti cal effi  ciency 
of new outcome measures. We found that age and neurological status on admission are the main 
characteristi cs associated with poor clinical outcome aft er ischemic stroke, aSAH and moderate and 
severe TBI. Prognosti c models are increasingly externally validated, which is a crucial step before we 
start implementati on in clinical practi ce. However, providing reliable predicti ons for individual pati ents 
with acute neurological diseases remains challenging. Further, we found substanti al variati on between 
hospitals in clinical outcomes aft er aSAH, which could not be explained by random variati on, case-mix 
and ti ming of aneurysm treatment. Finally, a simulati on study evaluati ng the stati sti cal effi  ciency of the 
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UW-mRS showed that pati ent-centered outcome measures may reduce the power of clinical trials in 
detecti ng treatment eff ects, and may complicate interpretati on of trial results.
 Although the vast body of prognosti c research in acute neurological diseases implies that outcome 
predicti on is considered relevant for clinical practi ce, prognosti c models for ischemic stroke, aSAH and 
TBI are rarely implemented. Several barriers for use of prognosti c models in clinical practi ce can be 
identi fi ed, including the lack of knowledge among clinicians on existence and use of prognosti c models, 
and the few evidence-based treatment recommendati ons in acute neurological diseases. The clinical 
applicability of existi ng prognosti c models should be examined with decision-analyti c evaluati ons and 
impact studies.
 Diff erences in clinical outcomes between hospitals should, as a next step, be related to variati on 
in clinical practi ce with comparati ve eff ecti veness research to provide recommendati ons for best 
clinical practi ce, preferably based on large observati onal cohort study. To enable this, heterogeneity 
in defi niti ons and measurement of clinical characteristi cs and outcomes in acute neurological diseases 
needs to be reduced by standardizing data collecti on through common data elements.
 Functi onal outcome measures have been widely implemented and provide objecti ve evaluati on 
of treatment eff ects. PROMs, on the other hand, incorporate pati ent percepti on on physical and 
mental well-being and allow for individual variati on in clinical outcomes. However, the development 
of PROMs is diffi  cult, and it remains uncertain whether implementati on of these outcome scales in 
research or clinical practi ce is achievable given the challenges associated with their validity. Therefore, 
we recommend to use functi onal outcome scales to evaluate treatment eff ects and to assess individual 
variati on in quality of life separately with validated scales.
Summary
- 265 -

Samenvatting
- 268 -
Samenvatti  ng
- 269 -
Samenvatti  ng
Deel I Introducti e
De meeste behandelingen en interventi es in de gezondheidszorg zijn gericht op het verbeteren van 
klinische uitkomsten. Het meten van klinische uitkomsten is belangrijk voor diverse doeleinden, 
waaronder predicti e en analyse van uitkomsten. Predicti e van klinische uitkomsten omvat het gebruik 
van prognosti sche factoren of een prognosti sch model om pati ënten met een hoog risico op ongunsti ge 
uitkomst in een specifi eke klinische context vroeg te herkennen. Dit kan clinici ondersteunen 
bij beslissingen rondom behandeling, inclusie van pati ënten in gerandomiseerde studies en het 
benchmarken van kwaliteit van zorg. Analyses van uitkomsten omvatt en onder andere het evalueren 
van verschillen in uitkomsten tussen ziekenhuizen en het beoordelen van de toegevoegde waarde van 
nieuwe uitkomstmaten. Variati e in klinische uitkomsten tussen ziekenhuizen en landen komt voor bij veel 
ziektebeelden, maar is zeer ongewenst wanneer dit wordt veroorzaakt door verschillen in management. 
Het verkrijgen van inzicht in verschillen in uitkomsten tussen ziekenhuizen faciliteert evaluati e van 
variati e in behandeling van individuele pati ënten en kwaliteit van zorg. Verder is er een trend richti ng 
het ontwikkelen en gebruiken van uitkomsten waarin zowel functi onele uitkomst als kwaliteit van leven 
verenigd zijn, de zogenaamde “pati ent-reported outcome measures” (PROMs). Nieuwe uitkomstmaten 
moeten stati sti sch effi  ciënt zijn om betrouwbare schatti  ngen van behandeleff ecten te verkrijgen en 
moeten daarnaast voorzien in eenvoudige interpretati e van behandeleff ecten.
 Het herseninfarct, de aneurysmati sche subarachnoïdale bloeding (aSAB) en traumati sch 
hersenletsel zijn acute neurologische ziekten met een heterogeen beloop, en zijn vaak geassocieerd 
met ongunsti ge functi onele uitkomsten en verminderde kwaliteit van leven. Dit sti muleert het meten 
van uitkomsten in termen van prognose, variati e tussen ziekenhuizen en nieuwe meetmethoden. 
Het doel van dit proefschrift  was het identi fi ceren van pati ënten met acute neurologische ziekten met 
een hoog risico op ongunsti ge uitkomst (Deel II) en het vergroten van onze kennis ten aanzien van 
variati e in uitkomsten en stati sti sche effi  ciënti e van nieuwe uitkomstmaten (Deel III).
Specifi eke onderzoeksvragen waren:
 1.    Welke kenmerken zijn geassocieerd met ongunsti ge uitkomst na acute neurologische ziekten?
 2.    Wat is de methodologische kwaliteit van prognosti sche modellen voor acute neurologische 
ziekten?
 3.    Kunnen deze modellen betrouwbare voorspellingen genereren voor pati ënten in een specifi eke 
klinische context?
 4.    Wat zijn de verschillen in klinische uitkomsten tussen pati ënten met aSAB in een reeks 
internati onale ziekenhuizen, en kunnen deze verschillen verklaard worden door variati e in 
pati ëntkarakteristi eken?
 5.    Wat is de stati sti sche effi  ciënti e van nieuwe uitkomstmaten voor acute neurologische ziekten?
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Deel II Predicti e
In Hoofdstuk 2 hebben we een retrospecti eve cohortstudie verricht in 285 aSAB pati ënten voor het 
onderzoeken van de relati e tussen maximaal serum lactaat en glucose gemeten binnen 24 uur na 
ontstaan van de aSAB en het optreden van secundaire cerebrale ischemie of ongunsti ge functi onele 
uitkomst (modifi ed Rankin Scale [mRS] 4-6). Na correcti e voor pati ënt- en radiologische karakteristi eken 
waren lactaat en glucose onafh ankelijk geassocieerd met cerebrale ischemie en ongunsti ge uitkomst 
met odds rati os tussen 1.17 en 1.56. Lactaat en glucose waren sterk gecorreleerd, en na inclusie van 
beide parameters in het multi variabele model was alleen glucose geassocieerd met cerebrale ischemie 
en alleen lactaat geassocieerd met ongunsti ge uitkomst. De rol van serum glucose en lactaat in 
prognosti sche modellen voor uitkomst na aSAB en de gerelateerde pathofysiologische mechanismen 
(bijv. de relati e met acti vati e van het sympathische systeem bij stress) moet verder bestudeerd worden.
Hoofdstuk 3 beschreef de ontwikkeling en validati e van prognosti sche modellen voor de Barthel 
Index (BI) bij ontslag uit het ziekenhuis (Dutch Stroke Score [DSS]-ontslag) en de mRS op 3 maanden (DSS-3 
maanden) na een herseninfarct. We hebben data geanalyseerd van pati ënten uit drie gerandomiseerde 
studies, waarvan één als ontwikkelcohort (n=1227) en twee als validati ecohort fungeerden (n=1589 
en n=2107). De DSS-ontslag bevatt e leeft ijd, Nati onal Insti tutes of Health Stroke Scale (NIHSS) en 
diabetes als prognosti sche factoren, en liet redelijke discriminati e zien bij interne validati e (area under 
the receiver operati ng characteristi c curve [AUC] van 0.76). The DSS-3 maanden bestond uit leeft ijd, 
NIHSS, diabetes, eerder herseninfarct en atriumfi brilleren, en resulteerde in ordinale AUCs rond 0.70 bij 
interne en externe validati e. Kalibrati e liet echter zien dat de DSS-3 maanden het aantal pati ënten met 
ongunsti ge uitkomst (mRS 3-6) overschatt e. De DSS kan clinici ondersteunen bij het effi  ciënt plannen 
van ontslag vanaf de stroke unit, mits verder gevalideerd.
Hoofdstuk 4 bestond uit een systemati sch overzicht van beschikbare prognosti sche modellen 
voor functi onele uitkomst na mati g ernsti g en ernsti g traumati sch hersenletsel. We hebben 58 
studies geïncludeerd waarin 67 verschillende modellen werden beschreven. De meest voorkomende 
prognosti sche factoren waren leeft ijd, de volledige Glasgow Coma Scale of de motor component, en 
pupilreacti es. We vonden dat bestaande prognosti sche modellen steeds vaker extern worden gevalideerd 
(149 externe validati es van 31 modellen). De methodologische kwaliteit van prognosti sche modellen 
voor mati g ernsti g en ernsti g traumati sch hersenletsel kan echter nog steeds worden verbeterd. 
Kalibrati e werd bijvoorbeeld slechts in de helft  van de validati es (54%) grafi sch gerapporteerd. De 
Internati onal Mission on Prognosis and Analysis of Clinical Trials (IMPACT) en Corti coid Randomisati on 
Aft er Signifi cant Head injury (CRASH) modellen waren het meest vaak extern gevalideerd (n=91) en 
hadden goede discriminati e in verschillende populati es (gemiddelde gewogen AUCs 0.77-0.82). De 
betrouwbaarheid van de voorspellingen was echter zeer variabel. Dit illustreert het belang van conti nue 
externe validati e en updaten van prognosti sche modellen over de ti jd en voor iedere specifi eke klinische 
context.
 In Hoofdstuk 5 en 6 werden externe validati e studies van prognosti sche modellen gepresenteerd 
voor respecti evelijk aSAB en mati g ernsti g en ernsti g traumati sch hersenletsel. Het Internati onal 
Subarachnoid Aneurysm Trial (ISAT) model voor mortaliteit 60 dagen na aSAB bevat leeft ijd, World 
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Federati on of Neurological Surgeons score, Fisher score en groott e van het aneurysma als prognosti sche 
factoren. Het ISAT model liet goede discriminati e zien in een retrospecti ef cohort van 307 aSAB 
pati ënten die opgenomen waren op de intensive care van het Erasmus Universitair Medisch Centrum 
(AUC 0.82). De IMPACT en CRASH modellen voor mortaliteit en ongunsti ge uitkomst (Glasgow Outcome 
Scale Extended 1-4) na mati g ernsti g en ernsti g traumati sch hersenletsel hadden goede discriminati e in 
een prospecti ef observati oneel cohort van 1742 Europese pati ënten (AUCs 0.80-0.88). Het genereren 
van betrouwbare voorspellingen voor pati ënten met aSAB en traumati sch hersenletsel in een specifi eke 
klinische context blijft  echter lasti g. 
Hoofdstukken 4.1 en 5.1 behandelden een aantal methodologische concepten met betrekking 
tot het ontwikkelen en valideren van prognosti sche modellen in acute neurologische ziekten. Adequate 
rapportage van prognosti sch onderzoek met aandacht voor de beschikbare literatuur is cruciaal voor 
de betrouwbaarheid en reproduceerbaarheid van prognosti sche modellen. Voor acute neurologische 
ziekten zijn de belangrijkste prognosti sche factoren voor functi onele uitkomst bevesti gd. Daarom heeft  
validati e en updaten van bestaande prognosti sche modellen de voorkeur boven het ontwikkelen van 
nieuwe modellen.
Deel III Uitkomst analyses
In Hoofdstuk 7 hebben we gekeken naar verschillen in klinische uitkomsten na aSAB tussen ziekenhuizen 
en landen. We hebben data geanalyseerd van 5972 aSAB pati ënten uit een grote internati onale database 
die waren behandeld in 179 ziekenhuizen uit 20 landen. We vonden aanzienlijke variati e tussen 
ziekenhuizen, welke niet verklaard kon worden door random variati e, pati ëntkarakteristi eken of ti ming 
van aneurysma behandeling (geadjusteerde median odds rati o 1.21, 95% betrouwbaarheidsinterval 
1.11-1.44). Er waren geen stati sti sch signifi cante verschillen tussen landen. Omdat de individuele 
schatti  ngen op ziekenhuis niveau erg onzeker waren, was het lasti g om ziekenhuizen te identi fi ceren die 
beter of slechter presteerden dan anderen. De data waren relati ef gedateerd, en de causaliteit tussen 
de geobserveerde uitkomst verschillen en variati e in behandeling van individuele pati ënten (anders 
dan aneurysma behandeling) en kwaliteit van zorg kon niet worden geëvalueerd. Daarom was het niet 
mogelijk om aanbevelingen te doen voor de huidige klinische prakti jk.
 In Hoofdstuk 8 werd de stati sti sche effi  ciënti e van de uti lity-gewogen mRS (UW-mRS), een 
recent voorgestelde pati ëntgerichte uitkomstmaat na een herseninfarct, onderzocht middels een 
simulati estudie. De simulati es waren gebaseerd op de data van 500 pati ënten vanuit een multi center 
gerandomiseerde studie gericht op de eff ecti viteit van trombectomie na een herseninfarct. Lineaire 
analyse van de UW-mRS was minder effi  ciënt in het detecteren van behandeleff ecten dan ordinale 
analyse van de mRS (power 85% versus 87%). Bovendien houdt de UW-mRS geen rekening met de 
individuele variati e in kwaliteit van leven binnen iedere mRS categorie, en kan deze uitkomstmaat de 
interpretati e van behandeleff ecten bemoeilijken. Deze bevindingen benadrukken het belang van het 
bestuderen van de stati sti sche effi  ciënti e en interpretati e van nieuwe pati ëntgerichte uitkomstmaten, 
zoals ook beschreven in Hoofdstuk 8.1.
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Deel IV Discussie
Het doel van dit proefschrift  was het identi fi ceren van pati ënten met acute neurologische ziekten met 
een hoog risico op ongunsti ge uitkomst en het vergroten van onze kennis ten aanzien van variati e 
in uitkomsten en stati sti sche effi  ciënti e van nieuwe uitkomstmaten. Leeft ijd en neurologische status 
bij opname zijn de belangrijkste factoren geassocieerd met ongunsti ge klinische uitkomst na een 
herseninfarct, aSAB en mati g ernsti g en ernsti g traumati sch hersenletsel. Prognosti sche modellen 
worden steeds vaker extern gevalideerd, wat van groot belang is voordat ze toegepast worden in de 
klinische prakti jk. Het genereren van betrouwbare voorspellingen voor individuele pati ënten met acute 
neurologische ziekten blijft  echter lasti g. Verder is er aanzienlijke variati e tussen ziekenhuizen in klinische 
uitkomsten na aSAB, welke niet verklaard kon worden door random variati e, pati ëntkarakteristi eken 
en ti ming van aneurysma behandeling. Tot slot heeft  een simulati estudie voor het bestuderen van 
de stati sti sche effi  ciënti e van de UW-mRS aangetoond dat pati ëntgerichte uitkomstmaten de power 
van een gerandomiseerde studie in het detecteren van behandeleff ecten kunnen reduceren, en 
interpretati e van behandeleff ecten kunnen bemoeilijken. 
 De grote hoeveelheid literatuur op het gebied van prognosti sche modellen in acute neurologische 
ziekten impliceert dat predicti e van uitkomsten relevant wordt geacht voor de klinische prakti jk. 
Prognosti sche modellen voor het herseninfarct, aSAB en traumati sch hersenletsel worden echter 
nauwelijks geïmplementeerd. Er zijn verschillende barrières voor het gebruik van prognosti sche 
modellen in de klinische prakti jk, waaronder het gebrek aan kennis over beschikbaarheid en gebruik 
van prognosti sche modellen onder clinici, en het beperkte aantal evidence-based behandelingen voor 
acute neurologische ziekten. Besliskundige evaluati es en impactstudies moeten worden uitgevoerd om 
een indruk te krijgen van de klinische toepasbaarheid van prognosti sche modellen.
 Verschillen in klinische uitkomsten tussen ziekenhuizen dienen, als volgende stap, gerelateerd te 
worden aan variati e in behandeling van individuele pati ënten en kwaliteit van zorg om aanbevelingen 
te kunnen doen voor de klinische prakti jk. Dit is mogelijk met vergelijkend eff ecti viteitsonderzoek, 
bij voorkeur op basis van een grote observati onele cohortstudie. De heterogeniteit in defi niti es en 
meetmethoden van klinische kenmerken en uitkomsten in acute neurologische ziekten kan gereduceerd 
worden door het standaardiseren van dataverzameling met behulp van common data elements.
 Functi onele uitkomstmaten zijn breed geïmplementeerd en voorzien in objecti eve evaluati e van 
behandeleff ecten. PROMs representeren zowel fysiek als mentaal welzijn, en houden rekening met 
individuele variati e in klinische uitkomsten. De ontwikkeling van PROMs is echter ingewikkeld, en het 
blijft  de vraag of implementati e van deze uitkomstmaten in onderzoek of klinische prakti jk haalbaar is 
gezien de problemen met betrekking tot validiteit. Daarom kan voor het evalueren van behandeleff ecten 
het beste gebruik worden gemaakt van functi onele uitkomstmaten, en dient individuele variati e in 
kwaliteit van leven apart beoordeeld te worden met gevalideerde uitkomstmaten.
Samenvatti  ng
- 273 -

Dankwoord
- 276 -
Dankwoord
- 277 -
Dankwoord
Begin 2017 ben ik de uitdaging aangegaan om mijn proefschrift  in een verkort traject te voltooien, en ik 
ben ontzett end blij en trots dat dit gelukt is! Gedurende de afgelopen 2.5 jaar heb ik veel (levenslessen) 
geleerd, met briljante mensen mogen samenwerken, en de gelegenheid gekregen om mijn onderzoek 
te presenteren op een groot aantal leuke congressen.
Dit proefschrift  was er nooit gekomen zonder de begeleiding die ik heb gehad en de steun van familie 
en vrienden. Graag wil ik iedereen bedanken die heeft  bijgedragen aan de totstandkoming van dit 
proefschrift , en in het bijzonder de volgende personen.
 Ewout, ondanks je overstap naar Leiden ben je alti jd betrokken geweest bij mijn traject en 
reageerde je snel en met goede input op mijn manuscripten. Bij projecten omtrent ‘prognose’ werd 
direct een link gelegd met mij. Dank ook voor de vrijheid en ruimte die je me gegeven hebt om mijn 
eigen draai te geven aan dit proefschrift .
 Diederik, dank voor je input en betrokkenheid op de momenten dat ik daar om vroeg. Ik heb 
geleerd van je ontnuchterende (soms handgeschreven en lasti g te ontcijferen) feedback. Tevens heb 
je me op de juiste momenten teruggeﬂ oten als ik bepaalde dingen net iets te sterk verwoordde in een 
manuscript of lett er (“die Italianen zijn net zo blij dat ze in Stroke gepubliceerd hebben, dus die moet je 
niet zo neersabelen”).
 Hester, bedankt voor de leuke en leerzame wekelijkse besprekingen. Met name het brainstormen 
over nieuwe stukken en analyses gaf moti vati e. Je hebt me de mogelijkheid gegeven om betrokken te 
zijn bij vele leuke projecten op het gebied van herseninfarct, subarachnoïdale bloeding en traumati sch 
hersenletsel. Daarnaast waardeer ik het heel erg dat er alti jd ruimte was om mee te denken over mijn 
persoonlijke en wetenschappelijke ontwikkeling. 
 Mathieu, mijn enthousiasme voor wetenschappelijk onderzoek is gegroeid toen ik in 2014 
bij jou mijn masteronderzoek mocht doen. Je gaf me de mogelijkheid tot het schrijven van twee 
manuscripten op het gebied van subarachnoïdale bloedingen als eerste auteur, nu onderdeel van dit 
proefschrift . Tijdens mijn coschappen heb je me voorgedragen bij CENTER-TBI, wat heeft  geleid tot dit 
promoti etraject. Dank daarvoor. Als copromotor heb je me vervolgens geloof ik wel 100 keer gevraagd 
“Heb je al een datum (voor je promoti e)?” want “ik ging zo snel”. Nu kan ik (eindelijk) zeggen: JA!
 Aan al mijn supervisors: dank voor het vertrouwen de afgelopen jaren. De input vanuit 
verschillende invalshoeken (medische besliskunde, neurologie en intensive care) heeft  ervoor gezorgd 
dat dit proefschrift  een mooi coherent geheel is geworden. 
 Verder wil ik prof. dr. Peter Koudstaal, prof. dr. Saskia le Cessie en prof. dr. Geert Meyfroidt 
bedanken voor het beoordelen van dit proefschrift . De overige commissieleden wil ik hartelijk bedanken 
voor het lezen van mijn proefschrift  en het deelnemen aan de oppositi e. En natuurlijk iedereen die 
als coauteur een bijdrage heeft  geleverd aan de manuscripten in mijn proefschrift  en met wie ik heb 
mogen samenwerken: dank!
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 Voor de manuscripten die onderdeel zijn van dit proefschrift  heb ik gebruik mogen maken van 
data van verschillende gerandomiseerde en observati onele studies. Dank aan de PAIS, PRACTISE, PASS 
en MR CLEAN onderzoekers voor het beschikbaar stellen van de door jullie verzamelde data en de 
samenwerking. Further, I would like to thank prof. dr. Loch Macdonald and all members of the SAHIT 
collaborati on for their pati ence and trust, and for giving me the opportunity to work with the SAHIT 
repository. Finally, two manuscripts in this thesis are part of the CENTER-TBI project. Many thanks to 
the CENTER-TBI parti cipants and investi gators for the collaborati on and the possibility to work with this 
unique dataset.
Gelukkig was er naast (en ti jdens) het schrijven van dit proefschrift  ook voldoende ti jd voor ontspanning, 
waarbij de volgende personen een belangrijke rol hebben gespeeld.
 Heel veel dank gaat uit naar Kelly, Maaike en Vicky. Ik ben ontzett end blij dat ik toevallig op (toen 
nog) kamer 2424 terecht kwam en de gelegenheid heb gekregen om jullie te leren kennen. Jullie zijn 
enorm lieve, betrokken en ambiti euze meiden en ik heb jullie echt in mijn hart gesloten. We hebben 
samen heel veel gelachen, mooie maar ook verdrieti ge momenten gedeeld en leuk samengewerkt. 
Kelly, je hebt me wegwijs gemaakt op de afdeling en binnen CENTER-TBI, we hebben alti jd goed kunnen 
sparren over onze gezamenlijke projecten, en onszelf in hilarische situati es gebracht. Maaike, jouw 
humor, de vele goede gesprekken (met natuurlijk de benodigde hoeveelheid cafeïne en RUMAG quotes), 
pogingen om R te verslaan, en alti jd spot-on Netf lix-ti ps waren (en zijn) zeer waardevol. En natuurlijk 
bedankt dat je mijn paranimf wilt zijn! Vicky, met jouw zorgzaamheid en doorzetti  ngsvermogen heb 
je me enorm gesteund en geïnspireerd, en ik vond het alti jd heel gezellig om (soms hele werkdagen) 
met je te kletsen. Mijn promoti etraject is begonnen en geëindigd met een overload aan sushi in jullie 
gezelschap. We gaan nu allemaal een andere weg, maar ik hoop dat we nog lang bevriend zullen blijven! 
En om af te sluiten met een onmisbare (en iets aangepaste) RUMAG quote: JULLIE.ZIJN.FUCKING.
GEWELDIG.
 Eliza, Gwen, Jara en Mijna, ik weet eigenlijk niet eens waar ik moet beginnen. We kennen elkaar 
al vanaf de basisschool of middelbare school, en hebben heel veel met elkaar meegemaakt: van 
kinderfeestjes tot aan een examenreis. Hoewel we sinds onze studententi jd door Nederland verspreid 
zijn vind ik het onwijs leuk en waardevol dat we elkaar nog steeds af en toe zien en belangrijke mijlpalen 
samen kunnen vieren. Ik hoop dat we in de toekomst nog meer mooie herinneringen kunnen maken!  
 Anna en Lisett e, we zijn samen afgestudeerd, en de gezelligheid ti jdens de studie en coschappen 
hebben we daarna voortgezet met leuke etentjes en weekendjes weg. Ik heb van jullie al wat mogen 
meekrijgen van het werken in de kliniek en begrijp dat me nog wel het een en ander te wachten staat. 
Maar heb het idee dat dat wel goedkomt, zeker als ik af en toe een avond kan ontspannen, lachen en 
genieten met jullie.
 En dan mijn lieve familie, juist omdat we maar met een kleine groep zijn heb ik het extra 
gewaardeerd dat jullie alti jd veel interesse tonen in (en soms ook rekening houden met) mijn studie en 
werk. Selma, Ria en Theo: ik heb vele goede herinneringen aan leuke verjaardagen, en het logeren in het 
uiterste noorden van het land. “Ria Curaçao”, zoals we je vaak noemen om verwarring te voorkomen: 
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je woont natuurlijk veel te ver weg, maar daarom is het extra speciaal wanneer we elkaar weer zien. En 
natuurlijk niet te vergeten lieve Yvonne, lieve “oma”, je hebt een enorm waardevolle bijdrage geleverd 
aan mijn opvoeding en ik geniet alti jd weer van je verhalen over mijn jeugd. Dus daarom deze keer voor 
jou “een dikke knuff el en een zoen op iedere wang”.
 Mijn lieve zus Maren, we zijn zo verschillend maar lijken toch zo veel op elkaar. Alles wat met 
geneeskunde te maken heeft  vind jij maar niks, en ik snap niet zoveel van de consultancy wereld. Maar 
we hebben allebei enorm veel doorzetti  ngsvermogen en we weten precies wat we willen. Ik heb alti jd 
gezien dat je veel bewondering hebt voor mij, maar dat heb ik misschien nog wel meer voor jou. Mede 
daarom ben ik erg blij dat je mijn paranimf wilt zijn. Ik wens jou en Sander alle geluk van de wereld. Love 
you! 
 En tot slot mijn lieve ouders, dankzij jullie heb ik de mogelijkheid gekregen om de studie 
geneeskunde en ook dit promoti etraject te doorlopen. Dat was zeker niet gelukt zonder de goede basis 
en mooie herinneringen die jullie me van jongs af aan hebben meegegeven. Mama, ik kan alti jd bij 
je terecht, kan alles met je delen en je herinnert me er regelmati g aan dat ik goed voor mezelf moet 
blijven zorgen. Daarnaast waardeer ik het enorm dat je van elke mijlpaal, hoe klein ook, een feestje hebt 
gemaakt. Papa, op het moment dat jij je uitschreef uit het BIG-register mocht ik me daar registreren. 
Hoewel je het niet vaak zegt, zie en weet ik dat je trots op me bent. Jullie hebben alti jd achter me 
gestaan en me in iedere keuze gesteund. Mam en pap, ik houd van jullie.
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